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Using a semi-PBPK modeling/quantitative meta-analysis approach, this project
investigated what factors affect pulmonary and systemic exposures of Budesonide
(BUD), Tobramycin (TOB), and Ciprofloxacin (CIP) after inhalation:
Three structurally different pulmonary disposition models were developed for
each drug, including pulmonary absorption (all three), excretion (TOB and CIP) and
sequestration (TOB) in a peripheral and central lung compartment. Systemic
disposition parameters were estimated using available human mean plasma (cp(t)) and
sputum (cs(t)) concentration profiles after IV administration, and GI absorption
parameters were estimated from these profiles after oral administration. Pulmonary
disposition parameters were estimated from cp(t) and cs(t) profiles after inhalation using
various devices along with their published pulmonary deposition characteristics.
Appropriate covariate models accounted for effects of Cystic Fibrosis on the systemic
disposition/GI absorption for TOB and CIP. Monte Carlo Simulations (MCS) were used
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to optimize parameters and validate the final models and parameter spaces against
published data.
Despite limited available data, especially cs(t) for BUD and CIP (after IV
administration), the point estimates for the final model parameters were mechanistically
plausible for all three drugs and consistent with their known differences in
physicochemical and ADME properties. Model predictions adequately described the
observed cp(t) and cs(t) profiles as well as exposure metrics across studies.
As the most lipophilic drug, BUD showed the fastest pulmonary absorption rates
and highest Fpul (83%). TOB, a very hydrophilic drug, exhibited (intracellular) pulmonary
sequestration, resulting in slow pulmonary absorption and excretion and low Fpul (10%).
CIP - as zwitterion - showed relatively slow pulmonary absorption and excretion, leading
to low Fpul (8%); pulmonary excretion accounted for 27% of CIP overall elimination.
Results of a formal parameter sensitivity analysis demonstrated that, for all three
drugs, after inhalation, (1) their systemic exposures (cp(t)) depend primarily on CLtot
along with Fpul/sequestration combined with Foral; (2) increasing pulmonary exposures
(cs(t)) can be accomplished by slowing down pulmonary absorption rates (kca) and/or
slowing down mucociliary clearance from the lungs into the GI tract (kcm) – affirming the
overall hypothesis guiding the project.
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CHAPTER 1
INTRODUCTION

1.1. Inhalation as a Dosing Route
Historical evidence has shown that inhalation (INH) of drugs for medicinal purposes
has been around since 1554 BC in Egypt.1 INH as an intended route of drug
administration is typically utilized for either, a) its ability to deliver the drug directly to its
site of action, i.e. the lungs, or b) delivering the drug into the blood stream (systemic
circulation) while avoiding any hepatic first-pass elimination, which reduces
bioavailability after oral administration.2 Delivering drug directly to the lungs may allow
use of a lower dose, and minimizes the systemic exposure of the drug relative to
intravenous (IV) or oral dosing (PO) routes. 3
After INH, a fraction of the dose will:1) remain in the INH device, 2) be deposited in
the mouth where it may be exhaled, 3) be swallowed and delivered in the GI tract where
it may be available for GI absorption (similar to PO administration), and 4) deposited in
the lungs for further disposition, namely pulmonary uptake, sequestration, and
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mucociliary clearance. Mucociliary clearance can transport drug from the lung into the
GI for possible GI absorption.4
The fraction of the dose that undergoes each of the four fates listed will depend on
factors such as the efficiency of the device, the INH maneuver, patience compliance
with the INH technique, patient health/disease state, and other factors.5 Some studies
that evaluate drug deposition after INH further characterize the fraction of the dose that
is deposited in the lungs by specifying whether it is deposited into the peripheral lung or
in the central lung.6 Given that some disease states require targeting of the central lung,
while other disease states require the targeting of the peripheral lung, a number of
authors have discussed the necessity of obtaining peripheral versus central lung
deposition device data.7
Cellular structure and airway geometry varies based on the region within the
lung.8 As such, drug disposition once deposited in the lung will also vary. Drugs
deposited in the lung can undergo processes including: dissolution, absorption,
enzymatic metabolism, macrophage degradation, intracellular sequestration, and/or
mucociliary clearance of the drug into the esophagus/GI tract.9 Accordingly, a model
developed for describe INH of drugs, should attempt to capture these different
processes.

1.2. Semi-PBPK Modeling of Inhaled Drugs
While the PK within the systemic circulation can be well described based on
available experimental data, less is known about the pulmonary kinetics of drugs after
IV administration or oral INH. To date, no modeling work has been done in an attempt to
describe or predict the pulmonary drug concentration after IV administration even
2

though this is a frequently utilized dosing route. For example, given that the primary
function of antibiotics is to prevent/treat pulmonary infections, their site of action is the
lungs.
Notably, some authors have attempted to compare isolated sputum drug
concentrations to minimum inhibitory concentrations (MIC) values for bacteria
responsible for pulmonary infections, however, no work so far has attempted to develop
a mathematical model the concentration time profile in the lungs or sputum. 10,11 Others
have looked at of bacteria concentrations in sputum and have drawn conclusions
regarding the likely effectiveness of various antibacterial therapies.12–14 This method
however, may not be an appropriate indicator of pulmonary drug exposures. A possible
method to directly determine drug levels within the lung is to administer the compound
and obtain a lung biopsy. While this method may be considered the most accurate and
reliable technique for determining PUL drug concentrations, it is an invasive and
dangerous procedure.
Physiologically -based Pharmacokinetic (PBPK) modeling and simulation (M&S)
is an alternative method to estimate and predict drug concentrations, not only lung
concentration(s), but also within systemic body compartments, including the blood
stream. However, PK Modeling, and more so PBPK modeling, is heavily dependent on
the data available for the construction of the final model and parameter estimation,
namely the physiological, biochemical, and physicochemical processes that occur in
biological systems under certain physiological and pathological conditions.15 This
information, however, may not be readily available, or the reliability of the available data
may be in question or in conflict with published literature. As such, PBPK models reflect
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current scientific knowledge, attempting to include all available experimental data, so as
to provide the best-informed predictions. It is, however, important to note that the
validity and quality of the simulations and conclusions reached are highly dependent on
the utilized model, and how well informed the model is, i.e., the information incorporated
in the construction of the model.
1.3. Sputum Composition, Physiological Components, and Purpose
Lining the surface of the lungs is a substance known as the airway surface liquid
(ASL), which is composed of the periciliary fluid in immediate contact with the
pulmonary (PUL) epithelium and the mucus layer resting on top of the periciliary fluid.16
The periciliary fluid is a low-viscosity aqueous layer that surrounds the cilia of the
epithelia and allows them to beat in order to propel the mucus layer towards the
trachea, and ultimately to the esophagus. The principal polymeric components of the
mucus layer are mucins (specifically MUC5AC or MUC5B), which are high-molecularweight, heavily-glycosylated proteins that are produced by epithelial tissues, and serve
to create the gel-like viscosity of the mucus.17,18 While the periciliary fluid’s main
function is to allow the cilia to beat, the mucus also serves an immunological purpose as
a form of chemical barrier against external pathogens. It finally serves to maintain
airway hydration and plays a role in cell signaling.17 When the mucus layer is propelled
by the cilia and expectorated, the resulting matrix is called sputum.
Most studies of airway secretions in people with lung disease have been done
using expectorated sputum, given the relative ease of obtaining specimens, compared
to the difficulty in obtaining normal mucus from healthy airways.
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Researchers have attempted to estimate the volume of the airway surface liquid
via two primary methods; the first, estimated based on a bronchoalveolar lavage
method, and the second, morphometry-extrapolation of the area and thickness of the
fluid layer covering the respiratory epithelia: The bronchial lavage method is thought to
lead to an underestimation of the ASL volume, as the recovery by lavage is typically
incomplete, and hence leads to a lower calculated volume.19 The surface area of the
lung has been previously compared to the area of a tennis court,20 however, more
recently, researchers have suggested that it would only be half that area,21 and some
have proposed that the area should be calculated based on body weight. 22
1.4. Fundamentals of Covariate Modeling
In addition to PBPK modeling, covariate models often need to be used to
describe observable/ predictable sources of PK variability arising from known patient
characteristics. A covariate is any patient-specific variable such as body weight, age,
gender, or renal function that is specific to an individual and may explain some of the
between-subject variability observed in drug exposure or drug response (PK/PD).
The implementation of covariate models can be accomplished for either
continuous or categorical covariates. The most frequently utilized mathematical
implementation of these covariate models for continuous covariates across literature
are: linear, proportional, piecewise, power, and exponential. Typically, power models
(also known as allometric models) have been utilized for both volume of distribution
(Vdss) and total clearance (CLtot), given biological plausibility and clinical relevance.23 It
is noteworthy, however, that the scaling factors for both those models are not the same,
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namely, Vdss typically has a scaling factor of 1.0 and CLtot typically has a scaling factor
of 0.75.
As compared to continuous models, categorical models are binary, i.e.
male/female, or healthy/diseases. Covariate models are able to aid in bridging the gap
across various studies in the literature, as they are able to explain some of the interpatient variability that may arise due to disease state, body weight, and other patient
specific factors.
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CHAPTER 2

HYPOTHESIS, SPECIFIC AIMS AND OVERALL STRATEGY

2.1. Hypothesis
After inhalation of drugs that target the lungs, increasing pulmonary exposures
can be accomplished by slowing down uptake from the lungs into systemic circulation
and/or reducing mucociliary clearance from the lungs into the GI tract. Additionally,
systemic levels can be decreased primarily by increasing the total clearance of the drug
from the body rather than reducing pulmonary absorption.

2.2. Specific Aims
The overall objective of this research is to utilize semi-PBPK modeling for
selected drugs to determine which physiological processes/PBPK model parameters
have the most influence on systemic and pulmonary exposures after INH administration.
The following specific aims will be addressed to accomplish this objective:

1. Collect available literature studies reporting cp(t) and cs(t) profiles for BUD,
TOB, CIP after IV, PO, and INH administration to humans.
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2. Develop and validate a structural semi-PBPK model for each drug including
relevant disease state and appropriate covariate models and optimize model
parameters.
a. The final model(s) have a common sub-model describing pulmonary
disposition in order to allow comparison across drugs.
b. For each drug, the final model will be validated by matching model
predictions with available cp(t) and cs(t) profiles, as well as reported
systemic and pulmonary exposure metrics.

3. Using the final PBPK model and optimized model parameter space,
determine which model parameters have the most influence on systemic and
pulmonary exposures using a sensitivity analysis.
a. Perform a sensitivity analysis to identify which model parameters elicit the
largest fold-change in both systemic and pulmonary exposure.
4. Compare across drugs to relate physiochemical properties to pulmonary
absorption, sequestration, and excretion
2.3. Selection of Final Three Drugs For Investigation
To ensure that the sensitivity of the systemic and pulmonary exposure to model
parameters was not an experimental artifact, as well as to increase the generalizability
of the results from this work, the semi-PBPK modeling was performed on three drugs:
budesonide (BUD), tobramycin (TOB), and ciprofloxacin (CIP).
These drugs were selected based on various criteria:
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First, these drugs were selected due to the availability of published cp(t) profiles
(and cs(t) for TOB and CIP) after both IV and INH administration. This was necessary
since the model development and validation step required these data sets.
In order to allow for generalization of the conclusions from the results of this work,
the selected compounds also varied in their underlying physical chemical properties:
For example, the lipophilicity of the three compounds included BUD as moderately
lipophilic compound (log(P) = 1.7), while CIP is also a lipophilic compound (log(P) = 0.13), and TOB which is a hydrophilic compound (log(P) = -7.3).
Furthermore, their ionizability within physiological pH range varied. BUD will be
uncharged in the physiological pH range with a pKa = 12.9, TOB is polycationic with
pKa’s = 6.7, 8.3, and 9.9, and CIP is likely to be zwitterionic (pKa = 6.1, and 8.7).
However BUD, TOB, and CIP all have similar molecular weight (431, 468, and 331
g/mole, respectively).
Presumably due to their difference in lipophilicity and charge, BUD has a plasma
protein binding of 80% (predominantly to albumin), TOB has negligible plasma protein
binding, and CIP has a plasma protein binding of 20-40%.
As a result of, these drugs vary in their clearance pathways: BUD predominantly
undergoes hepatic metabolism, TOB is virtually exclusively cleared via renal pathways,
and CIP is known to be subject to both renal and non-renal clearance pathways. Their
oral bioavailability varies as well, with BUD’s Foral of ≈ 10% due to extensive hepatic
first-pass metabolism, TOB with negligible Foral as it is too polar to cross the GI
epithelial, and CIP has a reported Foral 70% presumably due to some first pass
metabolism and possible GI efflux.
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As can be seen, while there are sufficient in-vivo PK data available for these
drugs after the dosing routes of interest, the three selected drugs are sufficiently
different from each other such that the results from this work should be generalizable.
2.4. PK and Semi-PBPK Models Utilized for Analysis
Three structurally different semi-PBPK models were utilized within this work to
simultaneously describe systemic and pulmonary.
2.4.1. Model #1
The first model, Model #1, includes the drug absorption organ only. Figure 1.
depicts the movement of drug as it is administered by IV, PO, or INH routes:
After INH, the emitted dose, which is the fraction of the dose that escapes the
inhalation device, is obtained from deposition information, based on the metered dose
and the fraction of the dose that remains in the inhaler (Din). The model assumes that a
fraction of the nominal dose (as known as device dose, or total dose) is instantaneously
deposited in the oropharynx (DtGI) where it is swallowed and available for subsequent
absorption from the gastrointestinal (GI) tract.
Alternatively, portions of the nominal dose are deposited into the lung (DtL). The
DtL is fractionated into the peripheral lung compartment (Fpd), central lung compartment
(Fcd). Lastly, a fraction of the dose is exhaled (Fex). Drug that is deposited in the
peripheral lung compartment is available for (a) absorption into the central compartment
by the rate constant kpa or (b) for mucociliary clearance into the central lung
compartment via kpm. Similarly, drug that is either transferred (from the peripheral lung
compartment) or originally deposited (from the device) into the central lung
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compartment is available for (a) absorption into the central compartment by the rate
constant kca or for (b) mucociliary clearance into the GIT compartment via kcm.
Lastly, drug that is either cleared (from the central lung compartment) or
deposited (from the device) into the GIT compartment is available for gastrointestinal
absorption into the central compartment by the rate constant k ga, given oral
bioavailability (Foral).
Drug that reaches the central compartment distributes to and redistributes from
the peripheral body compartment via first- order rate constants k12 and k21, respectively,
while also undergoing first order elimination from the central compartment via CL tot.
Deposition parameters, pulmonary disposition, oral absorption, and systemic
disposition parameters are color coded in the three figures below as: black, blue, yellow,
and green parameters.

Figure 1 Semi-PBPK Model #1
Scheme describing pulmonary deposition, absorption, and systemic disposition
following IV, PO, or INH administration
dinhaler
= −k in ∗ Dm ∗ (1 − Din )
dt
dPLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fpd − PLU ∗ (k pa + k pm )
dt
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dCLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fcd − CLU ∗ (k ca + k cm ) + PLU ∗ k pm
dt
dGI
= k in ∗ Dm ∗ (1 − Din ) ∗ Fgd + CLU ∗ k cm − GI ∗ k ga
dt
dCC
CLtot
= CLU ∗ k ca + PLU ∗ k pa + PC ∗ k 21 + GI ∗ k ga ∗ Foral − CC ∗ (k 21 +
)
dt
V0
dPC
= CC ∗ k12 − PC ∗ k 21
dt
Equations 1 Differential equation expression for Model #1

2.4.2. Model #2
In Model #1, after IV administration of a drug, drug cannot distribute into the
lungs from the systemic circulation (central compartment). This precludes pulmonary
exposures after IV administration and is contrary to reported data for some drugs that
show in-vivo pulmonary exposure after IV administration (i.e., drug concentration in
sputum). Furthermore, after INH, it may be biologically plausible that drug that is
absorbed into the systemic circulation is able to redistribute back to the lung, however,
Model #1 does not allow for this.
To address this limitation, Model #2, incorporates the lungs as absorption and
excretion organs. Figure 2. shows Model #2, accounting for distribution from the central
compartment into the lungs after any dosing route. This is accomplished through the
addition of two new rate constants; kpd and kcd, which describe distribution from the
central compartment to the peripheral and central lung compartments, respectively.
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Figure 2 Semi-PBPK Model #2
Scheme describing pulmonary deposition, absorption, and systemic disposition
following IV, PO, or INH administration.

dinhaler
= −k in ∗ Dm ∗ (1 − Din )
dt
dPLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fpd + CC ∗ k pd − PLU ∗ (k pa + k pm )
dt
dCLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fcd + CLS ∗ k cd − CLU ∗ (k ca + k cm ) + PLU ∗ k pm
dt
dGI
= k in ∗ Dm ∗ (1 − Din ) ∗ Fgd + CLU ∗ k cm − GI ∗ k ga
dt
dCC
CLtot
= CLS ∗ k ca + PLU ∗ k pa + PC ∗ k 21 + GI ∗ k ga ∗ Foral − CC ∗ (k cd + k pd + k 21 +
)
dt
V0
dPC
= CC ∗ k12 − PC ∗ k 21
dt
Equations 2 Differential equation expression for Model #2

2.4.3. Model #3
Some studies have shown that certain compounds, for example TOB, can be
sequestered within pulmonary epithelium.24 To account for this sequestration, Model #2
13

was expanded to include two pulmonary sequestration compartments along with
corresponding the rate constants to mimic pulmonary sequestration of drugs.
Here the drug is an absorption, sequestration and excretion organ. This new
model is shown in Figure 3. and will be referred to as Model #3:
kpls1 and kcls1 allow for drug distribution from the central compartment into the
peripheral and central lung sequestration compartments (PLS and CLS) respectively.
Similarly, kpls2 and kcsl2 represent absorption from the PLS and CLS into the central
compartment, respectively. The differential equations describing the intercompartmental
movement of the drug in Model 3 are reported in Equations 3.

Figure 3 Semi-PBPK Model #3
Scheme describing pulmonary deposition, absorption, and systemic disposition
following IV, PO, or INH administration. Plasma concentrations (systemic exposure) are
calculated by dividing the amount of drug that is in the central compartment by the
central compartment volume (V0). For both TOB and CIP, sputum concentrations are
calculated by dividing the amount of drug in the central lung unbound compartment with
the central lung volume (CLV). CLV is set to 80% of total lung volume, which was
obtained from literature.25
dinhaler
= −k in ∗ Dm ∗ (1 − Din )
dt
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dPLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fpd + PLS ∗ k pd − PLU ∗ (k pa + k pm )
dt
dCLU
= k in ∗ Dm ∗ (1 − Din ) ∗ Fcd + CLS ∗ k cd − CLU ∗ (k ca + k cm ) + PLU ∗ k pm
dt
dGI
= k in ∗ Dm ∗ (1 − Din ) ∗ Fgd + CLU ∗ k cm − GI ∗ k ga
dt
dPLS
= PLU ∗ k pa − PLS ∗ (k pd + k pls2 ) + CC ∗ k pls1
dt
dCLS
= CLU ∗ k ca − CLS ∗ (k cd + k cls2 ) + CC ∗ k cls1
dt
dCC
= CLS ∗ k cls2 + PLS ∗ k pls2 + PC ∗ k 21 + GI ∗ k ga ∗ Foral
dt
−CC ∗ (k cls1 + k pls1 + k 21 +

CLtot
)
V0

dPC
= CC ∗ k12 − PC ∗ k 21
dt
Equations 3 Differential equation expression for Model #3

2.5. Model Optimization and Parameter Estimation
2.5.1. IV NCA
Estimation of NCA was performed on cp(t) profiles following IV, PO, and INH for
the three drugs. The slope of the terminal phase (λ) of the cp(t) profile was estimated by
a log-linear regression in excel using the Analysis ToolPak add-in for Excel 2016. Area
under the curve and area under the moment curve was estimated using the trapezoidal
rule as described by Gibaldi.26 AUCt-∞ was estimated by dividing the last measured
concentration by λ, AUC∞ was then calculated the sum of AUC0-t and AUCt-∞. Total
15

clearance (CLtot) was estimated as the total administered dose divided by AUC∞.
Systemic mean residence time (MRTIV) was estimated by AUMC∞ divided by AUC∞ (for
infusion studies the calculation was modified to AUMC∞/AUC∞-Tinf/2), and then was
used to estimate volume of distribution (Vdss) when multiplied by CLtot.
A meta-analysis of the available data was performed to explore dose
proportionality by investigating how AUC relates with the various tested doses after IV
administration and after INH.
2.5.2. PO NCA
For PO studies, Foral was estimated using NCA by dividing the product of AUCPO
and CLtotIV by the orally administered dose (DosePO). Mean absorption time after oral
administration (MATpo) was calculated by subtracting the systemic mean residency time
after IV administration (MRTIV) from the mean residency time after PO administration
(MRTpo). Subsequently, kga was estimated initially by taking the ratio of 1 over MATpo.
The total clearance and systemic mean residence time utilized in estimating F oral
and MAT, respectively, were the overall means of the HV and CF groups estimated
using IV data sets.
2.5.3. INH NCA
For INH studies, bioavailability after INH (Finh) was calculated as shown in
Equation 4 below using NCA values for AUC after both INH and IV administration and
their respective doses. The device dose represents the nominal dose placed in the INH
device.
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𝐹𝑖𝑛ℎ

𝐼𝑁𝐻
𝐴𝑈𝐶0−∞
= 𝐷𝑒𝑣𝑖𝑐𝑒𝐼𝑉𝑑𝑜𝑠𝑒
𝐴𝑈𝐶0−∞
𝐷𝑜𝑠𝑒𝐼𝑉

Equation 4 NCA-calculated bioavailability after INH
After INH, drug can reach systemic circulation after absorption from either the
lungs or from the GI tract. As such, FINH depends on (1) fraction of the dose that is orally
bioavailable (Foral), and (2) the fraction of the dose that is bioavailable through the lungs
(pulmonary bioavailability = Fpul). The contribution of the each of the two pathways is
weighted by the amount of the dose that is originally deposited in that pathway:
Specifically, the contribution of Fpul to FINH will depend on the fraction of the dose
deposited in the lung (DtL), and the contribution of Foral to FINH will depend on the
fraction of the dose deposited in the GI tract (DtGI). This is expressed in Equation 5.

𝐹𝑖𝑛ℎ = 𝐹𝑝𝑢𝑙 ∗

𝐷𝑡𝐿
𝐷𝑡𝐺𝐼
+ 𝐹𝑜𝑟𝑎𝑙 ∗
𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼
𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼

Equation 5 FINH as the sum of Fpul and Foral multiplied by their relative contributions to
Finh.

Rearranging equation 5 to solve for Fpul, we derive Equation 6. Equation 6 allows
estimation of Fpul based on FINH and Foral.
𝐹𝑝𝑢𝑙 =

𝐹𝑖𝑛ℎ ∗ (𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼) − 𝐹𝑜𝑟𝑎𝑙 ∗ 𝐷𝑡𝐺𝐼
𝐷𝑡𝐿

Equation 6. Estimating pulmonary bioavailability (Fpul) after inhalation
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In addition to this equation, there is an additional method that will be used to
estimate Fpul when adequate systemic exposure data with sufficient plasma data is
available after with and without administration of a charcoal block solution after drug
INH. This method will be described in Chapter 5.

2.5.4. Covariate Analysis
For PO studies, exploratory plots of Foral, MATPO, and kga vs dose, age, body
weight, and disease state were inspected to determine if any these covariates may
affect these PK parameters.
2.5.5. NCA Acceptance Criteria
The validity of NCA performed was determined based on several criteria. Firstly,
the log-linear regression performed to obtain lambda for the reported terminal points on
the cp(t) profiles needed to pass a visual inspection, specifically that all points were
evenly distributed above and below the regression line. Furthermore, the r2 of the
regression had to be greater than 0.9. Regression results were deemed acceptable if
the sampling schedule was long enough such that two terminal half-lives were covered.
The extrapolated AUC could not contribute more than 30% of the AUC∞. Additional
confidence in the results of the NCA was gained if the estimated PK parameters were
similar to the literature reported parameter exposure metrics. Finally, cmax and tmax had
to be captured for both PO and INH studies i.e. points on both sides of cmax.
2.5.6. Model Fitting and Parameter Estimation
Initial estimates for systemic disposition and oral absorption parameters were
obtained from NCA. Pulmonary disposition parameter initial estimates were obtained
18

from similar modeling works in literature, with exception of mucociliary clearance initial
estimates, which were obtained from in-vivo studies.27,28
The acceptability of the model fits that were performed was also based on
numerous acceptance criteria. Firstly, a visual inspection of the model predicted results
relative to the reported cp(t) profile was crucial to determine if the estimate fit was
acceptable. Additionally, the overall goodness of fit for the model was evaluated by
checking if the r2 was greater than 0.90 and if the model selection criteria (MSC) was
greater than 3. Lastly, confidence in the estimated values of the various model
parameters was based on the CV of each of the parameters being less than 30% and
the correlation between parameters being less than 0.5 and greater than -0.5 modelestimated parameters. The results of the model fitting were also compared with PK
parameters obtained from NCA, to confirm agreement.
2.5.7. Monte Carlo Simulations
MCS were performed by first specifying the number of simulations (n) the model
should be run. Parameter variability distributions were specified, with a mean and a
coefficient of variation.
The results of MCS were also assessed against several acceptance criteria. A
visual predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t)
profiles was also performed. Mean (and SD when available) had to be within this VPC.
When possible, studies were grouped together based on dose, route, population, or INH
device. Reported mean exposure metrics for both plasma and sputum exposure were
compared with model-predicted exposures. Individual difference model-predicted and
reported exposures had to be less than 50% for plasma exposure and less than 150%
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for sputum exposure. The average of these differences across each of the individual
data had to be not different from zero. Additionally, an informal comparison between
model predicted exposure metric variability (SD) and reported variability (SD when
available) was performed. Comparison of the predicted and reported variabilities was
used for parameter variability estimation (CV’s associated with parameter estimate
uncertainty).
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CHAPTER 3

SEMI-PBPK MODELING OF INHALED BUDESONIDE

3.1.

Background

3.1.1. Pathophysiology of Asthma
A common chronic disease that affects nearly 26 million individuals across the
United States, asthma is a complex disease that involves airway inflammation, sporadic
airflow obstruction, and bronchial hyperresponsiveness.29 According to the Center of
Disease Control, asthma in the U.S is associated with over fifty-six billion dollars in
annual expenses. Patients may experience symptoms such as wheezing, labored
breathing, chest tightness, coughing, and shortness of breath. Although it has not been
clearly pinpointed as to why some patients develop asthma and others do not, both
environmental and genetic factors have been identified as key contributing factors. In
some patients, exposure to airborne substances, such as pollen, dust mites, mold
spores, and pet dander have been known to trigger asthma, while in others, physical
activity (exercise-induced asthma), strong emotions and stress have also induced
asthma.30 Cells that respond to these triggers include (but are not limited to) mast cells,
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T-lymphocytes, macrophages, neutrophils, and epithelial cells.31 Exposure to these
triggers leads the patients to have 1) an inflamed/thickened airway wall, 2) tightened
muscles leading to a constricted airway, and 3) increased mucus production. These
three symptoms lead to a narrowed airway and hence limited air flow. It is this limited air
flow that causes the symptoms mentioned above.

3.1.2. Treatment of Asthma
Treatment options for asthma include methylxanthines, as well as inhaled βadrenergic agonists, muscarinic cholinergic antagonists, and glucocorticoids. Of these
treatments, one of the mainstay options used by asthma patients to manage symptoms
and slow down disease progression are the orally inhaled glucocorticoids, including
BUD. BUD has been shown to exhibit anti-inflammatory response in including T
lymphocytes, eosinophils, mast cells, and dendritic cells both in-vitro and in-vivo.32,33 It
is potent glucocorticoid, exhibiting high local pulmonary anti-inflammatory activity after
inhalation.34 When clinically tested at a dose of 800 µg twice daily, it was shown that
BUD reduced the acute and delayed pulmonary reactions of asthma as measured by a
reduction in the forced expiratory volume in one minute(FEV1). 35 While it has been
shown to be efficacious, the use of INH BUD is limited by its systemic absorption,
leading to inhibition of the hypothalamic-pituitary-adrenal axis, increasing the risk for
adverse reactions, e.g., stunting of bone growth in pediatric patients.35
3.1.3. Relevant Physiochemical Properties of Budesonide
BUD is a small lipophilic molecule with a log(P) value of 1.7 and a molar mass of
431 g/mole. The epimer structures of BUD are shown in Figure 4. Additionally, BUD
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has a pKa of 12.9, which is not physiologically relevant. The aqueous solubility of BUD
was experimentally determined to be between 19 ᛫ 10-3 and 26 ᛫ 10-3 g/L.36 At a
concentration of 30 µM in the apical compartment of a Calu-3 cell monolayer model, the
linear concentration-time profile allowed to determine a Papp value of 8.59 ᛫ 10-6 cm/sec,
which indicated high permeability.37 Similar studies were also performed in Caco-2 cell
monolayers. Permeability was estimated in both directions (A-B and B-A) with resulting
Papp values equal to 11 ᛫ 10-6 cm/sec, and 8.7 ᛫ 10-6 cm/sec respectively.38 Based on
the experimental Papp values both in Caco-2 and Calu-3 cell models, it can be
concluded that BUD is a high permeability compound, crossing epithelia via
transcellular diffusion.

Figure 4 Epimer structures of BUD
3.1.4. Summary of Known PK/ADME Properties of Budesonide
With a reported plasma protein binding 88% predominantly, to albumin¸ BUD still
exhibits extensive extravascular distribution throughout the body with a Vdss after a 10
minute 500-µg IV infusion dose in HV of 2.2 ± 0.46 L/kg. Total clearance values (CLtot)
are also estimated after the same dosing regiments in those subjects to be 0.86 ± 0.13
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L/min.39 While there are 16 detectable BUD metabolites, only two metabolites account
for the majority of the elimination.40 6β-hydroxybudesonide and 16α-hydroxyprednisoine
are two major metabolites and were predominantly formed by the CYP3A4 enzyme. 41
There was no evidence of BUD undergoing renal elimination, which was well supported
in literature and is likely due to its lipophilic nature. Additionally, it has been shown that
BUD can undergo reversible fatty acid conjugation within airway tissue.
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When administered with via IV infusion as well as PO administration in HV, the
calculated experimental Foral was 10.7%. In light of the high clearance value and the
known metabolic pathways, it was noted that BUD undergoes extensive first-pass
metabolism and as such is considered a high hepatic extraction ratio drug. After
inhalation from a Turbuhaler ® (again with a known IV reference data set), the authors
reported that the systemic availability of BUD was 38%.
3.2.
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Objectives

The major objectives of the chapter were to:
1. Develop a semi-mechanistic PBPK model for INH BUD;
2. Estimate and optimize model parameters (point and variability estimates);
3. Validate the final model and parameters on plasma exposures using MonteCarlo simulations (MCS);
4. Determine the sensitivity of plasma exposures to model parameters.
3.3.

Methods

3.3.1. Summary of Identified IV, PO and INH studies
All six identified of BUD after IV administration studies were included in the
analysis performed. Four of the studies utilized HPLC-MS as the analytical method,

24

while the two other studies utilized HPLC-Radiometry methods. All studies were
performed in HV and provided a total of six mean level cp(t) profiles.
Four studies were identified in which BUD was administered orally. Of the four
studies, two studies were not intended to characterize the oral absorption rate constant
and hence had an insufficient sampling schedule. Additionally, one study utilized an
inadequate analytical method for measuring plasma concentrations and hence as not
included in the analysis. One study was included in analysis and provide a single mean
cp(t) profile. The dose was formulated in tablet form in the included study.
Thirteen studies were identified where BUD was INH. Of the thirteen studies,
eight studies did not report any cp(t) profiles, and two studies did not report what device
were utilized. Accordingly, only three studies where the dose was administered through
a Turbuhaler were utilized in the analysis that was performed.

3.3.2. Digitization and Noncompartmental PK Analysis
NCA was performed on the digitized cp(t) profiles for each of the individual
studies across the dosing routes (IV, PO, and INH). To assess PK dose-linearity, AUC
vs dose and log(AUC) vs log(dose) plots were inspected. For the PO study, Foral was
estimated using NCA by dividing the product of AUCPO and CLtotIV by the orally
administered dose (Dpo).
Mean absorption time after oral administration (MATpo) was calculated by
subtracting the systemic mean residency time after IV administration (MRT IV) from the
mean residency time after PO administration (MRTpo). Subsequently, kga was estimated
by taking the ratio of 1 over MATpo. These calculations were performed with CLtot and
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MRTIV of each of the individual IV studies, a Foral and MATpo range was determined.
NCA was not performed for INH studies.

3.3.3. Semi-PBPK Models Tested
Model #1 was used for both fit to the reported data for BUD as well as the MCS
performed. Elimination from the central compartment was modeled using an elimination
micro-rate constant k10. The differential equation for the central compartment (CC) was
derived (Equation 7) and the explicit solution (Equation 8) was solved for using the
Laplace transformation method.

𝑑𝐶𝐶
= 𝑃𝐿 ∗ 𝑘𝑝𝑎 + 𝐶𝐿 ∗ 𝑘𝑐𝑎 + 𝐺𝐼 ∗ 𝑘𝑔𝑎 ∗ 𝐹𝑜𝑟𝑎𝑙 + 𝑃𝐶 ∗ 𝑘21 − 𝐶𝐶 ∗ (𝑘12 + 𝑘10 )
𝑑𝑡
Equation 7 Differential equation for central compartment
𝐶𝐶(𝑡) = 𝐶𝑝𝛼 𝑒 (−𝛼𝑡) + 𝐶𝑝𝛽 𝑒 (−𝛽𝑡) + 𝐶𝑝𝑐 𝑒 (−𝑘𝑐 𝑡) + 𝐶𝑝𝑝 𝑒 (−𝑘𝑝 𝑡) + 𝐶𝑝𝑔𝑎 𝑒 (−𝑘𝑔𝑎𝑡)

Equation 8 Explicit solution derived by Laplace transformation calculating central
compartment concentration at time = t after INH
3.3.4. Software
The NCA will then be performed in MS Excel, modeling work was performed with
Scientist® v3.0, and MCS will be performed with Matlab® R2015a.
For the included studies, captured cp(t) and cs(t) profiles were digitized using the
GetData© Graph Digitizer Version 2.24 software. NCA was performed on the plasma
concentration data. Model parameter fitting was performed in Scientist v. 3.0.0.215
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Build: 1334 using a stiff integrator. MCS and data visualization was performed in
Matlab® R2015a. Since the explicit solution was derived via the Laplace transform
method, differential equations and numerical solvers were not programmatically utilized.

3.4.

Results

3.4.1. Summary of Final IV, PO, and INH Studies Identified
A search of the literature on PubMed and Google Scholar resulted in the
identification of 6 publications where BUD was administered as an IV infusion. These
publications and their respective key study design elements are listed in Table 1. 34,44–48
These studies enrolled between 3 and 24 subjects and tested doses ranging from 0.1
mg to 0.5 mg that were infused over the course of 5 to 10 minutes.
An additional four studies were identified in which BUD was administered orally.
These four studies including the relevant study design parameters are tabulate in Table
2. 34,48–50The administered doses ranged from 2.0 to 4.8 mg. Only one of the five PO
administration studies was acceptable. One study was excluded from analysis due to an
inadequate sampling schedule that would not allow for the estimation of oral absorption
parameters. A second study was excluded due to an insensitive analytical method that
was used for the detection of plasma concentrations. Lastly, a study was excluded from
analysis due to the use of an ad-hoc formulation (an aqueous solution was administered
instead of a tablet) that showed altered cp(t) and absorption PK parameters.
A total of 3 studies were identified where BUD was administered by INH. These
studies and their key study design elements are listed in Table 3.

44,51,52All

three studies

were suitable for analysis as they satisfied the inclusion criteria, and provided c p(t)
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profiles, and plasma exposure metrics. Only one device was tested in these three
studies, and the same dose was tested in all three studies (1 mg). The Turbuhaler DPI
was the inhalation device utilized in this study, for which the deposition data was also
reported in literature.53
BUD 101

BUD 102

BUD 103

BUD 104

BUD 105

BUD 106

0.5

0.1

0.4

0.5

0.5

0.5

9

5

8

10

10

10

0.17 → 8

0.08 → 8

0.24 → 10

Number of Data Points

10

10

10

10

10

10

Total Subjects (N)

24

4

16

3

15

15

Gender (Healthy)

M= 12 (✓)

M= 4 (✓)

M= 6 (✓)

M= 3 (✓)

M= 7 (✓)

M= 8 (✓)

Age

39 (22-53)

22-46

31 (20-44)

--

42 (26-56)

37 (27-45)

Body Weight (kg)

68 (42-92)

63-95

67 (53-94)

--

68 (49-88)

68 (50-95)

HPLC - MS

HPLC Radiometry

HPLC - MS

HPLC Radiometry

HPLC - MS

HPLC - MS

Dose (mg)
Infusion Time (min)
First/Latest Sampling
Time Points (hrs)

Assay

0.10→ 8.22 0.14 → 8.22

0.17→10

Table 1 Six identified studies with key study design elements wherein BUD was
administered by IV infusion to HV
BUD 201

BUD 202

BUD 203

BUD 204

5

1

2

3

Number of Data
Points

11

5

10

14

Sampling Time
Scheme

0.5, 1, 1.5, 2, 3,
4, 5, 6, 8, 12, 24

2, 3, 4, 6, 8

Total Subjects (N)

6

3

11

12

Gender (Healthy)

M= 6 (✓)

M= 3 (✓)

M= 8 (✓)

M= 6 (✓)

46.7(43 - 56)
Deuterium label
+ lactose

-Tritium label +
micronized
HPLC Radiometry

37 (27-45)

43.7 ± 7.1
10 mL Aqueous
Solution

Dose (mg)

Age
Adhoc Formulation
Assay (LOQ)

LC - MS

0.33, 0.5, 0.67, 1,
0.5, 1, 1.5, 2, 3,
1.33, 1.67, 2, 3, 4,
4, 6, 8, 10
5 ,6, 8, 12

micronized
LC - MS

LC - MS/MS

Table 2 Four identified studies with key study design elements wherein BUD was
administered PO to HV.
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BUD 308
1

Dose (mg)
First and Latest Sampling
(10, 480)
Time Points (min)
Number of Plasma Samples
10
Total Subjects (n)
24
Gender (Healthy)
M= 12 (✓)
Assay
Inhalation Device

BUD 309
1

BUD 313
1

(15, 480)
(10, 480)
11
11
44
6
M= 6 (✓) M= 6 (✓)
HPLC HPLC HPLC - MS
MS/MS
MS/MS
Turbuhaler Turbuhaler Turbuhaler

Table 3 Three identified studies with key study design elements wherein BUD was
administered via INH to HV.

3.4.2. NCA results
NCA was performed on the six individual data sets obtained from the included
studies. Visual inspection for each of the log-linear regression of the terminal slope used
in estimating λ were acceptable, R2 values were all larger than 0.9853, and the AUC
percent extrapolated did not exceed 15% for each of the individual data sets analyzed.
The estimated PK parameters are tabulated in Table 4.

Table 4NCA estimated PK parameters for each of the individual data sets from the
six included IV studies.
Inspection of the AUC vs IV dose plotted on a linear scale as well as on a log-log
plot did not provide any evidence of deviation from linear PK after IV administration.
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When a linear and a power model was fit to both plots respectively, the resulting R2
value was 0.8293 and the exponential coefficient of 0.90. These plots are shown in
Figure 5.

Figure 5 BUD IV dose escalation plots
IV infusion dose escalation plotting AUC with increasing IV dose on a linear plot with a
linear regression through the estimated AUC values (left plot), and on a log-log plot with
a power model fit to the estimated AUC values (right plot).

The same analysis could not be performed with the available data after PO
administration as there was only a single study included in the analysis.
NCA was performed on the single PO data set available. Visual inspection for the
log-linear regression of the terminal slope used in estimating λ was acceptable, the R2
value was 0.9990, and the AUC percent extrapolated was 1.2%. The estimated F oral
ranged from 8.7% to 13.5% and the estimated kga ranged from 0.0047 to 0.0088 min-1.
The observed and estimated PK parameters are tabulated in Table 5.
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Table 5 NCA estimated PK parameters for the available data set from the included
PO study.
3.4.3. Modeling of IV Data
Successful fits were obtained for each of the 6 data sets from the seven studies.
No weighting factor was applied to any of the fits. MSC was higher than 3.6, R2 values
were above 0.9950 for all the selected fits, correlation matrix values were all below 0.5,
coefficients of variation for each of the parameter estimates were below 30%, and visual
inspection of the observed versus simulated values were all acceptable. Table 6 shows
the resulting parameter values based on the fits produced by the individual data sets.
The model file for the various fits are reported in the Appendix 1 as Code 1 of this
chapter.
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Table 6 IV BUD two compartment body model results
Two compartment model parameter estimates and goodness of fit validation criteria
results for each of the twelve data sets obtained from the final seven included IV
studies.

MCS resulted in an acceptable parameter space that described observed c p(t)
profiles and exposure metrics after IV administration. The four systemic disposition
parameters were optimized and the optimized central tendency (mean) and a variation
(CV) as shown in Table 7. V0 followed a normal distribution with a 20% CV, while the
three micro-rate constants followed a log-normal distribution with a 20% CV.

Table 7 Final optimized systemic disposition model parameters point and
variability estimates.
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Table 8 shows the percent difference for predicted vs observed exposure metrics
for each of the individual studies. The predicted AUC values did not exceed 30% of the
reported values for each of the studies. Additionally, the calculated PK parameters were
also within 50% of the reported values. VPC for studies BUD 101, 104, 105, and106 are
grouped in Figure 6 since these studies all utilized a dose of 0.5 mg infused over 10
minutes. VPC for BUD 102 and BUD 103 are shown in Figures 7 and 8, respectively.

Study

101

102

103

104

105

106

Mean

SD

AUC∞

29%

16%

25%

7.9%

5.4%

12%

16%

9

β

40%

6%

11%

21%

31%

30%

23%

12

37%

1.2%

5.4%

24%

21%

14%

17%

12

14%

32%

11%

2.6%

18%

25%

17%

10

t½

IV

MRT
CLtot

Table 8 Percent difference between reported and predicted values for AUC, t
MRTIV, and CLtot.

½

Figure 6 MCS-predicted versus observed cp(t) after IV dosing for BUD studies
101, 104, 105, and 106.
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β,

Figure 7 MCS-predicted versus observed cp(t) after IV dosing for BUD 102

Figure 8 MCS-predicted versus observed cp(t) after IV dosing for BUD 103
3.4.4. Modeling of PO Data
MCS resulted in an acceptable parameter space that described observed cp(t)
profile and exposure metrics after PO administration. The two oral absorption
parameters were optimized and the optimized central tendency (mean) and a variation
(CV) as shown in Table 9. Parameter variation was 40%, which was twice the variation
associated with the systemic disposition parameters.
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Table 9 Final optimized oral absorption model parameters point and variability
estimates.

Table 10 indicates the percent difference for each of the predicted exposure
metrics; namely, AUC, cmax, tmax, and MRTpo. The predicted AUC value was 3.7%
different than the reported in the study. Additionally, the remaining exposure metrics
were also within 50% of the reported values. VPC for the reported cp(t) profile is shown
in Figure 9.

Table 10 Percent difference between reported and simulated values for AUC, cmax,
tmax, and MRTPO

Figure 9 MCS-predicted versus observed cp(t) after PO dosing for BUD 201
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3.4.5. Modeling of INH Data
MCS resulted in an acceptable parameter space that described the observed
cp(t) profiles and corresponding exposure metrics after INH administration. Published
scintigraphy results indicated that 27.9% of the device dose is delivered to the lungs.
Parameter optimization resulted in approximately a 3:1 deposition ration favoring the
peripheral lung compartment. The fraction of the drug exhaled was less than 1%, and
the fraction of the dose that remained in the inhaler was 14%. As such, the remaining
57% of the dose was deposited into the GI compartment. The variation for these
deposition parameters followed a log-normal distribution and ranged from 9% to 57% as
reported in literature. A summary of the central tendencies of these parameters along
with their associated variabilities is reported in Table 11.
Both optimized mucociliary clearance values were below the literature estimates
that were used for initial estimates. The resulting values of kcm and kpm were 0.016 and
0.0078 min-1 respectively. The optimized value for kpa was twice that of kca; 0.066 and
0.033 min-1 respectively. The variation associated with these four pulmonary disposition
parameters was 30%. These parameters along with their associated variabilities are
also reported in Table 11.
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Table 11 Final optimized pulmonary deposition and pulmonary disposition model
parameters point and variability estimates.
Deposition data obtained from pharmacoscintigraphy studies and final optimized
pulmonary disposition model parameters point and variability estimates. Deposition
parameters are experimental values, while pulmonary disposition was optimized using
the semi-PBPK model.

Since the three INH studies analyzed all utilized the same device, the MCS were
grouped and the VI plot is shown on both a linear and a logarithmic scale in Figure 10.
The model slightly underpredicted the reported cp(t) profiles; however, all the observed
concentrations were within the 5-95th percentiles. This slight underprediction is also
observed in the under prediction of AUC as reported in Table 12. The difference
between the predicted and reported AUC was below 30% for the three studies, and the
difference between the predicted and the remaining exposure metrics reported in Table
12 did not exceed 50%.
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Study

101

102

AUC∞

-18%

-5%

-22% -15.0% 7.26

cmax

4%

-11%

10%

tmax

32%

8.7% 32.0% 24.2% 10.98

MRTINH -26%

103

-15%

-4%

Mean

0.9%

SD

8.80

-15.0% 8.98

Table 12 Percent difference between reported and simulated values for AUC,
cmax, tmax, and MRTINH

Figure 10 MCS-predicted versus observed cp(t) after INH dosing for BUD 308, 309,
and 313
3.4.6. Parameter Sensitivity Analysis Results
Sensitivity analysis results were generated for all model parameters (including
the device deposition parameters) and are tabulated in Table 13.
AUC and cmax were most sensitive to V0 with a 25-fold change in V0 directly
resulting in a 25-fold change in both AUC and cmax. k10 was the second most influential
model parameter on AUC, while Fpd was most influential on cmax, as expected. The top
three most influential parameters are tabulated in Table 14. Predicted cp(t) profile after
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the 25-fold change in Fpd and kpa is shown in Figure 11, and those for Fcd and kca in
Figure 12.

Table 13 Sensitivity analysis results after INH of a single 2323 nmol dose.

Table 14 Top three most influential parameters for each of the evaluated exposure
metrics and PK parameters
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Figure 11 Resulting cp(t) profile from a 25-fold change in Fpd (left plot) and kpa
(right plot) after INH of 2323 nmol dose.

Figure 12 Resulting cp(t) profile from a 25-fold change in Fcd (left plot) and kca
(right plot) after INH of 2323 nmole dose.

3.5.

Discussion and Conclusions

3.5.1. Study Limitations
Given that BUD was developed a while ago, and the majority of the clinical
investigations were performed in the early 1960’s and 1970’s, there was only limited
availability of data and poor the reliability of some of the analytical methods that were
experimentally used: For the IV studies, BUD given as IV infusion. IV infusion data
leads to greater uncertainty in estimating distribution and redistribution rate constants
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(k12 and k21) in the two-compartment open body model. This is because as those two
processes are occurring, the drug is also being infused. As such, it is difficult to
accurately determine these parameters unless very frequent plasma samples are
collected during both the dosing and distribution phase is. IV bolus studies with frequent
early sample collection is considered optimal for determining those two parameters.
Furthermore, no sputum samples were available after any of the dosing routes.
The availability of such data would have allowed for more confidence in the pulmonary
disposition parameters. Additionally, there was no repeated dosing studies available for
IV, PO, or INH. These studies would have been useful in studying drug accumulation in
the various compartments as well as time dependence. We were also unable to obtain
any data for the pediatric population. This is notable since they may often be the
targeted population for this treatment. The lack of access to patient level data (both
plasma and sputum) limited the ability to study the possible effects of covariate on both
plasma and sputum exposure.
Lastly, the INH data available was produced from the same device across the
four studies. Additional data for various devices including pressurized inhalers and
nebulizers would have been useful in studying the effect of device of plasma and
sputum exposure.

3.5.2. PK Dose-Proportionality
The dose dependence plots after IV infusion shown in Figures 5 support linear
PK based on the high r2 value for the linear model. Additionally, when the same data
were plotted on a log-log scale (shown in the same figure), and a power model was
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utilized for fitting the data, the coefficient of the exponential coefficient is close to 1.0
which also indicates linear PK. This finding is in agreement with the literature as several
authors have also reported that BUD experience’s linear PK across a similar dose
range.18 These pieces of evidence provided a strong basis for the major modeling
assumption, namely that all rate constants were first-order rate constants.

3.5.3. Final Parameter Space after IV Administration
An empiric open body two compartment model of BUD with an optimized model
parameter space resulted in mechanistically plausible parameter estimates and was
able to adequately predict the reported cp(t) profiles from six clinical PK studies with HV
after single IV doses.
Model-optimized values indicated that are consistent with that BUD undergoes
high hepatic clearance as its clearance value (k10*V0= 1170 ml/min) approaches hepatic
blood flow (1200 ml/min). This results in a short β-half-life (t½k10 = 27 min). The
𝑘

peripheral tissue compartment is a shallow compartment (𝑘10 = 0.26) with intermediate
12

𝑘

capacity (𝑘21 = 1.2). The model indicated that BUD is widely distributed throughout the
12

body with a Vdss of 190 L. This is likely due to its lipophilicity as mentioned in the
introduction of this chapter. All systemic disposition parameter point estimates are
consistent with published values.

3.5.4. Final Parameter Space after PO Administration
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The final optimized oral absorption model and parameters for BUD suggest that
BU has a low Foral of 10% that is due to extensive hepatic first pass metabolism.
Additionally, its oral absorption was noted to be slow with an oral absorption half-life of
95 minutes. As such, BUD may experience “flip-flop” PK in, ie, the rate constant of
absorption (kga) maybe slower than the rate constant of elimination of BUD (k10).
Some authors have already demonstrated that this slow absorption rate is due to
the absorption of BUD throughout the entire GI tract, and therefore the absorption rate
may be affected by GI motility.10

3.5.5. Final INH Model
The final INH model incorporated the two-compartment systemic disposition
model, the oral absorption model, and two pulmonary compartments. This is Model #1
as described in chapter two. The selection of this model was based on the lack
availability of sputum data, specifically, after IV administration. The model allowed for
(unidirectional) absorption from the lungs (central and peripheral) to the central
compartment through kpa and kca, however, the model did not allow redistribution from
the central compartment back to the lungs due to the absence of any evidence.
Mucociliary clearance was possible from both the peripheral and the central lung into
the central lung and the GI tract compartments, respectively.
The explicit solution for each of the five compartments in the model were derived.
This solution for the central compartment indicated that the four hybrid rate constants
are calculated from model micro rate constants. Five intercepts incorporate dose,
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deposition fractions and ratios of rate constants and had a sum of zero (i.e., some are
negative).
3.5.6. Final Parameter Space after Inhalation
The final parameter set (listed in Table 15) that was optimized using the available
inhalation data, was able to adequately describe the available cp(t) profiles as well as
the exposure metric. The final, optimized PBPK model parameters (point estimates)
indicate a small fraction exhaled from Turbuhaler (Fex = 0.9%) as well as 3-1 relative
peripheral-to-central pulmonary deposition (Fpd = 21% vs. Fcd = 7%) with an absorption
t½ of 11 min for kpa and 21 min for kca, preferential absorption from peripheral vs central
compartment, respectively. Model optimization during MCS required addition of
parameter variability, ranging from to 9% to 57% (CV), primarily in pulmonary deposition
parameters. Furthermore, mucociliary clearance from the central lung was twice as fast
as from the peripheral lung. However, due to the lack of sputum data, the ability to
accurately resolve these parameters was limited.
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Table 15 Final (optimized) model parameters, point and variability estimates

3.5.7. Sensitivity Analysis
The sensitivity analysis indicated that AUC depends primarily on V 0, k10, and Fpd;
cmax on V0, Fpd, and k12; tmax on kpa, k12, and k21; and MRT on k10, k12, and k21. While the
results of the sensitivity analysis allowed for a numerical comparison between each of
the model parameters on the various exposure metrics, there appeared to be an
apparent overarching theme. After inhalation, the model appears to be most sensitive to
the systemic disposition parameters and least sensitive to the oral absorption
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parameters within the BUD model parameter space. None of the pulmonary disposition
parameters were found to be important for plasma exposure.
3.5.8. Overall Conclusions
The final semi-PBPK model incorporated published in-vitro and in-vivo
information and established a model parameter space for BUD that gave acceptable
predictions and mechanistically plausible parameter estimates. Pulmonary absorption
parameters (kpa and kca) were the most uncertain estimates. Most of the model
parameter variability was associated with pulmonary deposition parameters. Overall,
plasma exposure metrics for BUD after inhalation are more sensitive to differences in
systemic disposition rather than pulmonary deposition/absorption or GI absorption.
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CHAPTER 4

SEMI-PBPK MODELING OF INHALED TOBRAMYCIN

4.1.

Background

4.1.1. Background on Cystic Fibrosis demographics, pathophysiology, effects on
pulmonary functioning
Cystic Fibrosis (CF) diagnoses are increasing at a rate of 1000 new cases per
year and over 70,000 reported worldwide which are caused by mutations in the Cystic
Fibrosis Transmembrane Regulator (CFTR) gene.54 While there are over 400 reported
gene mutations that cause the disease in these patients, pulmonary (PUL) infections
leading to exacerbation of the disease symptoms have been reported as the leading
cause of death in CF patients and the leading cause for a shortened average life span
of only 37 years.54,55 Irrespective of the patient’s disease severity classification, the
most common pulmonary infection that leads to exacerbations is Pseudomonas
aeruginosa, which is a gram-negative bacteria infection.56 This gram-negative infection
occurs because the mutated CFTR gene leads to the accumulation of chloride ions
within the cell, which results in the accumulation of sodium ions. Therefore, water
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content increases intracellularly and decreases extracellularly.57 The decreased
extracellular concentration of water leads to a thickening of the mucus in the intestine
(leading to malnutrition), and in the lungs, resulting in the aforementioned potentially
fatal infection.54 Patients are spending annually on average $29,000 for hospitalization
related costs, and an additional $20,000 on prescription medication for treatment. 55
Despite this spending, patient prognosis is still relatively bleak, with 30% of children and
47% of adults being hospitalized at least once for exacerbations of lung infections
reported in 2007.56 As a result of these incidents, most pharmaceutical treatments thus
far, have been aimed at symptom relief and treatment of these lung infections to prevent
the aforementioned fatal pulmonary infections.
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4.1.2. Treatments, IV and INH, MOA, efficacy/toxicity
Antibiotics, steroids, bronchodilators, inhaled hypertonic saline solution, oxygen
therapy, mucolytic agents (Dornase Alfa), and lung transplants (for patients in which the
disease is more advanced), are the current treatment options for CF pulmonary
exacerbations, with administration of antibiotics being the most widely used method. 54
According to the Cystic Fibrosis Foundation, some of the current classes of antibiotics
that are clinically used include: penicillins, cephalosporins, aminoglycosides (AGs),
macrolides, tetracyclines, quinolones, and aztreonam.58
While their exact mechanism of action is not fully understood, AGs are known to
prevent sensitive bacteria from synthesizing proteins vital for growth, by disrupting the
ribosomal mRNA reading process. AGs are also responsible for creating fissures in the
outer membranes of bacterial cells. Given this dual mechanism of action, AGs are
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considered to be potent antibiotics that exhibit strong bactericidal activity against
aerobic gram-negative and certain gram-positive bacteria.59
Due to their strong bactericidal effects against gram-negative bacteria, AGs are
often used for lung infections in CF. Patients often require several courses of IV
antibiotics per year to combat these infections. Typically, these treatments require that
a certain concentration be achieved such that concentration-dependent killing of
bacterial cells can be accomplished. As a consequence of antibiotic use, the survival of
patients with CF has improved, but the side effects of treatments have become
increasingly important. A number of studies have extensively discussed the systemic
toxicity of AGs (namely ototoxicity and nephrotoxicity).12,60,61 AGs can accumulate in
the proximal tubule epithelial cells (either in the cytoplasm or in the endoplasmic
reticulum) within the kidney where they can activate the intrinsic pathways leading to
apoptosis. 62 The apoptotic cascade can also be initiated within the hair cells of the
inner ear by free radicals (specifically oxygen and nitrogen free radical species) which
have been documented to lead to permanent hearing loss, i.e. ototoxicity.
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It has also been reported that IV administered AGs have poor penetration into
the lung, reaching mean peak sputum concentrations that are only 12% to 20% of the
peak serum concentrations. Hence there is a desire to shift from IV administration to
inhalation (INH) as this is likely to increase the pulmonary local concentrations while
minimizing systemic exposures.64–66 While most of the aforementioned classes of
antibiotics have IV dosage forms, few have oral (PO) dosage forms, and even fewer
have orally inhaled dosage forms. Only AGs (tobramycin (TOB), gentamycin (GEN),
and amikacin), Quinolones (ciprofloxacin, and levofloxacin), and aztreonam are
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available for both IV and INH administration.58 Among the AGs, TOB has been reported
to be the most active against isolated Pseudomonas aeruginosa with an MIC50 of
1µg/ml and a MIC90 of 8µg/ml.67 In addition to its efficacy against Pseudomonas
aeruginosa, it was one of the earliest antibiotics (of those available for inhalation)
introduced for clinical use. Accordingly, TOB has the most available data sets across
the literature.

4.1.3. Relevant TOB-Specific Physiochemical Properties
Tobramycin is a low molecular weight compound with a molar mass of 468
grams per mole and a chemical formula of C18H37N5O9. Based on its chemical structure
depicted in Figure 13 below, it has an experimentally determined partition-coefficient
log(P) value of -7.3, indicating that it is a hydrophilic compound that is very soluble in
water(according to the USP definition) with a solubility of 1000 mg/ml.68,69 Accordingly,
it has been shown to have low permeability across Caco-2 cell models with an apparent
permeability of Papp = 1.78 ᛫ 10-6 cm/sec, at a tested concentration of 5 mg/ml.70
Additionally, at a tested concentration of 100 µM, only 32% of the initial concentration
was detected in the basolateral compartment, hence a Papp could not be calculated for a
Calu-3 cell model, but was assumed to be low.68 Caco-2 and Calu-3 cell models are
used to gauge permeability in the GI tract and lungs, respectively. This is likely due to
both its hydrophilic structure, as well as its likely polycationic charge within the
physiological pH range. TOB is known to be stable at a pH range from 1-11 at
temperatures ranging from 5 to 37°C.71
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Figure 13 Chemical Structure of TOB

4.1.4. Summary of ADME of TOB, IV and INH
While TOB has not been identified as a substrate for any major metabolic
pathways in mice after IV administration, its oral bioavailability has been reported as
negligible, primarily due to this low GI permeability, and not due to a first-pass effect.14
Due to its hydrophilic nature, TOB is primarily eliminated by the kidneys by glomerular
filtration, with 60% of the dose showing up unchanged in urine within 6 hours, and by 24
hours 85% has been recovered in urine.72 Some authors have suggested that up to
10% of the IV administered dose could be eliminated via extrarenal mechanism such as
elimination in the lung or elimination via other non-renal pathways.73 Another plausible
explanation for the remaining 15% that is not recovered in urine at the 24-hour sampling
time point, is that the drug may still be distributed in tissues throughout the body.
It is known that TOB has negligible plasma protein binding, with a reported
binding that is not statistically different from zero when tested under controlled
conditions of physiological pH, and temperature, by means of an ultrafiltration method in
human serum.74 When a dose of 60mg/m2 was administered IV in CF patients, the
authors reported a volume of distribution of 0.30 ± 0.5 L/kg, and a CLtot value of 4.9 ±
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2.1 L/h/1.73m2. Similarly, in HV with a similar dose of 55 mg/m 2, the reported values
were 0.23 ± 0.07 L/kg and 6.12 ± 1.17 L/h/1.73m2, respectively.75 After 6 CF patients
received a 600mg dose via an ultrasonic nebulizer, the estimated apparent volume
(Vdss/Foral) was higher than that after IV dosing at 1.74 ± 0.96 L/kg and the apparent
clearance (CLtot/Foral) values were reported to be 6.98 ± 2.89 L/h.76
PK parameter estimation has been noted to suffer from larger standard
deviations, as there are numerous sources or variability that are difficult to regulate
including but not limited to: device efficiency, inhalation maneuver technique, and lung
function of study subjects.

4.1.5. Summary of Literature Effect of CF on ADME, Focus on TOB
Gastrointestinal absorption of TOB is known to be negligible due to its
aforementioned hydrophilic nature, hence, there is unlikely to be detectable difference in
GI absorption between HV and CF patients.57
Pulmonary absorption on the other hand has been noted as highly variable; thus
while there may exist a difference in pulmonary absorption between HV and CF
patients, there has not been conclusive evidence of this presented in the literature. 76
However, compared to healthy volunteers, CF patients have been documented to
have higher volumes of distribution and higher CLtot.77Some authors have noted that the
higher volumes of distribution in CF patients is secondary to their state of malnutrition
and reduced levels of adipose tissue. The decrease in adipose tissue leads to a higher
percentage of lean body mass, potentially explaining the larger Vd.78,79 CF patients
have also been noted to suffer from hypoxemia (low concentration of oxygen in blood)
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which leads to erythrocytosis (increase in red blood cells). The increase in red blood
cells ultimately leads to an increase in blood volume which may be the cause for the
increased volume of distribution for TOB.80
Some investigators have theorized that the increase in CLtot in CF patients is due
to their enlarged kidneys, which leads to glomerulomegaly (abnormal enlargement of
glomeruli) which causes hyperfiltration. This hyperfiltration results in an increase in
glomerular filtration rate and an increased urine flow, thereby increasing the renal
clearance of TOB.77,81 Others, however, have speculated that in an effort to
compensate for the CFTR defect, tubular cells have higher activity of other types of
cellular membrane channels or increased paracellular diffusion.64 Both of these
phenomena would result in higher CLtot of TOB. Finally, the contribution of clearance
from the lung has also been noted as a possible explanation for the increased total
clearance in CF patients, as they are known to have increased sputum production. 82

4.2.

Objectives
1) Collect available cp(t) and cs(t) and exposure metrics for TOB after IV, and
INH administration to HV and CF patients in addition to all relevant dosing
information such as dose, infusion time, fraction of the dose left in the inhaler,
and the dose deposited into lung.
2) Develop a structural semi-PBPK model with a nested covariate model(s) to
describe sputum and plasma concentrations of TOB, after IV administration
and INH in both HV and CF patients.
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3) Validate the model developed for specific aim 3.3.2 with the collected data
from aim.
4) Assess the sensitivity sputum and plasma exposure to each of model
parameters.
5) Assess pulmonary bioavailability (Fpul) after INH administration of TOB.

4.3.

Methods

4.3.1. PK Data collection
A systematic review of literature to identify studies where TOB was administered
IV or was INH. Studies were included if: (1) study population size and covariates (body
weight and disease state) were clearly identified, (2) either individual or mean level
plasma concentration time (cp(t)) profile or PK exposure metrics were reported, (3) the
analytical method was deemed to be reliable (specifically, that the observed c p are
larger than Lower Limit of Quantification (LLOQ)), and (4) the sampling schedule was
appropriate to capture drug disposition. Optimal studies will also have reported data
regarding sputum concentrations at known time points (cs(t)) or sputum exposure
metrics, however this was not necessary for the incorporation of a study into the
analysis. When available, the central tendency and its dispersion or variability of any
reported exposure metrics were also collected. Additionally, for INH studies,
scintigraphy data describing the percentage of the dose that was placed in the
inhalation device that ultimately reached the lungs (Dose to Lung or DtL) was also
sought after from the identified studies for the tested inhalation devices or from
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references studies that provided this information for the devices of interest. This data
collection would directly satisfy specific aim 3.3.1
4.3.2. Digitization and Non-compartmental PK analysis
For the included studies, captured cp(t) and cs(t) profiles were digitized using the
GetData© Graph Digitizer Version 2.24 software. A non-compartmental analysis (NCA)
was performed on the plasma concentration data.

4.3.3. SEMI-PBPK Models Tested (Models 1 – 3)
The three semi-PBPK models schematically depicted in chapter 2 (Figure 1 Model 1, Figures 2 - Model 2, and Figures 3 - Model 3) were tested to determine which
model best described the collected data from the IV and INH studies sequentially. As
depicted below, model 1 assumes (1) that equilibration of TOB within a given
compartment is much faster than equilibration between compartments, (2) linear PK (all
rate constants describe non-saturable non-inducible first order processes), and (3) that
drug elimination only occurs through the central compartment. Model 1 was utilized to
determine the systemic disposition parameters by fitting model parameters to the four IV
data sets (from three studies) that did not contain sputum data. A single repeated
dosing IV study was identified that contained sputum data that was utilized for obtaining
model parameter estimates. Due to the presence of detectable sputum levels after IV
administration, Model 1 could not be utilized for further investigation, as it did not allow
for the distribution of TOB from the central compartment to the pulmonary
compartments. While the introduction of the distribution pathway from the central
compartment to the pulmonary compartments in Models 2 and 3 allows the models to
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describe sputum levels after IV administration, it violates the third assumption listed
above in that the drug is administered systemically, can now be eliminated through the
GI tract after distribution to the pulmonary compartments in addition to clearance
through the central compartment. These distribution pathways however, allow for the
simulation of sputum concentrations after IV dosing which satisfies the model
requirements listed in specific aim 3.3.2.
With the systemic disposition parameters fixed (as the average of the four
individual fits generated with model 1), an attempt was made to fit pulmonary disposition
parameters from model 2 and model 3 using Scientist 3.0 utilizing both the method of
least-squares as well as simplex fit, to the IV data set that included both plasma and
sputum values. The software however was unable to converge on values for the six or
ten parameters that were to be estimated from model 2 and model 3 respectively. To
minimize the number of parameters that needed to coverage while satisfying the least
square optimization algorithm, mucociliary clearance (kpm, and kcm) values were fixed to
values estimated from a previous work, and a second attempt to estimate the remaining
four or eight parameters from model 2 and 3 respectively. Although various initial
estimates for the model parameters were tested, this approach did not lead to the
software converging on a parameter set. Since the standard least square optimization
algorithms technique did not lead to a final parameter space, the Monte Carlo
Simulation approach described below was utilized to obtain the final parameter
estimates.
In model 3, TOB was dosed into the central compartment (CC) of a twocompartment open body model with volume of distribution V0, distribution and
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redistribution rate constants k12 and k21, and total clearance CLtot. Both V0 and CLtot
were dependent on body weight power covariate models that were centered around the
population body weight for either healthy or CF patients as shown in Equation 9 and 10.
The lung was modeled with four compartments: (1) peripheral lung unbound (PLU), (2)
peripheral lung sequestered (PLS), (3) central lung unbound (CLU), and (4) central lung
sequestered (CLS). The CC distributes drug to both PLS and CLS via kpls1 and kcls1 and
the drug redistributes back to CC via kpls2 and kcls2 respectively. PLS and CLS are also
each connected to PLU and CLU via distribution (kpa and kca) and redistribution rate
constants (kpd, and kcd). The PLU connects to the CLU via mucociliary clearance (kpm),
and CLU is connected to the GI compartment via mucociliary clearance/swallowing
(kcm). CLU and PLU were characterized with a total lung volume (TLV) which followed
the covariate model expressed in Equation 11.

𝟎.𝟕𝟓

𝑪𝑳𝒊𝒕𝒐𝒕

𝑩𝑾𝒊
= 𝑪𝑳𝒑𝒐𝒑 ∗ (
)
𝑩𝑾𝒑𝒐𝒑

𝑪𝒍𝒕𝒐𝒕

∗ 𝜺𝒊

Equation 9 Total clearance covariate model for the ith patient.

𝑽𝒊𝟎 = 𝑽𝟎𝒑𝒐𝒑 ∗ (

𝑩𝑾𝒊
𝑽
) ∗ 𝜺𝒊 𝟎
𝑩𝑾𝒑𝒐𝒑

Equation 10. Volume of the central compartment covariate model for the ith patient.

𝑻𝑳𝑽𝒊 = 𝑻𝑳𝑽𝒑𝒐𝒑 ∗ (

𝑩𝑾𝒊
) ∗ 𝜺𝑻𝑳𝑽
𝒊
𝑩𝑾𝒑𝒐𝒑

Equation 11. Total volume of the lung covariate model for the ith patient.
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4.3.4. Monte Carlo Simulation MATCHING/ACCEPTABILITY criteria
Monte-Carlo simulations (MCS) were then performed with model 2 and model 3
to determine if there existed an optimal parameter space to describe all the collected IV
data (both plasma and sputum). Parameter point and variability estimates were
optimized using the MCS simulation by simultaneously (1) attempting to minimize the
sum of the residual error for both plasma and sputum concentrations, (2) performing a
visual predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t)
profiles, and (3) matching model-predicted with observed (mean) cp(t) profiles and
exposure metrics. For the final IV parameter space to be accepted, the percent
difference between the observed plasma and sputum exposure metrics and the
simulated exposure metrics had to be less than ±40% for IV. Due to the increased level
of variability associated with INH, the plasma exposure metrics had to be less than
±45% for AUC and 75% for cmax, and the sputum exposure metrics had to be less then
±120% for both AUC and cmax. The MCS were performed using log-normal distributions
for each parameter, and initial estimates for parameter optimization were obtained from
a previous study modeling BUD in HV administered via IV, PO, and oral inhalation.83
The number of subjects to simulate (n) for the MCS was determined by comparing
various simulations, and selecting the lowest n (to minimize computational time) while
ensuring the observed variability did not appear to be minimized due to a lower value of
n. This MCS approach served as the validation step required to address specific aim
3.3.3. MCS were performed in Rstudio Version 1.0.136 with the deSOLVE package
add-in.
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An attempt was made to utilize model 3 and the final optimized parameters from
the IV data sets to predict cp(t) and cs(t) from INH studies (approach #1). Additionally,
we attempted to identify a universal parameter space that was capable of describing
both the IV and INH data sets by re-optimizing the parameters to both the IV and INH
data sets simultaneously (approach #2). Given that there was no identifiable parameter
space that was capable of describing all the available IV and INH data sets
simultaneously, the parameter optimization was then preformed solely on the available
INH data sets. Optimization was performed by attempting to minimize the sum of the
residual error for both plasma and sputum concentrations by preforming a visual
predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t) profiles,
and match model-predicted with observed (mean) cp(t) profiles and exposure metrics for
a single inhalation study. The optimized parameters were then utilized to predict the
reported cp(t) and cs(t) as well as the exposure metrics of the three-remaining studies.
To be acceptable, predictions were to be within the aforementioned VPC criteria and not
show any systematic bias of over-prediction or under-prediction (approach #3). Next,
parameter optimization was performed using only the data sets from each of the four
INH studies where the Pari nebulizer was used as the inhalation device. Parameter
estimates were deemed acceptable once the predicted plasma exposure metrics were
within 40% of the reported exposure metrics for the four data sets. Once the parameter
space was identified, predictions of the remaining inhalation data sets (where other
inhalation devices were utilized) were generated and evaluated for a systematic bias
relative to the reported exposure metrics in addition to the evaluation of the VPC
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(approach #4). Lastly, the sixteen sets of data including the all available c p(t) profiles,
cs(t) profiles, plasma exposure metrics, and sputum exposure metrics from the four
selected inhalation studies were all simultaneously utilized for validation. In this fifth
approach, results were checked to ensure that there was no consistent over or
underprediction (bias) for any of the sub-group of data (HV vs CF, a specific inhalation
device, a given dose, or a specific study).
4.3.5. Sensitivity analysis
As an indicator of how sensitive plasma and sputum levels are to the model
parameters, a sensitivity analysis was performed with the final parameter estimates for
both the IV and INH parameters for model 3. Variability across the parameters was
disabled by setting all the CV’s to zero, parameter values were set to either one-fifth or
five times the mean optimized value, and simulations were performed to the 24-hour
timepoint. AUC and cmax values in plasma and sputum were calculated at each of the
extremes. The fold change was calculated as the ratio between the maximum and
minimum values of the simulated plasma AUC multiplied by a negative one if the
maximum value was obtained from when the parameter being tested was multiplied by
1/5. This was also calculated for plasma cmax, as well as sputum AUC and cmax. Both
cp(t), and cs(t) profiles were generated for comparison. The top three parameters to
cause the largest fold change in the four exposure metrics were determined at the end
of the sensitivity analysis. This sensitivity analysis would then allow for a better
understanding as to how to increase sputum concentrations or how to minimize
systemic exposure as well as specifically address specific aim 3.3.4.
4.3.6. Mass balance and overall excretion simulations
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The cumulative drug eliminated via each pathway (CLtot, and kcm (given that TOB
has no oral bioavailability)) was investigated after IV administration and after INH.
These mass balance excretion simulations were performed to t= 4 days with a
resolution of 1 hour. Additionally, Finh (fraction of the drug that shows up in systemic
circulation after inhalation) will be calculated for each of the inhalation studies using the
reported dose and AUC as well as the reported dose and AUC from IV study TOB
103A. This was performed to aid in estimating pulmonary bioavailability and to address
specific aim 3.3.5.
4.4.

Results

4.4.1. Summary and Discussion of final IV and INH studies identified
A search of the literature on PubMed and Google Scholar resulted in the
identification of 8 publications where TOB was administered as an IV infusion. These
publications and their respective key study design elements are listed in Table
16.10,11,73,84–88 Due to study design flaws, studies TOB 105 – 108 were excluded from
the data analysis. Some of these studies did not have a sufficiently low enough LLOQ to
capture the cp(t) reliably, others did not have an appropriate sampling scheme that
permitted any type of data analysis, and others did not report a cp(t) or a cs(t) profile. For
the purpose of the following analysis, only studies TOB 101 – TOB 104 were utilized for
analysis. These studies were characterized by infusion doses ranging from 1.5 mg/kg to
10 mg/kg administered to both healthy subjects and CF patients. The authors in TOB
103 investigated two dosing regiments; 3.3 mg/kg administered as a 30-minute infusion
every 8 hours (TOB103A), and 10 mg/kg infused over 60 minutes every 24 hours
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(TOB103B). TOB 104 was a unique study in that it provided both cp(t) and cs(t) profiles
after 8 mg/kg repeat dosing.
A total of 10 studies were identified where TOB was inhaled in either HV or CF
patients. These studies and their key study design elements, such as number of
subjects (n), mean body weight, mean age, etc., are listed in Table 17.76,89–97
Additionally, the availability of cp(t), cs(t), exposure metrics for either plasma or sputum,
and availability of deposition data is also tabulated. Of the ten identified studies, six
studies were not suitable for analysis either for similar reasons as those excluded
among the IV studies or due to lack of pulmonary deposition data that was necessary to
perform the modeling described above. A summary of the four INH studies that were
included in the analysis is reported in Table 17 along with the reported exposure metrics
available for plasma and sputum data. The four studies were all single dose studies
testing doses ranging from 28 mg to 300 mg that were inhaled through the Pari
nebulizer, AeroDose inhaler, PulmoSphere inhaler, or the eFlow nebulizer in HV and CF
patients.
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Healthy
2 mg/kg as either
30 minute infusion

Healthy

1.5 mg/kg as 30
min infusion
FPI

Dose Strength

Assay
method
FPI

CF (CrCl ~127
ml/mi)
3.3 mg/kg q8h or
10 mg/kg q24h as
30 or 60 min
infusions

2002
6

TOB 103

Body weight
(kg)
Cp(t) Profile
Cs(t) Profile
✔
x

-✔
x

✔
x

79.3 ± 9.1 (60 - 90) 55.3 ± 13.8 (45 - 75)

8, 12, 21, 30, 35,
0, 10, 20, 30, 40, 50 0, 10, 20, 30, 45
40, 45 min, 1, 1.25,
min, 1, 1.25, 1.5, 2, min, 1, 1.5, 2, 4, 7.5
PK Sampling
1.5, 1.75, 2, 2.5, 3,
4, 6 hrs
hrs
4, 6, 8 hrs
-22.9 ± 0.7 (22 - 24) 29 ± 4.6 (23 - 34)
Age (years)

FPI

1995
6

1988
11

Year
n
Subject
Disease State

TOB 102

TOB 101

✔
✔

✔
✔

--

--

30.3 (18 - 50)
57.4 (36 - 88)

5, 7

Antibiotic Activity

0, 0.5, 1, 4, 6, 8

HPLC

x

66 - 78.5

--

0, 1, 1.75, 2.25,
2.75, 3, 4, 4.5, 5,
5.5, 6, 7, 8, 9 hrs

Antibiotic Activity

108

Antibiotic Activity

80 mg and 1.5
mg/kg as a bolus
injection (15 sec)

Healthy + Other

1976
30

x

50 - 80

22 - 67

x

64.5 (33 - 87)

55 (25 - 87)

0, 1, 1.5, 2, 2.5, 3, 0, 1, 2, 5, 10, 20, 30
3.5, 4 hrs
min, 1, 2, 4, 5 hrs

Antibiotic Activity

1 mg/kg as a 2
minute infusion

1976
16

TOB 107

8 mg/kg once daily
Bolus: 1 mg/kg,
100 mg as 60 min
as a 10 minute
Infusion: 2 -3.5
infusion + 30 mg as
infusion
mg/kg for 8 hours
2 hour infusion

1972
4

TOB 106

Healthy (ClCr > 80
ml/mi)

normal level of
creatinine

1981
7

TOB 105

Healthy (CrCl ~120
ml/mi)

CF

2007
14

TOB 104

Table 16 Identified TOB IV studies

Eight identified studies wherein TOB was
administered IV. Tabulated key study design
elements: year of publication, number of
subjects (n), subject disease state (Healthy,
CF – cystic Fibrosis, or other), dose strength
and regiment, analytical method, sampling
schedule, age (yrs), body weight, availability
of cp(t) profile, and the availability of cs(t)
profile
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6/7
12
60
10
258
49
24
84

TOB 302 2011

TOB 303 2003

TOB 304 1997

TOB 305 1993

TOB 306 2002

TOB 307 2003

TOB 308 1995

TOB 309 2007
20

6

TOB 301 1997

TOB 310 1989

n

Year

--

--

--

64/53

--

--

--

--

--

57.5

Body
Weight

--

7-50

17

24

21

--

21.5

34

33/21

25

Age

--

43

18

19

149

--

32

10

6/4

4

Male

O

CF

CF

CF

CF

H/O/O

CF

H

H/CF

CF

H - CF - O

Enzyme Immunoassay
(0.1mg/L)

FPI (0.05 mg/L)

Radioimmunoassay

FPI (0.18 mg/L)

80 mg

28/56/56/84/112
/300 mg

666

30/60/90/300

300 mg /BID

300

Immunoenzymatic (0.3
mg/L)
FPI (0.18 mg/L)

600/300/300

80 / 300 mg

300 mg

600 mg

Dose

HPLC

FPI (0.05 mg/L)

FPI

FPI (0.025 mg/L)

Analytical Method
(LLOQ)

Jet nebulizer

Jet nebulizer
(PARI LC PLUS)
AeroDose/
PARI LC PLUS
DeVilbis UltaNeb
99/100
T-326 DPI/
PARI LC PLUS

--

X

✓

X

~

~

✓

✓

--

~

~

~

~

~

UltraNeb/
Sidestream/Pari-LC
✓

X

✓

PulmoSphere / TOBI

X

Cs(t)

X

✓

Cp(t)

X

Ultrasonic nebulizer
(Wisto Senior)
Pari LC Plus / eFlow
Nebuliser

Device

X

X

X

~

X

~

X

X

✓

✓

✓

X

X

X

✓

✓

✓
✓

✓

Exposure
Meterics

X

Deposition

Table 17 Identified TOB INH studies
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Eight identified studies wherein TOB
was INH. Tabulated key study design
elements: year of publication, number
of subjects (n), body weight (kg) age
(yrs), number of male participants,
subject disease state (Healthy, CF –
cystic Fibrosis, or other), analytical
method (LLOQ if reported), dose
strength and regiment, inhalation
device, availability of cp(t) profile, and
the availability of cs(t) profile

4.4.2. Dose Linearity for IV and INH studies

Cltot (mL/min)
BW Normalized
Cltot (ml/min/kg)
Vdss (Liter)
BW Normalized
Vdss (L/kg)
AUC (mg*min/L)
MRTsys (min)
t1/2 (min)
% Extrapolated
r2 , VI

TOB 101
105

TOB 102
96

TOB 103A
94

TOB 103B
89

TOB 104
78

1.3

1.2

1.7

1.6

1.4

18

16

16

16

18

0.230

0.201

0.284

0.289

0.314

1120
172
131
8.0%

1652
165
125
14%

1949
167
135
8.0%

6166
179
154
2.9%

5913
232
167
16%

0.9973, (✓) 0.9988, (✓) 0.9939, (✓) 0.9873, (✓) 0.9440, (✓)

Table 18 NCA results for the four selected IV studies
The NCA results of the cp(t) profiles from TOB 101 – TOB 104 are shown in
Table 18. The estimated half-lives (t1/2) for the hour studies ranged from 125 minutes to
167 minutes which was in line with reported literature values. This short half-life is
known to be a consequence of the small volume of distribution which was between 16
and 18 liters in the NCA, and clearance values approaching glomerular filtration which
range from 78 to 105 ml/min in the NCA performed in this study. When the administered
dose was corrected for bodyweight (BW), there did not appear to be a difference in CLtot
or Vdss between healthy and CF subjects as shown in Figure 14. Given that there is no
difference between CF patients and HV, the data from these studies can be pooled for
performing a dose dependence study. When comparing CLtot and Vdss as the nominal
dose is increased from 1.5 mg/kg to 10 mg/kg, there is no evidence to support nonlinear PK after IV infusion dosing within the tested dose range as shown in Figure 15.
This is further supported by the dose escalation graph with dose (on the x-axis) plotted
against AUC (on the y-axis) which had a linear model fit r2 of 0.9998 (Figure 16) and the
Log-Log plot where the exponent in the power model is 1.0898 (Figure 17). These
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results were in line with literature and supported the use of disease state and BW as
covariates to be modeled.

Figure 14 NCA CLtot and Vdss plotted against BW corrected doses for TOB 101 –
TOB 103B

Figure 15 NCA CLtot and Vdss plotted against none BW corrected doses for TOB
101 – TOB 103B
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Figure 16 Dose escalation plotting AUC with increasing dose on a linear plot with
a linear regression through the estimated AUC values.

Figure 17 Dose escalation plotting AUC with increasing dose on a log-log plot
with a power model fit to the estimated AUC values.

Similar to the IV meta-analysis, the meta-analysis incorporating plasma exposure
metrics (namely AUC and cmax) after inhalation did not show any evidence of non-dose
linearity and or any differences between HV and CF patients. Sample results from the
meta-analysis are shown in Figures 18 and 19 where the reported AUC was plotted
against the device and the calculated dose to lung respectively. A linear model and a
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power model was fit to these data points to emphasize the lack of conclusive
information suggesting non-linearity, and hence the assumption of a linear model.

Figure 18 Reported serum AUC plotted against the device dose.
Blue circles represent HV studies and red circles represent studies conducted in CF
patients.

Figure 19 Reported serum AUC plotted against the calculated lung dose (device
dose*dose to lung).
Blue circles represent HV studies and red circles represent studies conducted in CF
patients.
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4.4.3. IV Data Modeling Results
Successful fits were obtained for each of the four data sets from the three studies
(TOB 101-103). Model selection criteria was higher than 4.1, R2 values were above 0.99
for all the selected fits, correlation matrix values were all below 0.5, coefficients of
variation for each of the parameter estimates were below 30%, and the visual inspection
of the observed versus simulated values were all acceptable. A weighting factor of 1/y2
was used for all but TOB 101 which did not utilize a weighting factor in fitting the model
to the collected data. The model file for the various fits are reported in Appendix 2 as
Code 1 of this chapter along with the results of all the attempted fits (Table 1 – 4) and
the visual inspection plots for the various weighting factors (Figures 1 – 8).

4.4.4. IV MCS Optimization
No parameter space could be identified for models 1 and 2 that would have been
able to describe all the observed data. While there was a parameter space for model 1
that accurately described the observed cp(t) profiles, due to its lack of pulmonary
distribution, it was incapable of capturing the reported cs(t) profiles. On the other hand,
model 2 was able to capture the plasma concentration time profile and some of the
sputum levels, but was not able to describe the measured accumulation of the drug in
sputum after repeated IV dosing as shown in TOB 104 (Figure 9 and 10 in Appendix 2).
Model 3 was able to predict the observed data well as the observed c p(t) and cs(t)
profiles data fell within the predicted 5%-95%-percentiles. The VPC plots and visual
comparison of PK parameters from study TOB 104 are shown in Figure 20 below and
the remaining VPCs are shown in Appendix 2 as Figures 11 – 14.
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Figure 20 TOB 104 VPC and exposure metric variability comparison.
Top left -cp(t) profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax
box and whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP

Additionally, in the figure above there are box and whisper plots that compare the
reported exposure metrics to their respective simulated exposure metrics. As can be
seen there is no evidence that would support a difference between the reported and
simulated exposure metrics. A sample code used for both the optimization process as
well as for generating these plots is listed in Appendix 2 as Code 2. The numerical
comparison of the reported and simulated exposure metrics is reported in the Appendix
2 of this chapter as Tables 5 – 9. The optimized parameters for these simulations are
listed with their associated variability in Table 19. For the MCS, an n = 3000 has not
shown improvements in matching the reported cp(t) and cs(t) profiles or reported PK
parameter variability compared to an n =300. The time interval for the simulations for
TOB 101- TOB 103B was 0.5 minutes, and for TOB 104 was 1 minute. Drug amounts
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in all the model compartments as well as the cumulative amount eliminated via
pulmonary excretion and central compartment elimination are shown in Figure 21.
Based on this, the CC elimination accounts for 92% of the total elimination of the drug
from the body while pulmonary elimination accounts for the remaining 8%.

Table 19 Model 3 parameter point and variability estimates with their respective
distributions after final optimization with IV data sets
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Figure 21 Amounts of drug in various compartments of Model 3 simulated over
5760 minutes after IV administration using the final optimize IV parameters
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4.4.5. IV Sensitivity analysis results
With a single dose of 105 mg infused over 10 minutes, simulations run to 24
hours showed AUC in plasma was sensitive to changes in CLtot, kpls1, kpls2, such that a
25-fold change in these parameters resulted in -13, -1.3, -1.3-fold change respectively
in AUC. Similarly, the fold change in k12, CLtot, and k21 resulted in a -1.7, -1.5, 1.1-fold
change in cmax respectively. In addition to CLtot, which was one of the top three most
influential parameters on sputum AUC and cmax, kca resulted in a -4.6, and -5.1-fold
change to AUC and cmax respectively, and kcm resulted in a-5.4, and -4.9-fold change to
AUC and cmax respectively. Similar results were obtained after a repeated dosing
sensitivity analysis study where 105mg was administered as an IV infusion for three
consecutive days. Plasma AUC was still predominantly altered by CL tot, kpls1, and kcls1,
and cmax was no longer influenced by k21, with only CLtot and k12 leading to any notable
fold changes in cmax. The fold change elicited in each of the exposure metrics as a
response to a 25-fold change in each of the model parameter is tabulated in Table 20
for the single dose and Table 21 for the repeated dosing experiment. The resulting
plasma and sputum profiles after single dose are shown in the appendix as Figure 15 –
27 and Figures 28 – 40 for the repeated dose. The code used to perform the sensitivity
analysis is shown in the appendix under Code 3.
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Table 20 TOB SD sensitivity analysis results
Single IV dose sensitivity analysis results for IV optimized parameter space. Table
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure
metric value)) in exposure metric given a 25-fold change in the model parameter (from
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg,
Dose = 1.5mg/kg (105mg), Infusion time = 30 min, and sampling schedule from 0 to 24
hours.

Table 21 TOB RD sensitivity analysis results
Repeated IV dose sensitivity analysis results for IV optimized parameter space. Table
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure
metric value)) in exposure metric given a 25-fold change in the model parameter (from
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg,
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Dose = 1.5mg/kg/day (105mg), Infusion time = 30 min, and sampling schedule from 48
to 72 hours.
4.4.6. INH Modeling Approach #1 – #4 as Negative results
The first approach attempted to utilize the final IV optimized model parameters
and model 3 to predict cp(t) and cs(t) from INH studies (approach #1). After repeated
attempts to optimize the fraction of the dose that was deposited in the peripheral lung
(Fpd) (and by consequence, the fraction deposited in the central lung-Fcd), no value of
Fpd allowed for acceptable prediction of the observed cp(t) and cs(t) profiles. As can be
seen in Figure 73, there was an underprediction of the plasma concentrations, and an
overprediction of sputum concentrations. In the second approach, we attempted to
identify a universal parameter space that was capable of describing both the IV and INH
data sets by re-optimizing the parameters to describe both the IV and INH data sets
simultaneously (approach #2). This approach was also unsuccessful as it was not
possible to capture both plasma profiles while at the same time capturing both sputum
profiles as seen in Figure 74. Approach 1 and 2 were likely unsuccessful due to the fact
that there was very limited sputum data after repeated dosing via IV administration and
the available data was a clustered close to the LOQ.
Given that there was no identifiable parameter space that was capable of describing all
the available IV and INH data sets simultaneously, the parameter optimization was then
preformed solely on the available INH data sets from study 307. Optimization was
considered successful as it was capable of describing the cp(t) and cs(t) profiles for the
four tested doses as shown in Figure 75. However, when attempting to predict the
exposure metrics from the remaining studies, there was a systematic overprediction of
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the exposure metrics across the three remaining studies (sample case shown in table
12). This systemic overprediction resulted in approach #3 being deemed unacceptable.
In approach #4, data from across the four inhalation studies for the same device (Pari
Nebulizer) was used to optimize the parameter space. This approach resulted in a
parameter space that was able to, without bias, predict the four data sets used in the
optimization process (307A, 303A, 30A, and 309F) (Table 13) but still resulted in the
systemic overprediction of the plasma exposure metrics for the remaining studies
(Figure 20).
4.4.7. Approach #5 as successful results
Initial estimates for the fifth approach for model 3 parameter optimization were
taken from the final estimated IV parameters. Model parameters were optimized to
match predicted with observed exposure metrics, incorporating up to 40% random
variability following a log-normal distribution. Clinical PK studies with inhaled TOB (28 300 mg in HV and CF after single dose) were used as reference for this optimization.
The four studies included in the analysis provided a total of 16 data sets (either cp(t)
profiles, cs(t) profiles, plasma exposure metrics, or sputum exposure metrics). All
sixteen data sets had plasma information while 10 of the 16 had sputum information that
was utilized for validation. Across studies, doses and inhalation devices, predicted cp(t)
and cs(t) profiles (95-percentiles) included observed profiles; predicted AUC and cmax
were within ±20% on average as can be seen in Table 22 below. The accepted VPC
plots for both cp(t) and cs(t), as well as the visual comparison for the reported and
simulated PK parameters from study TOB 104 are shown in Figure 22 below and the
remaining results are shown in Appendix 2 as Figures 41 – 55. Additionally, the
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simulated exposure metric central tendency and variability was compared with those
reported in each of the publications. These comparisons are shown below in Table 23
and for the remaining studies included in Appendix 2 as Tables 10 – 25. The final
optimized parameter space that was deemed acceptable and used to generate the
various tables and figures is listed in Table 24 below. Secondary derived model
parameters that allow for a comparison between the IV and INH optimized parameters
are reported in Table 25.
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Table 22 Percent difference between the reported exposure metrics for plasma
and sputum from the four selected inhalation studies.
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Figure 22 TOB 307D VPC and exposure metric variability comparison.
Top left -cp(t) profile, top center – cs(t) profile, top right - cs AUC box and whisker plot
(WHP), bottom left – cs,max WHP, bottom center- cp AUC WHP, bottom right – cp,max
WHP

Table 23 Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 307D
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Table 24 Model 3 parameter point and variability estimates with their respective
distributions after final optimization with INH data sets
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Table 25 Model 3, secondary derived parameters based on the final optimized
parameters
4.4.8. Pulmonary Bioavailability
Across the four inhalation studies analyzed, the traditional method of evaluating
Fpul via the AUC ratio method demonstrated that the mean Fpul was 18% and ranged
from 3.6% to 31%. The calculated Finh values (based on Equation 2) for each of the
studies are shown below in Table 26. Since TOB is not orally bioavailable (Foral ~0%),
the low Fpul reflects poor absorption of deposited TOB across pulmonary epithelia.
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Study ID
307A
307B
307C
307D
303A
303B
309A
309B
309C
309D
309E
309F
302A

Calculated Fpul (%)
9.3
27
28
25
3.9
31
26
28
25
23
23
9.0
6.2

302B
302C
302D

6.8
9.4
3.6

Table 26 Calculated Finh values using AUC-ratio method with study TOB 103A as
IV reference.

Using the parameters optimized with the available IV data, and performing mass
balance execration simulation after IV administration, demonstrated that 91% of the
administered dose was eliminated from the central compartment while the remaining
9% of the dose was eliminated from the central unbound lung compartment through
mucociliary clearance. Similarly, when the parameters optimized with the available INH
data were used to perform the same IV administration simulations, 91% was eliminated
from the central compartment while 1% was eliminated via the other pathway. After INH
simulations, however, using both the final IV and INH parameter space, results were not
as similar. 93% was eliminated from the central compartment and 7% via the other
pathway after INH administration simulation using the optimized INH parameters, and
82% eliminated from the central compartment and 18% via the other pathway after INH
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administration using the optimized IV parameter space. A simulation depicting the
amount in each compartment after INH administration using the final optimized INH
parameters is shown in Figure 23 below. The cumulative amount execrated plots for the
four bioavailability simulations are reported in Appendix 2 as Figures 56 – 59.
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Figure 23 Amounts of drug in various compartments of Model 3 simulated over
5760 minutes after INH administration using the final optimize INH parameters
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4.4.9. INH Sensitivity analysis results
With a single dose of 300 mg inhaled over 10 minutes, simulations run to 12
hours showed AUC in both plasma was sensitive to changes in CLtot, kpls1, kpls2, such
that with a 25-fold change in these parameters resulted in -4.8, -3.3, 2.9-fold change
respectively in AUC. Similarly, the fold change in kca, kpls1, and kcm resulted in a 1.7, 1.5, -1.5-fold change in cmax respectively. In addition to kca, which was one of the top
three most influential parameters to sputum AUC, kcm and kpa, resulted in a -18, -1.7 and
-1.6-fold change to AUC respectively. kca, kpa and kpd resulted in a-118, -23, and 23-fold
change to sputum cmax respectively. The fold change elicited in each of the exposure
metrics as a response to a 25-fold change in each of the model parameter is tabulated
in Table 27. The resulting plasma and sputum profiles after single dose are shown in
Appendix 2 as Figure 60 – 72. The code used to perform the sensitivity analysis is
similar to that utilized for the IV sensitivity analysis shown in Appendix 2 under Code 3.
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Table 27 INH TOB sensitivity analysis results
Single INH dose sensitivity analysis results for INH optimized parameter space. Table
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure
metric value)) in exposure metric given a 25-fold change in the model parameter (from
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg,
Dose = 300mg, Inhalation time = 10 min, and sampling schedule from 0 to 12 hours.

4.5.

Discussion and Conclusions

4.5.1. Study Limitations
Confidence in the results generated by any model is highly dependent on the
data used in the development of the model. As such, the data used in the development
of a given model often needs to be critically evaluated. For the semi-PBPK model that
was developed within this work, the data that was utilized in validating the constructed
model was evaluated based on the inclusion standards described in the methods
above. Of the collected IV studies listed above in Table 16, studies TOB 105 - 108 were
86

excluded from the data analysis for four primary reasons. First, these studies did not
sample plasma concentrations frequently enough such that the reported c p(t) profiles
could not have been analyzed nor used for estimating model parameters. With
infrequent and/or insufficient plasma concentrations samples, as is the case with those
studies, parameter identifiability is challenging. Second, the analytical method was not
considered to be reliable in those four studies. The method utilized for determining the
concentration of TOB in plasma was antibiotic activity using an Agar-well diffusion
method specific to the bacteria Bacillus subtilis. This method is known to be a
nonselective method for detecting TOB, and hence the concentrations reported were
associated with a high level of variability. Third, if measured concentrations were below
the lower limits of quantitation (LLOQ), they typically were replaced with zero. This was
problematic since the reported cp(t) profile is typically a mean profile, and individual
profiles are often not included. Thus, the mean plasma concentration at a given time
point can be skewed to a lower value due to these zero replacements. Concentrations
that are more susceptible to being below LLOQ are those that at later time points occur
after drug levels have had time to decrease throughout the body due to drug
elimination. The zero substitution for concentrations below LLOQ is more so
problematic with older analytical detection methods as they typically had higher LLOQs.
Fourth, the reported mean cp(t) data from these studies often were indistinguishable
from each other given their reported variability. Using this data would lead to very poor
parameter estimation as parameter identifiability would again not be possible with such
data sets.
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Aside from evaluating the available data to determine whether or not it was acceptable
for inclusion and analysis, it is also vital to discuss the lack of availability of certain data
sets. All the identified IV studies were performed as short 10 to 60-minute infusions and
none where administered as IV bolus. Assuming an appropriate data collection
schedule was followed, and IV bolus study would have been valuable in approximating
the distribution and re-distribution parameters (k12 and k21) with certainty. This is not the
case with IV infusion studies because while the drug is still being infused, the already
administered dose will be undergoing distribution. Hence distribution and redistribution
parameters become much more difficult to estimate after an IV infusion study.
In addition to the lack of IV bolus studies, there were also no IV SD studies performed in
HV or CF patients that reported sputum data. Study TOB 104 was the only study that
reported sputum data, namely a cs(t) profile and a cmax in sputum, however this was only
performed in CF patients and there were no HV studies available. In both IV and INH
studies, there is a scarcity of repeat dose studies providing sputum concentration data.
In addition, there were no repeat dosing INH studies available in either HV or CF
patients, and while there were single dose studies in for both HV and CF patients, no
sputum data was available for HV after single does INH. The lack of available sputum
data for HV either after IV or INH administration can be explained as HV do not naturally
expectorate, naturally limiting sputum data collection. This lack of data limits the validity
of the pulmonary parameters of the model as well as the ultimate generalizability of the
model.

4.5.2. Dose linearity after IV and INH and compare with literature findings
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As can be seen in Figure 14, when the IV infused dose was corrected for
bodyweight (BW), there was no apparent difference in CL tot or Vdss between HV and CF
subjects. Given the absence of a difference, PK exposure metric data was pooled
across studies, allowing the testing of dose dependence across the IV studies. When
comparing CLtot and Vdss as the nominal dose increased from 1.5 mg/kg to 10 mg/kg,
there was no evidence to support non-linear PK after IV infusion dosing within the
tested dose range. This can be clearly observed on Figure 15 with no changes
observed in both CLtot and Vdss values as dose increased along the x-axis. Dose
independent clearance and volumes are both key defining factors of linear PK.
Furthermore, in the linear dose escalation plot shown in Figures 16 comparing the
administered dose to the NCA calculated AUC, the high r2 value of the linear model
further suggested linear pk. Additionally, when the same data was plotted on a log-log
scale as in Figure 17, and a power model was utilized for fitting the data, the coefficient
of the exponential term is close to 1.0 which would also indicate suggest linear PK. After
INH administration the same conclusions were reached after evaluating the calculated
AUC as the administer dose increased. As seen in Figure 19, AUC increased in linear
fashion as dose to lung increased. The scatter of the reported AUC on this plot is likely
due to the variability associated with the INH device, INH technique and sampling of the
data. This finding is in agreement with the literature as several authors have also
reported that TOB experience’s linear PK across a similar dose range. 15,57 Moreover,
given that there are no saturable processes (absorption, distribution, metabolism, or
elimination) involved in kinetics of TOB, it is unlikely that additional data would
contradict these results.
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4.5.3. Final IV Parameter Space
This semi-PBPK model of I.V. administered TOB with an optimized model
parameter space resulted in mechanistically plausible parameter estimates, and was
able to predict both cp(t) and cs(t) profiles from clinical PK studies with HV and CF after
single or repeated therapeutic doses. This, however, was only plausible after the
addition of the pulmonary sequestration compartments, which was singularly driven by a
repeat-dose sputum data set that clearly demonstrated TOB accumulation in sputum,
but not in plasma. Based on the final optimized parameter value, and as peripheral
compartments to the central compartment, these pulmonary sequestration
compartments appeared to be deep and high capacity compartments. It appears that
they functioned as reservoir or donor compartments maintaining sputum concentration
for the repeated dosing study validation. As can be seen in Figure 21, the amount of
drug in the peripheral and central sequestration lung compartments is among one of the
larger levels, and remains higher than most compartments for a prolonged period of
time. Previous dissertation work by Min Li has shown in-vitro evidence supporting the
idea that the lung has the capacity to sequester drug and thus maintain sputum levels
after drug administration. 24
Furthermore, the secondary derived model parameters shown in Table 25 also
show that the sequestration compartments capacity rate constants (k plsratio and kclsratio)
given the final IV parameter space were greater than 1.0. These values therefore
indicate that with respect to the central compartment, the sequestration compartments
are high capacity compartments. Based on the capacity rate constants (kpratio and kcratio),
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however, the unbound peripheral and central lung compartments are relatively lower
capacity compartments. Equilibration rate constants (the sum of the input and output
rate constant from a given compartment) help elucidate how rapidly a compartment
equilibrates with respect to adjacent compartments. Larger values denote a more rapid
equilibration, while smaller values a slower equilibration. This is best observed when
these rate constants are instead converted to half-lives. For the unbound peripheral and
central lung compartments, the equilibration half-lives were 102 and 0.77 minutes
respectively, while for the sequestration peripheral and central lung compartments both
equilibration half-lives were much longer at 1155 and 990 minutes respectively.
IV administered TOB is expected to be predominantly cleared through the total
clearance route with nearly 93% of the dose eliminated via CLtot and the remaining 7%
being eliminated through the mucociliary clearance (kcm).

4.5.4. Sensitivity analysis results for IV parameter space
After a single IV administered dose, sputum exposures were found to be
sensitive to CLtot, but insensitive to all other systemic disposition parameters; with
regards to pulmonary disposition, only mucociliary clearance and pulmonary absorption
from the central lung appeared to influence these parameters. Unlike sputum
exposures, systemic exposures are not very sensitive to PUL disposition rates.
Systemic exposures were found to be insensitive to pulmonary and systemic disposition
parameters, except CLtot. Similarly, the sensitivity analysis after repeated dosing
displayed similar results (Table 20) in comparison to single dosing (Table 21). These
results reveal that in order to maximize pulmonary concentrations after IV administration
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while minimizing systemic concentrations, an optimization process needs to occur were
CLtot should be increased while kpa and kcm should be decreased. This supports the
hypothesis listed of the study.

4.5.5. Limitation of data leading to change of IV-> INH model
As discussed above, the only study that provided sputum data after IV
administration was a repeat dose study that provided a total of four mean sputum
concentrations. The first of these four concentrations, was a non-zero pre-dose
measurement of the concentration of TOB in sputum. This single data point was the
predominate driving factor in parameter optimization and selection. It was this data point
that lead to the introduction of the deep, high capacity pulmonary sequestration
compartments. Despite this, after INH administration, there was no repeated dose
studies available to provide sputum concentration. In addition, the data obtained from
the available INH studies did not support the use of the same parameter space
optimized in the IV studies (negative results shown in Appendix 2 Figure 73) nor was
there a single parameter space that was capable of simultaneously describing both the
available IV and INH data (negative results shown in Appendix 2 Figure 74). Therefore,
a separate parameter space was required to describe the INH data.
4.5.6. Final INH Parameter space
The final parameter set (listed in Table 24) that was optimized using the available
inhalation data sets indicated that with exception to PLS, the three-other remaining
pulmonary compartments (namely, PLU, CLU, and CLS) were low capacity
compartments as suggested by their respective secondarily derived ratio parameters
92

summarized in Table 25. This can be clearly observed in the PLS plot in Figure 23 as
this plot showed that the amount of drug in PLS was notably higher than the remaining
compartments. In addition to being a higher capacity compartment, PLS also appears to
be a slowly equilibrating compartment relative to the remaining three pulmonary
compartments. This slower equilibration is evidenced by the prolonged levels in the PLS
plot mentioned above as well as a prolonged equilibration half-life of 36 min (kplssum =
0.019 min-1).
Given the available data there was no evidence of differences in the pulmonary
disposition of TOB between CF patients and HV. Inspection of the reported PK data for
each of the inhalation publications included in the analysis showed that when the same
inhalation device was used to inhale a similar dose, no differences could be observed in
plasma exposure metrics. This is clearly observed in Table 26 of Appendix 2 when
comparing TOB studies 302A and 303A, as representative studies of HV using a Pari
inhaler, with studies 302C and 307A where CF patients were using the same device to
inhale the same 300 mg dose. Sputum information was not available for comparison
between the two groups. Due to the variability associated with sputum data, even if the
data were available, it is unlikely that a difference would have been detected. Likewise,
by evaluating the same reported exposure metrics, no difference was observed
between the various inhalation devices tested in the studies. When 300 mg was inhaled
with both the Pari inhaler and the eFlow nebulizer, no difference was evident in either
HV (TOB 302A vs 302B) and CF patients (TOB 302C vs 302D). While there are known
physiological differences between CF and HV patients, the lack of data and the
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resolution of the available data sets both lead to an inability to characterize these
physiological differences.

4.5.7. Sensitivity analysis results for INH parameter space
After a single dose inhalation, sputum exposures were found to be sensitive to
kca, kpa, kcm, and kpd, but insensitive to all other systemic disposition parameters.
Systemic exposures were found to be predominantly sensitive to pulmonary disposition
parameters: kca, kpls1, kpls2, and kcm, but were insensitive to systemic disposition
parameters except CLtot. As hypothesized in Hypothesis 3.2, slowing down PUL uptake
(kca and kpa) and mucociliary clearance (kcm) would in fact increase pulmonary exposure
as characterized by AUC and cmax. In addition to this, the results also indicated that
increasing kpd, efflux in the peripheral lung, would also lead to increased pulmonary
concentrations.

4.5.8. Reconciling IV and INH parameter spaces
While there was no parameter space that was capable of simultaneously
describing the available IV and INH data, there was an identifiable parameter space to
describe the IV data, and another parameter space was identified to describe the
available INH data. In comparing Figure 21 and Figure 23, as well as the numerical
values of the secondarily derived model parameters listed in Table 25, it becomes
apparent that major differences between the IV and INH parameter sets can be
observed in the CLS compartment. While the IV parameter space indicated that this
compartment is a high capacity slowly equilibrating compartment, the INH parameter
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space specified that it is a low capacity fast equilibrating compartment. The increase in
the equilibration rate may likely be due to the route of administration. Since TOB is
being administered via INH, pulmonary concentrations will likely be much higher than
those after IV administration. Consequently, cellular sequestration may be saturated
and hence a more rapid equilibration occurs. This therefore alters the CLS from
behaving as a reservoir compartment to behaving as a pass-through compartment. The
remaining three pulmonary compartments are comparable given both parameter
spaces.
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CHAPTER 5

SEMI-PBPK MODELING OF INH CIPROFLOXIN

5.1.

Background

5.1.1. Treatment of CF with Ciprofloxacin
Discovered in 1981 as the first oral broad-spectrum antibiotic of its class,
Ciprofloxacin (CIP), a fluoroquinolone antibiotic, has since been approved by the FDA
for use in treatment of urinary tract infections, chronic bacterial prostatitis, chronic
bacterial prostatitis, lower respiratory infections, and numerous other indications.98,99 It
also has numerous off-label and investigational uses such as in the treatment of
chlamydia infections, inflammatory bowel diseases, and pelvic inflammatory disease.100–
102

CIP is known to exhibit bactericidal effects on both gram positive and gram-negative

bacteria. Pseudomonas aeruginosa, a gram-negative bacterium, is known to be
susceptible to CIP, with CIP being very potent against it with an experimental MIC50 of
0.19 mg/L and a MIC90 of 32 mg/L.103 The bactericidal action of CIP results from
inhibition of the enzymes topoisomerase II and topoisomerase IV, which are required for
bacterial DNA replication, transcription, repair, and recombination.104

96

5.1.2. Relevant Physiochemical Properties of Ciprofloxacin
Often deemed as a small molecular weight compound, CIP has molecular weight
of 331.3 grams per mole. Additionally, it is moderately lipophilic with an experimentally
obtained partition coefficient log(P) value of -0.13 and is categorized as a sparingly
soluble compound according to the USP with a solubility than 40 mg/mL at a pH of 4. At
a concentration of 50 µm in the apical compartment, CIP has shown to have an
apparent permeability (papp) of 2.99·10-6 ± 2.92·10-7 cm/s in the Caco-2 cell line.105
When a similar study was conducted in a Calu-3 cell line with concentrations of either
10 or 20 µM, results were similar, indicating a larger Papp of 3.52·10-4 cm/s. Based on its
experimentally determined solubility and permeability, CIP was classified as a BCS
class IV compound.106 Additionally, it was noted that while 81% of the CIP was present
at the basolateral compartment at the end of the study when the initial concentration
was 10 µM, only 48% was recovered in the basolateral compartment when 20 µM was
tested.105 This indicate the possibility of transporter involvement, however, the authors
noted that further studies needed to be conducted. When the permeability of CIP was
compared with the permeability of fluorescein (a low permeability, paracellular marker)
in studies performed in the small intestine of rats, both compounds had similar
permeability values.107 This led the authors to conclude that CIP is a low permeability
drug. The same authors also tested the permeability of CIP in the same system with
benzbromarone (a MRP2 inhibitor), verapamil (a Pgp/MRP2 inhibitor) and quinidine (an
OCT1 inhibitor). There was no difference in the permeability of CIP when tested alone
versus when tested with any of these inhibitors. Accordingly, the authors concluded that
CIP was not a substrate for any of the tested transporters. However, Papp of CIP from
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the serosal to the mucosal was studied alone vs in presence of quinidine, a significant
difference was found suggesting the involvement of an efflux protein in CIP secretion.
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5.1.3. Summary of Known PK/ADME Properties of Ciprofloxacin
With a reported plasma protein binding 20-40%¸ CIP still exhibits extensive
distribution throughout the body with a Vdss (after a 100 mg IV infusion dose in HV) of
2.64 ± 0.5 L/kg and a similar volume of 2.54 ±1.2 L/kg in CF patients.13,104,108 Total
clearance values (CLtot) are also calculated after the same dosing regimens in those
subjects. For HV, the reported CLtot value was 0.51 ± 0.12 L/kg/hr which was slightly
lower than that of CF patients 0.61 ± 0.21 L/kg/hr, with renal clearance accounting for
53% of the total clearance in HV and 62% in CF patients.78 After oral administration of
radiolabeled CIP, 15% of the dose was detected in feces, and an additional 15% of the
dose was detected in the form of four metabolites eliminated in urine. Some authors
have shown that 15% of an orally administered dose is recovered in feces, while others
have indicated that recovery may be as high as 35%.104,109 Both authors, however, have
indicated that this may likely be due to biliary clearance or transintestinal elimination. In
their Clinical Pharmacology and Biopharmaceutics review of ®Cipro, the FDA identified
body weight, creatinine clearance, and the presence of CF in a patient, as significant
covariates in the Pop-PK modeling of CIP.110

5.2.

Objectives

The major objectives for this chapter were to:
a) Develop and validate semi-PBPK model for CIP after the INH;
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b) Determine sensitivity of plasma and sputum exposure to model parameters;
c) Investigate route-dependent elimination pathways.

5.3.

Methods

5.3.1. Summary and Discussion of final IV, PO, and INH studies identified
Out of the nine identified CIP IV studies, one study was eliminated from analysis
inclusion because of the non-selective, poorly sensitive microbiological assay utilized for
plasma concentrations. 111 Older microbiological assays are known to have poor
selectivity and have been shown to overpredict concentrations in plasma, and hence
this study was not included for analysis. 112 There was also another study that did not
report individual or a mean level plasma concentration time profile, and hence was
excluded from analysis. 113
Twelve studies were identified where CIP was administered orally to both HV and
CF patients. Two of those studies were excluded due to the use of the aforementioned
unreliable microbiological assay for plasma concentration analysis. One study was not
included in analysis as it only reported data from a single subject. Lastly, the study by
Michael et al. was also excluded from analysis as the reported exposure metrics, and
cp(t) profiles were inconsistent with each other and with the text.
All available and collected Ciprofloxacin studies satisfied inclusion criteria and hence
were utilized and all the performed analysis and modeling within this study. Studies
involving patients on Dialysis, or patients suffering from other medical conditions were
not collected.
5.3.2. Comparative NCA Results
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NCA was performed on the digitized cp(t) profiles for each of the individual
studies across the dosing routes (IV, PO, and INH). To ensure dose-linearity, AUC vs
Dose and log(AUC) vs log(Dose) plots were inspected. For IV studies, CLtot, CLnonren,
CLren, and Vdss were plotted against administered dose, age, body weight, and disease
state. This was done in an attempt to see if change in any of these potential covariates
led to a significant change in any of the estimated PK parameters. Additionally, since it
is known that CF patients have a lower BW on average relative to HV (due to their
malnutrition), the four PK parameters were also corrected for body weight and plotted
against disease state (i.e., HV vs CF patients).
5.3.3. Semi-PBPK Models Tested
An open two-compartment body model was used to fit the collected IV data. The
model incorporated loss from the central compartment via CLtot. Initial estimates for this
model were estimated obtained from the previously discussed work with TOB. Three
separate fits were performed: 1) with no weighting factor applied, 2) with a 1/y weighting
factor, and lastly, 3) with a 1/y2 weighting factor. Parameter selection was based on the
highest r2, MSC, as well as parameter certainty (lowest CV’s for the parameters). Model
parameter estimates from the individual studies were averaged and used as the initial
estimate for the MCS. MCS were performed to optimize the parameter space to
describe all the observed cp(t) profiles as well as minimize the percent difference for the
individual exposure metrics. Parameter variability was also optimized during the MCS.
CV for each of the parameters was increased in increments of 5% until the modelprecited SD for the exposure metrics from each of the individual studies were
comparable to those that are reported. In addition, CVs were also optimized such that
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the majority of the reported cp(t) profiles were within the 5th-95th percentiles of the
simulated cp(t) profiles.
Final optimized systemic disposition parameters identified using the IV data sets
were fixed, and the model was expanded to include a GI compartment. Initial estimates
for Foral and kga were obtained from the NCA estimation. Alternatively, MCS were
performed with this expanded oral administration model to optimize the central tendency
and the distribution values for the oral absorption parameters.
INH studies were grouped by dose and disease state during parameter
optimization and were individually simulated, once the final parameter space was
obtained. Specifically, cp(t) data from CIP 301A and CIP 303A were averaged for each
of the time points for which both studies reported a concentration. Both those studies
were conducted in HV, and a dose of 32.5 mg was inhaled through the same device.
Data from CIP 302A and CIP 304A, as well as CIP 302B and CIP 304B were also
combined as both sets of studies were conducted in CF patients where a dose of 32.5
mg and 65 mg was inhaled respectively. Data was combined due to the observed
variability across cp(t) profiles for studies at the tested the same dose in the same
patient population, suggesting considerable inter-study variation.
There was no evidence of pulmonary sequestration for CIP, and hence the
pulmonary sequestration rate constants kpls1, kpls2, kcls1, and kcls2 were all set to a value
of 10,000, ie virtually instantaneous transfer. This modification to inhalation Model 3 in
essence converts the sequestration compartment to high-throughput transfer
compartments. MCS were performed in an attempt to optimize the six remaining
pulmonary disposition parameters (kpa, kca, kpd, kcd, kpm, and kcm) with the systemic
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disposition and oral parameter fixed at their previously optimized values. No acceptable
parameter space was identified, primarily due to the inability to simultaneously simulate
the rapid distribution phase as well as the terminal phase specifically in CF data sets
after inhalation.
Therefore, a global re-optimization with IV, PO, and INH data sets was performed
to simultaneously optimize the systemic disposition, oral absorption, and pulmonary
disposition parameters. It was necessary to introduce a disease state specific covariate
model on each of the systemic disposition and oral absorption parameters.
5.3.4. Parameter Sensitivity Analysis
As an indicator of how sensitive plasma and sputum exposures are to the final
model parameters, a sensitivity analysis was performed with the final parameter
estimates after IV, PO, and INH dosing. BW was set to either 70 kg or 55 kg for HV and
CF patients, respectively. For the IV sensitivity analysis, a dose of 300 mg was infused
over 10 minutes, for the PO sensitivity analysis a dose of 100 mg was administered,
and for the INH sensitivity analysis a dose of 32.5 mg was inhaled. The models utilized
for parameter optimization were the same models utilized for the sensitivity analysis
(i.e., open two compartment body model, open two compartment body model with GI
compartment, and the full inhalation semi-PBPK model 3). Variability across the
parameters was disabled by setting all the CV’s to zero, systemic and oral absorption
parameter values were set to either one-fifth or five times the mean optimized values to
cover a 25-fold range around the point estimate. Pulmonary uptake, distribution and
redistribution parameters were set to one-tenth or ten-times the mean optimized values
to cover a 100-fold range around the point estimate. Simulations were performed for up
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to 24hrs. AUC and cmax values in plasma and sputum were calculated at each of the
extremes. The fold change was calculated as the ratio between the maximum and
minimum values of the simulated plasma AUC multiplied by a negative one if the
maximum value was obtained from when the parameter being tested was multiplied by
1/5. This was also done for plasma cmax, as well as sputum AUC and cmax. Both cp(t),
and cs(t) profiles were generated for comparison. The top three parameters to cause the
largest-fold change in the four-exposure metrics were determined at the end of the
sensitivity analysis. This sensitivity analysis would then allow for a better understanding
as to how to increase sputum concentrations or how to minimize systemic exposure.

5.3.5. Assessment of Pulmonary Kinetics
To gain insight of pulmonary disposition, and the contribution of pulmonary
exposure on systemic exposure, pulmonary kinetics were investigated. The total fraction
of the dose that was absorbed into systemic circulation was denoted as FINH and was
calculated as the sum of the Fpul and Foral as seen in Equation 12.

FINH *(DtL+ DtGI) = Fpul*DtL + Foral* DtGI
Equation 12 Calculation of bioavailability after inhalation with and without charcoal
block data.

The NCA estimate of FINH can also be described as the product of AUCINH and
𝐼𝑉
𝐶𝑙𝑡𝑜𝑡
divided by the total dose as in Equation 13. This calculation assumes that charcoal
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block does not affect CLtot, however it does assume that the concurrent administration
of charcoal black is able to prevent any oral absorption (essentially making Foral = 0).

𝐼𝑉
𝐴𝑈𝐶𝐼𝑁𝐻 ∗𝐶𝑙𝑡𝑜𝑡

𝐷𝑡𝐿+𝐷𝑡𝐺𝐼

*(DtL+ DtGI) = Fpul*DtL + Foral* DtGI

Equation 13 NCA method for adding Fpul and Foral to determine Finh

The availability of CIP cp(t) profiles after CIP inhalation with co-administration of
charcoal allows for the derivation of Equation 14 by dividing Equation 13 utilizing the no
charcoal block data by the same equation with the charcoal data set. The result is
shown in 5.3.5.3, is a NCA approach to estimating pulmonary bioavailability (Fpul).

𝐹

∗𝐷𝑡𝐺𝐼

𝑜𝑟𝑎𝑙
𝐹𝑝𝑢𝑙 = (𝐴𝑈𝐶 𝑅𝑎𝑡𝑖𝑜
−1)∗𝐷𝑡𝐿

Equation 14 Explicit Solution for pulmonary bioavailability after inhalation calculated
using with and without charcoal block data

Equation 15 below describes the MRTINH as the weighted sum of pulmonary
absorption and oral absorption in addition to the MRTsys. AUC Ratio referrers to the ratio
of the AUC obtained from the Charcoal study divided by the AUC obtained from the
data from when charcoal was not administered. Mean pulmonary absorption time from
the pulmonary compartments into systemic circulation was therefore calculated using a
modified solution of Equation 15.
𝐷𝑡𝐿

𝐷𝑡𝐺𝐼

𝑀𝑅𝑇𝐼𝑁𝐻 = 𝑀𝐴𝑇𝑝𝑢𝑙 (𝐷𝑡𝐺𝐼+𝐷𝑡𝐿) + 𝑀𝐴𝑇𝑃𝑂 (𝐷𝑡𝐺𝐼+𝐷𝑡𝐿) + 𝑀𝑅𝑇𝑠𝑦𝑠
Equation 15 Calculating mean residency time after INH
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5.3.6. Assessment of Mass Balance
The cumulative drug eliminated systemically, and via GI Tract (not absorbed and
pulmonary transfer via mucociliary clearance) was investigated after IV, PO, and INH
administration. These mass balance excretion simulations were performed up to 48
hours with a resolution of 10 minutes. These simulations were performed to understand
the contribution of each elimination pathway to total drug elimination since the
pulmonary model allows for transfer of CIP into the GI tract.
5.3.7. Software
For the included studies, captured cp(t) and cs(t) profiles were digitized using the
GetData© Graph Digitizer Version 2.24 software. NCA was performed on the plasma
concentration data. Model parameter fitting was performed in Scientist v. 3.0.0.215
Build: 1334 using a stiff integrator. MCS and data visualization was performed in Rstudio using the deSolve tool package with lsoda switching automatically between stiff
and non-stiff methods to handle the ordinary differential equations associated with the
model.

5.4.

Results

5.4.1. Summary of Final IV, PO, and INH Studies Identified
A search of the literature on PubMed and Google Scholar resulted in the
identification of 9 publications where CIP was administered as IV infusion. These
publications and their respective key study design elements are listed in Table
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28.13,111,112,114–118 Two studies were excluded from the analysis, specifically CIP 103 and
CIP 109. The remaining seven studies enrolled between 6 and 32 volunteers including
both HV and CF patients. Doses ranged from 50 mg to 400 mg and were infused over
the course of 5 to 60 minutes to both HV and CF patients. These studies only provided
cp(t) profiles, and no cs(t) profiles were available after IV administration.
Six of the included IV studies also included PO administration data, and another five
studies were identified where CIP was administered orally. Only one of the five PO
administration studies was acceptable. As such a total of 7 studies were included in the
PO analysis and resulted in 12 cp(t) profiles (2 of which were from CF patients). The
administered doses ranged from 100 mg to 1020 mg. All but one study specified that
the administrated formulation was a tablet, and for the study in which the formulation
was not specified, it was assumed to be as a tablet. The included PO administration
studies along with the relevant study design parameters are tabulated in Table 29.
13,108,112,115,116,118,119

A total of 4 studies were identified where CIP was inhaled either HV or CF
patients (n=2 for both). These studies and their key study design elements, such as
number of subjects (n), mean body weight, mean age, etc., are listed in Table 30.120–123
Additionally, the availability of cp(t), cs(t), exposure metrics for either plasma or sputum,
and availability of deposition data is also tabulated. All four studies were suitable for
analysis as they satisfied the inclusion criteria. Only one device was tested in these four
studies, and only two doses were tested (32.5 mg or 65 mg). The available date from
these studies included 8 cp(t) profiles and matching exposure metrics, as well as 2 cs(t)
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profiles. The Novartis' T-326 DPI was the inhalation device utilized in this study, for
which the deposition data was also reported in literature.
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HV

CF

HV

6

CIP 104

Body weight
(kg)
Cp(t) Profile
Cs(t) Profile

Age (years)

Assay method

✔
X

✔
X

✔
✔

75 ± 11

29 ± 9

67 (52 - 80)

30 (22 - 35)

48.17 ± 5.55

20.67 ± 3

HPLC/Fluorometric Detection HPLC/Fluorometric Detection
(0.005 mg/L)
(0.01 mg/L)

HPLC /Fluorometric
Detection
(0.01 mg/L)

IV: 50, 100, 200 mg as a (15,
IV: 100as a 6 min infusions
15, 20 min) infusions
PO: 100, 250, 500, 1000 mg
PO: 100, 250, 500, 750 mg

32

9

IV: 200 mg infusion
PO: 750 mg

CIP 102

CIP 101

IV: 300, and 400 as 60 min
infusions
PO: 500, and 750 mg

HV

12

CIP 105

X

✔

73.0 ± 6.7

27.4 ± 4.3

HPLC /Fluorometric
Detection
(0.025 mg/L)
16, 20, 26, 35, 45, 60, 75,
90, 120, 135, 150, 180, 240,
PK Sampling 15, 30, 45, 60, 90, 120, 180,
6, 14, 22, 35, 50, 65, 95,125,
90, 105, 120, 135, 195, 255,
300, 360, 420, 480, 660,
240,
360,
480,
600,
720
185,
245,
365,
485,
605,
725
(min)
375, 495, 615, 735
780, 1020, 1260, 1500

Dose Strength

Study
Identifier
n
Subject
Disease State

X

✔

82 (73 - 96)

(22 - 37)

105, 165, 225, 285, 345,
420, 495, 672, 1260, 1500

HPLC /Fluorometric
Detection
(0.01 mg/L)

IV: 400 as 60 min infusions
PO: 500 mg

HV

8

CIP 106

IV: HV = 4mg/kg CF=6mg/kg
as 20min infusion
PO: 15 mg/kg

HV, CF

5, 12

CIP 108

X

✔

NA

60, 75, 90, 120, 135, 150,
180, 240, 300, 420, 540,
660, 780, 1020, 1500
Young = 18 - 40
Elderly >65

X

✔

HV = 68 (62-73)
CF = 58 (41-77)

HV = 27 (21-31)
CF = 21 (16 - 28)

25, 30, 35, 50, 65, 80, 110,
140, 200, 260, 380, 500, 740

HPLC/Fluorometric Detection HPLC/Fluorometric Detection
(0.05 mg/L)
(0.01 mg/L)

IV: 400 as 60 min infusions
PO: 500 mg

HV

24

CIP 107

Table 28 Identified IV CIP studies

Seven included studies wherein CIP was
administered IV. Tabulated key study design
elements: number of subjects (n), subject
disease state (HV - Healthy, CF – cystic Fibrosis,
or other), dose regimen, bioanalytical method,
sampling schedule, age (yrs), body weight,
availability of cp(t) profile, and the availability of
cs(t) profile

108

20.67 ± 3

Age (years)

HV

Tablet

Tablet
HPLC /Fluorometric
Detection
(0.01 mg/L)

IV: 300, and 400 as 60 min
infusions
PO: 500 mg

HV

12

105

Body weight
(kg)
Cp(t) Profile
Cs(t) Profile
✔
X

67 (52 - 80)
✔
X

✔

✔

75 ± 11

29 ± 9

48.17 ± 5.55

30 (22 - 35)

X

✔

73.0 ± 6.7

27.4 ± 4.3

Tablet
HPLC /Fluorometric
Assay
HPLC/Fluorometric Detection HPLC/Fluorometric Detection
Detection
(0.005 mg/L)
(0.01 mg/L)
method
(0.025 mg/L)
16, 20, 26, 35, 45, 60, 75,
90, 120, 135, 150, 180, 240,
PK Sampling 15, 30, 45, 60, 90, 120, 180,
6, 14, 22, 35, 50, 65, 95,125,
90, 105, 120, 135, 195, 255,
300, 360, 420, 480, 660,
240, 360, 480, 600, 720
185, 245, 365, 485, 605, 725
(min)
375, 495, 615, 735
780, 1020, 1260, 1500

NA

Formulation

HV

CF

6

104

IV: 50, 100, 200 mg as a (15,
IV: 100as a 6 min infusions
15, 20 min) infusions
PO: 250 mg
PO: 100, 250, 500, 750 mg

32

9

IV: 200 mg infusion
PO: 750 mg

102

101

Dose Strength

Study
Identifier
n
Subject
Disease State

X

✔

82 (73 - 96)

(22 - 37)

Tablet

PO: 500 mg Q8H

HV, CF

12, 12

204

X

✔

HV = 68 (62-73)
CF = 58 (41-77)

HV = 27 (21-31)
CF = 21 (16 - 28)

X

✔

HV = 62 ± 7.0
CF = 52 ± 9.6

0, 15 ,30, 45, 60, 90, 120,
150, 180, 240, 300, 360,
480, 600
HV = 22.3 ± 2.0
CF = 20.5 ± 1.8

HPLC/Fluorometric Detection HPLC/Fluorometric Detection
(0.01 mg/L)
(0.01 mg/L)

Tablet

IV: HV = 4mg/kg CF=6mg/kg
as 20min infusion
PO: 15 mg/kg

HV, CF

5, 12

108

105, 165, 225, 285, 345,
25, 30, 35, 50, 65, 80, 110,
420, 495, 672, 1260, 1500 140, 200, 260, 380, 500, 740

Tablet
HPLC /Fluorometric
Detection
(0.01 mg/L)

IV: 400 as 60 min infusions
PO: 500, 750 mg

HV

8
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Table 29 Identified PO CIP studies

Seven included studies wherein CIP was
administered PO. Tabulated key study design
elements: number of subjects (n), subject
disease state (HV - Healthy, CF – cystic
Fibrosis, or other), dose regimen,
bioanalytical method, sampling schedule, age
(yrs), body weight, availability of cp(t) profile,
and the availability of cs(t) profile
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Study
Identifier
n
Subject
Disease State

301

302

303

304

6

6

12

6

HV

CF

HV

CF

Dose Strength

32.5 mg

32.5, 65 mg

32.5 mg

32.5, and 65 mg qd
32.5 mg BID

Device
Assay
method

Novartis' T-326 DPI

Novartis' T-326 DPI

Novartis' T-326 DPI

Novartis' T-326 DPI

HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L)
0.25, 0.5, 0.75, 1.0, 1.5, 2.0,

0, 0.083, 0.25, 0.5, 0.75,1,

32.8 (27-42)

31.5 (21-39)
26.8 (20-39)

34.8 (21-52)

31 (19 - 40), 31 (20-39),
26.8 (19-40)

80.2 (13.3)

58.5 (10.4)
64.5 (11.8)

NA

58.3 (10.7), 59.5 (13.1),
63.8 (5.7)

✔

✔

✔

✔

X

✔

X

(Patient level)

PK Sampling
0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 0, 0.083, 0.25, 0.75, 1, 1.5, 2,
2.5, 3.0, 4.0, 6.0, 8.0, 12, 16, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16,
8, 12, and24 hr
3, 4, 6, 8, 12, and 16 hrs
(min)
24, 36 and 48 hrs
24, 36, and 48 hrs
Age (years)
Body weight
(kg)
Cp(t) Profile
Cs(t) Profile

Table 30 Identified INH CIP studies
Four included studies wherein CIP was administered via INH. Tabulated key study
design elements: number of subjects (n), subject disease state (HV - Healthy, CF –
cystic Fibrosis, or other), dose regimen, bioanalytical method, sampling schedule, age
(yrs), body weight, availability of cp(t) profile, and the availability of cs(t) profile

5.4.2. Assessment of PK Dose-Proportionality
NCA was performed on the 12 individual data sets obtained from the seven
included studies. Visual inspection for each of the log-linear regression of the terminal
slope used in estimating λ were acceptable, R2 values were all larger than 0.9645, and
the AUC percent extrapolated did not exceed 10% for each of the individual data sets
analyzed. The estimated PK parameters are tabulated in Table 31.
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101A

102A

102B

102C

104A

105A

105B

106A

107A

107C

108A

108B

579

803

737

844

678

327

436

270

424

316

643

467

12.07

12.0

11.0

12.6

9.0

4.5

6.0

3.3

11.09

6.87

96

206

196

216

148

77

102

85

100

74

125

90

2.002

3.073

2.930

3.226

1.974

1.048

1.397

1.042

2.162

1.320

345

62

136

237

147

918

918

1480

942

1267

541

582

MRTsys (min)

166

256

266

256

218

234

234

316

236

234

195

192

t1/2 (min)

153

225

230

230

229

228

228

293

226

235

180

191

3.3%

8.4%

9.2%

8.3%

7.5%

7.0%

7.0%

1.6%

3.4%

3.7%

4.8%

5.2%

Cl tot (mL/min)
BW Normalized Cl tot
(ml/min/kg)
Vdss (Liter)
BW Normalized Vdss
Non-Compartmental (L/kg)
Analysis
AUC (mg*min/L)

% Extrapolated
VI

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

r2

0.9862

0.9993

0.9983

0.9966

0.9972

0.9946

0.9946

0.9645

0.9978

0.9964

0.9872

0.9966

Table 31 NCA estimated PK parameters for each of the individual data sets from
the seven included studies. (CIP IV administration)
Inspection of the AUC vs IV dose plotted on a linear scale as well as on a log-log
plot did not provide any evidence of deviation from linear PK after IV administration.
When a linear and a power model was fit to both plots respectively, the resulting R 2
value was 0.851 and the exponential coefficient of 1.44. These plots are shown in
Figure 24.

Figure 24 CIP IV dose escalation plots
IV infusion dose dependence plotting AUC with increasing IV dose on a linear plot with
a linear regression through the estimated AUC values (left plot), and on a log-log plot
with a power model fit to the estimated AUC values (right plot).

The same analysis was performed with the available data after PO
administration. When a linear and a power model was fit to both plots respectively, the
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resulting R2 value was 0.854 and the exponential coefficient of 1.05. These plots are
shown in Figure 25. Additionally, a linear model was fit to PO dose vs cmax data set, and
the resulting R2 was 0.82. The data and linear fit model are shown in Figure 26 below.

Figure 25 CIP PO dose escalation plots
PO dose dependence plotting AUC with increasing PO dose on a linear plot with a
linear regression through the estimated AUC values (left plot), and on a log-log plot with
a power model fit to the estimated AUC values (right plot). Blue dots indicate data
reported for HV while orange dots indicate data reported for CF patients.

Figure 26 CIP cmax with increase PO dose
PO dose escalation plotting cmax with increasing PO dose on a linear plot with a linear
regression through the estimated cmax values (left plot). Blue dots indicate data reported
for HV while orange dots indicate data reported for CF patients.

For the available data after INH, the analysis was performed on the total dose
that was deposited in the body. That deposited dose was defined as the sum of the
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dose deposited in the lungs and the dose deposited in the GI tract. When a linear and a
power model was fit to both plots respectively, the resulting R2 value was 0.7125 and
the exponential coefficient of 1.08. These plots are shown in Figure 27. Additionally, a
linear model was fit to inhaled dose vs cmax data set, and the resulting R2 was 0.68. The
data and linear fit model are shown in Figure 28 below. As such, there was no evidence
of nonlinearity.

Figure 27 CIP INH dose escalation plots
Pulmonary deposition dose dependence plotting AUC with increasing total deposited
dose in the lungs and the GI on a linear plot with a linear regression through the
estimated AUC values (left plot), and on a log-log plot with a power model fit to the
estimated AUC values (right plot). Blue dots indicate data reported for HV while orange
dots indicate data reported for CF patients.
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Figure 28 CIP cmax with increase INH dose
INH dose escalation plotting cmax with increasing INH dose on a linear plot with a linear
regression through the estimated cmax values (left plot). Blue dots indicate data reported
for HV while orange dots indicate data reported for CF patients.

Overall, there is no evidence of deviation from dose-proportional PK after IV, PO,
and INH administration.
5.4.3. Pulmonary Bioavailability
Across the four inhalation studies analyzed, the Fpul via the AUC ratio method
demonstrated discussed above ranged from 11% to 76%. Study 303B was the study
where CIP was co-administered with charcoal. The average Fpul for HV was 46% while
the average for CF patients was 34%. It is of note however, that only two studies were
available with data for HV. Similarly, the average MAT pul was 593 min for HV, and 268
minutes for CF patients. The individual values for each of the studies in tabulated below
in Table 32.
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MATpul (min) kinh (min-1)

Study

Fpul (%)

301A

17

678

0.003

302A

22

196

0.012

302B

36

286

0.007

303A

76

508

0.005

303B

46

377

0.005

304A

21

305

0.010

304B

78

338

0.008

304C

11

213

0.020

Table 32 CIP INH NCA analysis
Calculated Fpul values using NCA estimates values and CIP 303B as the charcoal
reference. MATpul also used NCA estimates from IV and PO studies as a reference.

5.4.4. PK Covariate Exploration
CLtot, CLnonren, CLren, and Vdss were plotted against administered dose, age, body
weight, and disease state. Disease state appeared to be the only covariate that may be
related to the PK parameters. For HV, both Vdss and CLnonren were 129 L and 309
ml/min respectively which were notably larger than those for CF; 111 L and 207 mL/min,
respectively. However, the opposite was try for CLtot and CLren with CF patients having
values of 611 mL/min and 381 mL/min, respectively, while HV had a CLtot value of 530
mL/min and a CLren values of 279 mL/min. These comparisons are visually represented
in Figures 29 through 32 below. When each of the PK parameters were body weight
normalized and compared across disease state, the difference was magnified.
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Figure 29 Comparison between NCA and model optimized Vdss
Vdss obtained through NCA plotted against disease state for individual data sets within
studies. Blue dots resemble individual studies while red lines represent model optimized
values.

Figure 30 Comparison between NCA and model optimized CLtot
CLtot obtained through NCA plotted against disease state for individual data sets within
studies. Blue dots resemble individual studies while red lines represent model optimized
values.
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Figure 31 Comparison between NCA and model optimized CLren
CLren obtained through NCA plotted against disease state for individual data sets within
studies. Blue dots resemble individual studies while red lines represent model optimized
values.

Figure 32 Comparison between NCA and model optimized CLnonren
CLnonren obtained through NCA plotted against the disease state for individual data sets
within studies. Blue dots resemble individual studies while red lines represent model
optimized values.
For PO studies, exploratory plots of Foral, MATPO, and kga vs dose, age, body
weight, and disease state were inspected to determine if there were covariates for those
PK parameters. Similar to the data shown for the IV studies, the PO PK parameters
appeared to be related to BW. Foral MATpo, and kga were 56%, 53 min, and 0.028 min-1,
respectively for HV, while 78%, 95 min, and 0.011 min-1 for CF patients, respectively.
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These three PK parameters are plotted against the disease state in Figures 33, 34, and
35 respectively.

Figure 33 Comparison between NCA and model optimized Foral
Foral obtained through NCA plotted against disease state for individual data sets within
studies. Blue dots resemble individual studies while red lines represent model optimized
values.

Figure 34 Comparison of MATPO between HV and CF patients
MATpo obtained through NCA plotted against disease state for individual data sets
within studies. Blue dots resemble individual studies.
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Figure 35 Comparison between NCA and model optimized kga
kga obtained through NCA plotted against disease state for individual data sets within
studies. Blue dots resemble individual studies while red lines represent model optimized
values.

5.4.5. Modeling of IV Data
Successful fits were obtained for each of the twelve data sets from the seven studies.
MSC values are higher than 4.9, R2 values were above 0.9950 for all the selected fits,
correlation matrix values were all below 0.5, coefficients of variation for each of the
parameter estimates were below 30%, and the visual inspection of the observed versus
simulated values were all acceptable. Weighting factor varied from data set to data set
and was selected based on the weight factor that resulted in the most acceptable
results. Table 33 shows the resulting parameter values based on the fits produced by
the individual data sets. The model file for the various fits are reported in Appendix 3.
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Two Compartment
Model Paramter
Estimates

101A

102A

102B

102C

104A

105A

105B

106A

107A

107C

108A

Vdss (L)

139

238

221

250

105

149

137

58

119

101

100

72

Vo (L)

36.13

63.36

67.74

98.67

25.31

32.09

30.91

14.92

24.72

21.46

35.38

10.56

k12 (min-1)

0.031

0.055

0.039

0.025

0.076

0.064

0.047

0.010

0.042

0.046

0.052

0.087

k21 (min-1)

0.011

0.020

0.017

0.016

0.024

0.018

0.014

0.003

0.011

0.012

0.029

0.015

607

871

791

915

900

768

597

205

536

432

719

496

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

r
MSC

0.9979

0.9951

0.9973

0.9964

0.9978

0.9988

0.9974

0.9993

0.9983

0.9972

0.9991

0.9996

5.0

5.0

5.5

5.5

5.1

5.1

4.9

5.4

5.7

5.1

5.5

6.7

Vo CV

3.3

14.0

8.2

10.4

2.9

10.9

10.1

21.3

4.9

0.0

8.4

3.0

k12 CV

9.7

19

14

21

9

18

16

9

9

14

12

4

k21 CV

18

8.4

6.8

11.5

15.8

10.6

9.7

12.2

6.9

9.1

6.1

6.2

Cl tot CV

10

2.2

1.6

2.0

9.4

3.7

2.7

6.2

2.1

2.8

3.8

4.3

Cl tot (mL*min-1)
Visual inspection
2

Two Compartment
Model Validation
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Table 33 NCA results for the seven selected CIP IV studies
Two compartment model parameter estimates and goodness of fit validation criteria
results for each of the twelve data sets obtained from the final seven included IV
studies.

Global MCS across studies and across dosing routes resulted in an acceptable
parameter space that described observed cp(t) profiles and exposure metrics after IV
administration. The five systemic disposition parameters were optimized with a binary
disease state covariate model for HV or CF following a normal distribution. For each
disease state, there was an optimized central tendency (mean) and a variation (CV) as
shown in Table 34. Optimized parameter values indicate HV have lower CLren (315
mL/min) as compared to CF (425 mL/min), however, the optimized CLnonren was faster
(315 mL/min) compared with the CF patients (225 mL/min). k12 and k21 were both faster
for CF patients than for HV; 0.050 and 0.020 min-1 respectively, and 0.025 and 0.015
min-1 respectively. Lastly, HV had a notably higher V0 (75 L) than the optimized V0
value for CF patients (20 L). With exception of k12 and k21 for HV, which followed a
normal distribution with a 25% CV, all other systemic disposition parameters followed a
normal distribution with a 20% CV.
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Table 34 Final optimized systemic disposition model parameters for CIP with
specified underlying covariate models and distributions

Table 35 indicates the acceptability of the VI of the cp(t) profiles as well as the
percent difference for the exposure metrics for each of the data sets. The predicted
AUC was on average 7.9% lower than the reported AUC, with a 12% standard
deviation. Additionally, predicted SD for each of the individual studies were below the
reported SD in 10 out of 12 of the analyzed data sets. Sample results of the VI of the
cp(t) profile can be seen in Figure 36 for study CIP 104A where 100 mg was IV infused
in HV. The remaining VI are included in Appendix 3.
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Table 35 Predicted vs reported AUC exposure metrics for individual analyzed IV
data sets using MCS approach

Figure 36 CIP 104 cp(t) VPC after a 100 mg IV dose in HV
5.4.6. Modeling of PO Data
Global MCS across studies and across dosing routes resulted in an acceptable
parameter space that described observed cp(t) profiles and exposure metrics after PO
administration. Both oral absorption parameters were optimized with a binary disease
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state covariate model for HV or CF following a normal distribution. For each disease
state, there was an optimized central tendency (mean) and a variation (CV) as shown in
Table 36. Foral for HV was optimized to mean a point estimate of 73% with a 35% CV,
and 85% with a 30% CV for CF. kga was optimized to 0.020 min-1 with a 10% CV for HV,
and 0.011 min-1 with a CV of 50% for CF patients.

Table 36 Final optimized oral absorption model parameters for CIP with specified
underlying covariate models and distributions

Table 37 indicates the acceptability of the VI of the cp(t) profiles as well as the
percent difference for the exposure metrics for each of the PO data sets. The predicted
AUC was on average 0.12% lower than the reported AUC, with a 17% standard
deviation. Additionally, there was, on average an underprediction in cmax by 13% with a
15% SD. The predicted SD for both AUC and cmax for each of the individual data sets
was numerically similar for all but three data sets where the predicted SD was +50%
larger than the reported SD. Sample results of the VI of the cp(t) profile can be seen in
Figure 37 for study CIP 204B where 500 mg was orally administered in HV. The
remaining VI are included in Appendix 3.
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Table 37 Predicted vs reported AUC exposure metrics for individual analyzed PO
data sets using MCS approach

Figure 37 CIP 204B cp(t) VPC after a 500 mg PO dose in HV
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5.4.7. Modeling of INH Data
Global MCS across studies and across dosing routes resulted in an acceptable
parameter space that described observed cp(t) profiles and exposure metrics after INH
administration. All 6 pulmonary disposition rate constants followed the same log-normal
distributions for both HV and CF as shown in Table 38. Both mucociliary clearance
values (kpm and kcm) were identical at 0.02 min-1, while kpa was half of kca (0.01 and 0.02
min-1, respectively). kpd was optimized to a value of 0.008 min-1 and kcd was much
slower at a value of 0.0002 min-1. All pulmonary rate constants were associated with a
variability of 20% CV.

Table 38 Final optimized pulmonary disposition model parameters with specified
underlying distributions

Table 39 demonstrates the acceptability of the VI of the grouped cp(t) profiles as
well as the percent difference for the exposure metrics for each of the INH data sets.
Both reported cs(t) profiles were compared with the predicted cs(t) profiles and were
deemed acceptable per the VI criteria specified in Chapter Two. No sputum exposure
metrics were available for comparison. The predicted plasma AUC was on average
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8.2% higher than the reported AUC, with a 26% SD. Additionally, there was on average
an underprediction in cmax by 4.9% with a 7.2% SD. Sample results of the VI of the
combined cp(t) profile can be seen in Figure 38 for studies CIP 302A and 304A where
32.5 mg was INH by CF patients. A comparison of one of the two reported c s(t) profiles
with the predicted cs(t) profiles after 65 mg was inhaled by CF patients is shown in
Figure 39. The remaining VI are included in Appendix 3.

Table 39 Predicted vs reported AUC exposure metrics for individual analyzed INH
data sets using MCS approach

Figure 38 CIP INH cp(t) VPC Plot for CIP 302A and 304A
VPC for model predicted cp(t) compared with the average reported cp(t) profiles from
study CIP 302A and CIP 304A VPC after a 32.5 mg dose was inhaled by CF patients
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Figure 39 CIP INH cs(t) VPC Plot for CIP 302B
VPC for model predicted cs(t) compared with the reported cs(t) profile from study CIP
302B after a 65 mg dose was inhaled by CF patients

5.4.8. Parameter Sensitivity Analysis Results
SD sensitivity analysis results for both HV and CF patients were generated for
the five systemic disposition parameters and are tabulated in Table 40. For a 25-fold
change in the model parameters, AUC was most sensitive to changes in CLren in HV
and CF patients (3.7- and 7.2-fold, respectively), and cmax was most sensitive to V0 in -both groups (21- and 14-fold respectively). Predicted cp(t) profile after the 25-fold
change in CLren is shown in Figure 40 for HV and CF patients.
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Table 40 Single IV dose sensitivity analysis results for both HV and CF patients
after a 100 mg infusion over 10 minutes

Figure 40 Resulting cp(t) from a 25-fold change in CLren after a SD IV infusion of
100 mg over 10 minutes in HV (left plot) and CF (right plot).

SD sensitivity analysis results for both HV and CF patients were generated for
the five systemic disposition parameters as well as both oral absorption parameters and
are tabulated in Table 41. AUC and cmax were most sensitive to Foral with a 25-fold
change in Foral directly resulting in a 25-fold change in both AUC and cmax in HV and CF
patients, as expected. CLren was the second most influential model parameter on AUC
exposure, while kga was most influential on cmax. Predicted cp(t) profile after the 25-fold
change in CLren is shown in Figure 41 for HV and CF patients.
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Table 41 Single PO dose sensitivity analysis results for both HV and CF patients
after a 100 mg administration

Figure 41 Resulting cp(t) from a 25-fold change in kga after a SD PO administration
of 100 mg in HV (left plot) and CF (right plot).

SD sensitivity analysis results for both HV and CF patients were generated for all
model parameters (five systemic disposition, two oral absorption, and six pulmonary
disposition parameters) and are tabulated in Table 42 Plasma AUC depends primarily
on Foral, V0, and CLren in HV, and CLren, k12, and CLnonren in CF patients. Plasma cmax
depends primarily on V0, Foral, and k12 in HV, and V0, k12, and kga in CF patients. Sputum
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AUC depends primarily on kcm, kca, and kpd in both HV and CF patients. Predicted cp(t)
and cs(t) profiles after the 100-fold change in kcm is shown in Figure 42 and Figure 43 for
HV and CF patients, respectively.

Table 42 Sensitivity analysis results for both HV and CF patients after inhalation
of a single 32.5 mg dose
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Figure 42 Resulting cp(t) and cs(t) (left and right plot respectively) from a 100-fold
change in kcm after a SD INH of 32.5 mg in HV.

Figure 43 Resulting cp(t) and cs(t) (left and right plot respectively) from a 100-fold
change in kcm after a SD INH of 32.5 mg in CF.
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The resulting plasma and sputum profiles after SD are shown in Appendix 3 as
Figure 15 – 27. The code used to perform the sensitivity analysis is shown in Appendix
3.
5.4.9. Assessment of Mass Balance Results
After an IV infusion in HV, 1.3% of the dose is predicted to be eliminated through
distribution into the lungs and subsequently being mucociliary cleared into the GI tract
for elimination. This percentage was notably larger in CF patients, with an estimated 8%
of the dose being cleared through the same pathway. 98.7% and 92% respectively for
HV and CF patients was cleared through either renal or nonrenal clearance after IV
administration.

Figure 44 CIP IV administration cumulative excretion
Cumulative excretion from the GI tract after IV administration of a 300 mg dose in HV
(left plot) and CF patients (right plot)
After PO administration, 33% and 16% was eliminated from the GI tract in both
HV and CF patients respectively, and the remaining portions were eliminated through
systemic clearance mechanisms from the central compartment.
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Figure 45 CIP PO administration cumulative excretion
Cumulative excretion from the GI tract after PO administration of a 100 mg dose in HV
(left plot) and CF patients (right plot)

However, after INH, 27% and 12% of the deposited dose was eliminated from the
GI tract while the remaining 73% and 88% was eliminated from the central compartment
in HV and CF patients, respectively.

Figure 46 Cumulative excretion from the GI tract after INH of a 32.5 mg dose of
CIP in HV
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Figure 47 Cumulative excretion from the GI tract after INH of a 32.5 mg dose of
CIP in CF patients

5.5.

Discussions and Conclusions

5.5.1. Study Limitations
For IV study CIP 101, the infusion time was not specified within the study, as
such, a 15-minute infusion time was assumed. This was based on other studies
performed during the same time period. From the nine identified IV studies, two studies
were eliminated due to an inadequate analytical method, and insufficient reported data.
The remaining seven studies provided a total of twelve cp(t) profiles for analysis. Out of
the twelve PO studies, only 6 studies that provided twelve c p(t) profiles used in analysis.
Lastly, all four INH studies identified were included in analysis and provided a total of 8
cp(t) and 2 cs(t) profiles. Given that CIP was developed and the majority of the clinical
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investigations were performed in the early 1980s, this resulted in the limited availability
of data or the reliability of some of the analytical methods that were experimentally
used.
Furthermore, none of the IV and PO studies provide sputum exposure data in
either HV or CF patients, and there were needed limited sputum data available for CF
patients after INH and none was available for HV after INH. The availability of such data
would have allowed for more confidence in the pulmonary disposition parameters.
Additionally, there was no repeat dose studies available for IV, PO, or INH in either HV
and CF. These studies would have been useful in studying possible drug accumulation
in the various compartments as well as time dependence. We were also unable to
obtain any data for the pediatric population, whether HV or CF patients. This is notable
since they may often be the targeted population for this treatment. The lack of access to
individual patient level data (both plasma and sputum) limited the ability to study the
possible effects of covariate on both plasma and sputum exposures. Lastly, the INH
data available was produced from the same device across the four studies. Additional
data for various devices including pressurized inhalers and nebulizers would have been
useful in studying the effect of device of plasma and sputum exposure.
5.5.2. PK Dose-Proportionality
The linear dose dependence plot after IV infusion shown in Figures 24 comparing
the infused dose to the NCA calculated AUC, supported linear PK based on the high r2
value for the linear model. Additionally, when the same data were plotted on a log-log
scale (shown in the same Figure), and a power model was utilized for fitting the data,
the exponential term is close to 1.0 which would also indicate linear PK. The PO data
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available also supported linear PK as can be seen in both the linear fit as well as the
power fit of the dose vs AUC data shown in Figure 2. Additionally, PO dose vs cmax was
inspected in Figure 26 and also supported the linear PK conclusion. The same
conclusion can be drawn after CIP is INH based on the results shown in Figure 27 and
Figure 28. This finding is in agreement with the literature as several authors have also
reported that CIP follows linear PK across a similar dose range. 109,124 These pieces of
evidence provided a strong basis for the major modeling assumption, namely that all the
rate constants were all first order rate constants.
5.5.3. Final Parameter Space after IV Infusion
An empiric two compartment open body model of IV infused CIP with an
optimized model parameter space resulted in mechanistically plausible parameter
estimates and was able to adequately predict the reported cp(t) profiles from clinical PK
studies with HV and CF after a single dose. For both HV and CF patients, the peripheral
compartment behaved as a high capacity, shallow compartment. Model optimized
values indicated that CIP undergoes both renal and nonrenal clearance. The renal
clearance values exceeded 120 mL/min suggesting that CIP undergoes net tubular
secretion. CF patients had similar nonrenal clearance values as HV, and the numerical
difference between both groups was further minimized when CLnonren was normalized by
BW. However, for CLren, there was a stark difference between CF patients and HV; that
difference was made more apparent when their respective values were BW normalized.
Some authors have suggested that this increased renal clearance in CF patients may
be due to overexpression for heightened activity of other transporters in the renal-tubule
due to the mutation of the CFTR transporter. 125
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When the optimized pulmonary disposition and oral absorption parameters were
introduced to the empiric model, and CIP was administered via IV infusion, CIP was
predominantly cleared through clearance from the central compartment with nearly 99%
and 92% of the dose eliminated via systemic clearance (sum of renal or nonrenal
clearances) in HV and CF patients respectively. After pulmonary excretion and transfer
into GI tract, the remaining 1% for HV and 8% for CF was eliminated from the GI tract.
These results may explain why none of the in-vivo clinic studies reported sputum
exposure after IV administration. Additionally, this would also explain that IV
administration is a sub-optimal dosing route when the lungs are being targeted as the
site of action as in the case of CF.
5.5.4. Final Parameter Space after PO Administration
The final optimized oral absorption model and parameters for CIP suggested that
HV and CF patients have a similar extent of absorption (73% and 85% respectively).
Since it has already been shown that CF have lower nonrenal clearance (likely hepatic
extraction), it is plausible that this lower nonrenal clearance would lead to higher F oral
due to reduced hepatic first-pass effect. The difference between both groups was more
evident in the rate of absorption (kga) where HV had an absorption rate constant that
was nearly double that of CF patients (0.020 and 0.011 min-1, respectively). Since CIP
is known to be zwitterionic within the physiological pH range of the GI tract, it is likely
that in CF patients (where some transporters are overexpressed to compensate for the
mutated CFTR transporter) CIP may undergo increased efflux transport.
5.5.5. Final INH Model
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The final INH model incorporated the two-compartment systemic disposition
model, the oral absorption model, and two pulmonary compartments. This is model #1
as described in Chapter Two. The selection of this model was based on the lack
availability of sputum data, specifically, after IV administration. The model allowed for
absorption from the lungs (central and peripheral) to the central compartment through
kpa and kca, however, the model did not show that drug can redistribute from the central
compartment back to the lungs. Mucociliary clearance was possible from both the
peripheral and the central lung into the central lung and the GI tract compartments
respectively.
5.5.6. Final Parameter Space after Inhalation
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Table 43 Final optimized model parameters with specified underlying covariate
models and distributions
The final parameter set, listed in Table 43, that was optimized using the available
inhalation data and was able to describe the available cp(t) and cs(t) profiles as well as
the exposure metrics. A single parameter space was used to describe both HV and CF
patients. While CF patients are known to have altered lung physiology (such as thicker
mucus and altered airway morphology), there were insufficient data to resolve the
differences between both groups. Furthermore, mucociliary clearance from both the
peripheral and the central lung was numerically identical. Experimental in-vivo data has
suggested otherwise, and similar modeling efforts with other drugs have also suggested
that mucociliary clearance values are different for both compartments.126 However,
again due to the limited sputum data the ability to resolve these parameters was limited.
Both the peripheral lung and the central lung compartments favored absorption
into systemic circulation as compared to distribution from the central compartment into
the lungs. This is especially evident in the central lung compartment where the
𝑘𝑝𝑎

is 100 relative to the 𝑘

𝑝𝑑

𝑘𝑐𝑎
𝑘𝑐𝑑

ratio

which is only 1.25. Due to the limited availability sputum data, a

75% CV was associated with all pulmonary rate constants.
5.5.7. Sensitivity Analysis
While the results of the sensitivity analysis were numerically different between
HV and CF, the rank order of most influential parameters was the same: IV sensitivity
analysis results showed that AUC for both HV and CF with mostly dependent on both
CLren and CLnonren, and for cmax, V0 was the most influential parameter.
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After PO administration, a 25-fold change in Foral directly lead to a 25-fold change
in both AUC and cmax for both HV and CF patients, as expected. Among the remaining
parameters, CLren was most influential on AUC, and V0 was the second most influential
parameter on cmax.
After INH, both HV and CF plasma exposures were most sensitive to systemic
disposition and oral absorption parameters. However, loss from the central lung
compartment (whether through absorption or mucociliary clearance) was the most
influential of pulmonary exposure/sputum in both HV and CF patients. This is plausible
since loss from a compartment would likely directly and proportionally influence levels in
that compartment.
5.5.8. Overall Conclusions
The validated IV, PO, and INH models were capable of describing the observed
cp(t) and cs(t) profiles as well as the reported exposure metrics. Linear PK was validated
across all three dosing routes. The data supported the application of a disease state
covariate model that distinguished between HV and CF patients on the systemic
disposition as well as the oral absorption parameters. This was most likely due to limited
sputum data. Pulmonary disposition parameters were the same for both groups and
followed log-normal distribution. The greatest parameter uncertainty was associated
with the oral absorption parameters. Across all three dosing routes, elimination from the
central compartment through renal or nonrenal pathways was the predominant
mechanism of drug elimination. In both HV and CF patients, CLren was most influential
on AUC and V0 was most influential on cmax after IV administration, while Foral was most
influential on plasma exposure after PO administration. After INH, systemic exposure
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was dependent on systemic disposition and oral absorption parameters, while
pulmonary exposure was dependent most on loss from the central lung compartment.
Lung disposition favored systemic uptake from the pulmonary compartments over
excretion from plasma into the lung compartments. CIP has a high bioavailability after
INH, but pulmonary excretion is a minor elimination pathway (relative to CLren and
CLnonren). Lastly, sputum exposures are driven primarily by (rapid) pulmonary absorption
and mucociliary clearances and not by systemic CIP exposure.
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CHAPTER 6

OVERALL CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS

6.1.

Available Data Used for Semi PBPK Modeling
As described in Chapter 2, three semi-PBPK models for lung disposition were

developed and validated to describe the experimentally observed data from published
literature, and the final parameter estimates were interpreted physiologically for each of
the three drugs. This chapter compares the individual models/model parameter
estimates, and prospective predictions for the three drugs.
Model #1 was used to describe the available cp(t) data for BUD, Model #2 was
used to describe the available cp(t) and cs(t) data for CIP, and Model #3 was used to
describe the available cp(t) and cs(t) data for TOB. In each of the three cases, the final
model that was selected based on its ability to adequately describe the existing data,
both mean concentration-time profiles and mean (±SD) exposure metrics as available
after IV, PO (BUD and CIP only), and INH.
Note, however, that Model #1 is a sub-model of Model #2, and Model #2 is submodel of Model #3. This does allow proper comparison of the final parameter sets: For
Model #1 (BUD), kpd and kcd were set to 0 (i.e., unidirectional pulmonary uptake), and
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the pulmonary sequestration compartments were assumed to equilibrate virtually
instantaneously (i.e., kpls1, kpls2, kcls1, and kcls2 = 10,000 min-1). For Model #2 (CIP), the
pulmonary sequestration compartments equilibrate virtually instantly (i.e., k pls1, kpls2,
kcls1, and kcls2 = 10,000 min-1), but drug can be absorbed from and excreted into the
pulmonary (unbound) compartments.
A summary of the available data after each route of administration for each of the
three drugs is shown in Table 44. These collected data sets satisfied specific aim #1
listed in Chapter 2.

Route of
Administration
IV
PO
INH
INH Devices

Drug
BUD
TOB
CIP
cp(t) cs(t) cp(t) cs(t) cp(t) cs(t)
6
0
5
1
11
0
1
0
0
0
12
0
3
0
16
10
6
2
1
5
1

Table 44 Number of available data sets (cp(t) and cs(t)) after each route of
administration for each of the three drugs of interest.
As discussed in earlier chapters, only a limited number of studies were available
for modeling. Major limitations included the absence or scarcity of sputum data for BUD
and CIP; this obviously impacted estimation of their respective final pulmonary
disposition parameters.
Additionally, only a single repeat-dose study for TOB after IV administration, but
not after INH, and none for BUD or CIP were reported in the literature. For BUD and
CIP, this prevented formal assessment of drug accumulation in the lungs, that may not
be discernible seen in plasma, as was the case for TOB.
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In addition, all 13 sputum profiles (1 IV TOB, 10 INH TOB, and 2 INH CIP) were
obtained from CF patients, and no information was available for HV; this prevented
evaluation of any disease effect on pulmonary disposition.
Moreover, there were only a few studies available in the desired patient
populations, including CF patients for TOB and CIP, and asthmatic patients for BUD.
Finally, some of the studies had to be excluded due to the use of an insensitive
analytical method, or inadequate sampling schedule.
In spite of these limitations, the available data sets were useful in generating
appropriate disease and BW covariate models for systemic and GI absorption
parameters. For pulmonary disposition, only TLV was assumed to be allometrically
related to BW, as discussed in chapter 1 and 4. As pointed out above, disease effect
could not be discussed from available data.
For BUD, Model #1 allows for unidirectional uptake of drug from the central and
peripheral lung compartments into the systemic circulation. There were no sputum data
available at all after IV administration of BUD, nor was there in-vitro or other evidence
data supporting pulmonary sequestration and or excretion of BUD.
For TOB, Model #3 allows for bidirectional movement, i.e., uptake from and
excretion into pulmonary (unbound) compartments to account for the fact that TOB
concentrations were achieved in sputum after IV administration; it also introduced
pulmonary sequestration compartments to account for known in-vitro (intracellular)
accumulation as well as reported in-vivo sputum accumulation after repeated INH
dosing. Thus, the lung was considered an absorption, sequestration and excretion
organ.
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For CIP, Model #2 allowed for bidirectional flow of drug from the pulmonary
compartments to and from the central compartment. This bidirectional flow allowed the
model to adequately describe sputum concentrations profiles after INH. Thus, the lung
was considered an absorption and excretion organ.

6.2.

Comparison Across Parameter Spaces for the Three Drugs

6.2.1. Systemic Disposition Properties
Pertinent key physicochemical properties of the three drugs are summarized in
Table 45. As can be seen from Table 45, all three drugs have similar molecular weights,
however they have different experimental log(P) values, ionization within physiological
pH, and different solubility. Additionally, there A to B Papp values in both Caco-2 cell
models and Calu-3 cell models are also different. The final optimized systemic
disposition parameters for each of the three drugs are listed for comparison in Table 46.
All parameters are for HV (BW = 75 kg).

Table 45 Physicochemical properties of the three selected drugs. (Both Papp
values are reported for A→B permeability).
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Parameter
CLtot (mL/min)
V0 (L)
k12 (min-1)
k21 (min-1)
k10 (min-1)
Vdss (L)
Depth (k10/k21)
Capacity (k12/k21)

BUD
1170
45
0.100
0.031
0.026
190
0.84
3.2

TOB
70
10
0.010
0.015
0.007
17
0.47
0.67

CIP
630
75
0.025
0.015
0.008
200
0.53
1.7

Table 46 Comparison across the final optimized systemic disposition parameters
for BUD, TOB, and CIP

As expected, BUD shows the highest CLtot, followed by CIP, and TOB has the
lowest value. Lipophilic compounds have been shown to undergo predominantly hepatic
metabolism/biliary excretion.127
Based on its lipophilicity, BUD, which is the most lipophilic of the three tested
drugs, has the largest total clearance approaching hepatic blood flow, indicating high
hepatic extraction. This also explains its low Foral as result of high pre- systemic hepatic
extraction (see below).
Based on its estimated CLtot and Foral values, its intermediate lipophilicity, as well
as its zwitterionic properties, CIP is known to undergo both hepatic and renal
elimination. Its renal clearance is reported in Chapter 5 and indicates net tubular
secretion, involving drug transporters (OATs). Renal excretion is the major route of
elimination as the fraction of the administered dose that is eliminated unchanged in
urine after IV administration is between 40% to 60%. 108,112
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Lastly, TOB, which has the lowest CLtot, virtually exclusively undergoes renal
excretion due to its hydrophilicity; specifically, it undergoes net tubular reabsorption due
to the possible involvement of some cationic transporters.128
The peripheral body compartment for all three drugs - needed to properly model
systemic disposition data - is a shallow body compartment, equilibrates rapidly with the
central compartment (plasma): Final parameter estimates for both BUD and CIP
indicate that these peripheral tissue compartment is a low-capacity compartment, i.e.,
contain only a small portion of the administered dose, while, for TOB, it is an
intermediate-capacity compartment. This increased capacity noted for TOB may be due
to the aforementioned intracellular tissue sequestration observed in in-vitro studies in
the lung.24
As both BUD and CIP are sufficiently lipophilic and small to cross epithelia, they
both have large Vdss, indicating extensive extravascular distribution. CIP has a slightly
smaller Vdss, which may be attributed to its zwitterionic charge in the physiological pH
range. On the other hand, TOB has quite a small Vdss, indicating limited extravascular
distribution. In addition to being a hydrophilic drug, TOB is highly charged and is likely to
be a polycationic drug within physiological pH range.
To better emphasize their differences in systemic PK properties comparative
simulations of cp(t) and cs(t) were performed. Using the final parameter estimates for
each of the three drugs, a 10-minute IV infusion of a non-therapeutic dose of 200 mg
was simulated. The results of these simulations are shown in Figure 48.
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As can be seen, there are no BUD concentrations in sputum after IV
administration. This is expected since the model (Model #1) does not allow distribution
from the systemic circulation to the pulmonary compartments.
However, the final models (Model #2 and #3) for both TOB and CIP predict drug
concentrations in sputum after IV administration. The magnitude of concentration
difference between plasma and sputum for TOB is greater than that for CIP. Notably,
TOB plasma concentrations are 100-fold higher than sputum concentrations due to its
limited distribution to the lungs, given the minor capacity the of central lung
sequestration compartment (kcls1/kcsl2 = 0.0007). Although the peripheral lung
sequestration compartment is a high-capacity compartment (kpls1/kpls2 = 3.75), the
peripheral unbound lung compartment that moves TOB via mucociliary clearance into
the central unbound lung compartment is a low-capacity compartment (kpd/kpa = 0.009).
As result, the central unbound lung compartment/sputum concentrations are quite small,
and most of TOB in the lung is trapped in the peripheral sequestration compartment,
which serves as reservoir for TOB to redistribute primarily into the central
compartment/plasma and, to a much lesser extent, into the central unbound lung
compartment/sputum. Additionally, the terminal slopes in the plasma and sputum
profiles appear to be parallel for both TOB and CIP. This indicates that the central
unbound lung and central (body) compartments are in equilibrium, and the rate-limiting
step for both compartments is distribution from the systemic circulation to the lungs, i.e.
pulmonary excretion with some intrapulmonary recycling.
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Figure 48 Simulations for BUD, TOB, and CIP after IV administration (Infusion of
200 mg over 10-minutes)

6.2.2. Oral Absorption Properties
The final optimized oral/GI absorption parameters for each of the three drugs are
listed for comparison in Table 47.
Foral for BUD is low, only about 10% due to high hepatic first-pass effect, given
that it is a high hepatic extraction ratio drug.
As previously discussed, TOB is hydrophilic and highly charged. These
characteristics lead to a negligible Foral of ~0%, predominantly due to poor GI
permeability (consistent with poor Caco-2 permeability, as shown in Table 45).
Foral for CIP was estimated to be 73% for HV and 85% for CF patients. These
values are in line with a small degree of first-pass effect and/ or the possible
involvement of GI efflux transporters. The difference between Foral for HV and CF
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patients has been discussed by several authors, who have theorized that it may be due
to the overexpression of GI uptake transporters to compensate for the mutated CFTR
transporter.125,129
Parameter
kga (min-1)
Foral (%)

BUD
0.007
10

TOB
0
0

CIP
0.020
73

Table 47 Comparison across the final GI absorption parameters for BUD, TOB,
and CIP

To better understand the implications of these differences in GI absorption
properties, comparative simulations of cp(t) and cs(t) were performed with a nontherapeutic dose of 1000 mg. The results of these simulations are shown in Figure 49.
Although there are concentrations of BUD in plasma, there are no sputum
concentrations of BUD, as is expected since the model (Model #1) does not allow
distribution from the systemic circulation to the pulmonary compartments.
Since TOB is not orally bioavailable, there are no plasma nor sputum
concentrations.
Lastly, CIP is absorbed well from the GI into plasma, and distributes into the
(unbound) lung compartments as shown by the sputum profile. Peak sputum
concentration for lags behind the peak plasma concentration due to slow distribution
from the central compartment into the (unbound) lung compartments. Additionally, the
terminal slopes in plasma and sputum profiles appear to be parallel for CIP, which
indicates that the (unbound) central lung compartment and the central body
compartment are in equilibrium, and the rate-limiting step for is distribution from the
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systemic circulation to the lungs, i.e., pulmonary excretion with some intrapulmonary
recycling.

Figure 49 Simulations for BUD, TOB, and CIP after PO administration (1000 mg)

6.2.3. Pulmonary Disposition Properties
Parameter
BUD
TOB
CIP
-1
kpa (min )
0.066
0.900
0.010
-1
kca (min )
0.033
0.650
0.020
kpm (min-1)
0.008
0.020
0.020
-1
kcm (min )
0.016
0.080
0.020
kpd (min-1)
0
0.008
0.008
-1
kcd (min )
0
0.0002
0.0002
kpls1 (min-1)
10000
0.015
10000
-1
kpls2 (min )
10000
0.004
10000
-1
kcls1 (min )
10000
0.002
10000
kcls2 (min-1)
10000
0.3
10000
Table 48 Comparison of the final, optimized pulmonary disposition parameters for
BUD, TOB and CIP.
Absence of pulmonary sequestration is indicated by large values (10,000) for kpls1, kpls2,
kcls1, and kcls2.
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Overall, the final parameters indicate that: a) BUD undergoes pulmonary
absorption only, b) TOB undergoes pulmonary absorption/sequestration and excretion,
and c) CIP undergoes pulmonary absorption and excretion. Both BUD and CIP are not
sequestered in the lungs and are absorbed rapidly into systemic circulation from their
pulmonary compartments. Both TOB and CIP also undergo intrapulmonary recycling
due bidirectional pulmonary uptake into and efflux from the central compartment, along
with mucocililary clearance from the peripheral to the central (unbound) lung
compartment.
Values for kpa and kca for BUD are notably faster when compared to CIP. This is
likely due to the lipophilicity as well as the neutral state of BUD, which would facilitate its
pulmonary membrane permeability and rapid uptake of the deposited dose.
On the other hand, TOB, which is hydrophilic and has polycationic charges, has
the fastest kpa and kca values but, slow kpls2 and kcls2 values. The latter micro rate
constants govern the movement of the drug from the pulmonary sequestration
compartments to the central compartment. The low values associated with TOB point to
a slow pulmonary absorption into systemic circulation. This again is in line with its
hydrophilic and cationic nature and consistent with the low Papp values in CaLu cell lines
(see Table 45).
A study of mucociliary clearance values for inhaled substances indicated that
mucociliary clearances values can depend on the pulmonary solubility of the inhaled
drug. 87 Specifically, more soluble compounds were shown to have mucociliary
clearance rate constants between 0.0167 and 0.0083 min-1, while less soluble
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compounds had a mucociliary clearance rate constant of 0.0013 min-1. TOB, had the
highest experimental solubility, with a solubility of 1000 mg/mL, followed by CIP with a
solubility 40 mg/mL, and BUD with a solubility 19 ᛫ 10-3 mg/mL. This rank order of
solubility leads to the observed rank order of the estimated kcm values, with TOB having
the fastest, CIP having the intermediate, and BUD having the slowest k cm values,
respectively.
The final optimized pulmonary deposition parameters and pulmonary
bioavailability estimates for each of the three drugs are listed for comparison in Table
49.

Parameter
DtL
DtGI
Device Dose (mg)
Fpul (%)
Finh (%)

BUD
28%
58%
1
83%
34%

TOB
15%
8.5%
300
10%
6%

CIP
53%
40%
32.5
8%
36%

Table 49 Comparison across the final optimized pulmonary deposition
parameters and pulmonary bioavailabilities for BUD, TOB, and CIP.
(Deposition values for BUD, TOB, and CIP are for the Turbuhaler, Pari LC Jet
Nebulizer, and Novartis T-326 DPI device, respectively)

The value for Finh depends on the composite of pulmonary and GI tract deposition
along with the respective bioavailabilities; i.e., Fpul and Foral (Equation5 in Chapter 2).
On the other hand, Fpul depends solely on the pulmonary disposition micro rate
constants.
For BUD, of the total inhalation device dose, 28% is deposited in the lungs while
58% is deposited in the GI tract. Pulmonary bioavailability (Fpul) for BUD is 83%,
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meaning that of the 28% deposited in the lungs, 83% is subsequently absorbed into
systemic circulation. On the other hand, the 58% deposited in the GI tract is available
for GI absorption but limited by a Foral of 10% due to high pre-systemic hepatic
metabolism. As such, after inhalation, the total bioavailability (Finh) for BUD is only 34%,
despite a high Fpul, but due to poor pulmonary deposition and poor oral bioavailability
For TOB, only 15% of the nebulized dose is deposited in the lungs, and only 8.5%
is deposited in the GI tract (due to the poor efficiency of the Pari Nebulizer). For TOB,
Fpul is only 10% - due to poor pulmonary permeability/sequestration-, and Foral is 0%,
which leads to a low Finh of 6%.
For CIP, while a large fraction of the dose (53%) of the inhalation device dose is
deposited the lung, Fpul is only 8%. The low Fpul value is the result of efficient
mucociliary clearance and pulmonary excretion, which reduced pulmonary absorption.
However, due to its high Foral and the fact that 40% of the dose are deposited in the GI
tract, Finh for CIP is 36%, similar to BUD
Overall, for both TOB and CIP Fpul values were low (10% and 8%, respectively)
due to their excretion from the central body compartment/plasma into the lungs.
Specifically, TOB was excreted from the central body compartment into the peripheral
lung sequestration compartment while CIP was excreted from the central body
compartment into the peripheral unbound lung compartment.
The final parameter spaces for both TOB and CIP was utilized in Chapters 4 and
5, respectively, to study the contribution of pulmonary excretion to the overall excretion
from the body after IV administration: For TOB and CIP, the lung contributed 7% and
1.3%, respectively, of the total dose to overall excretion. This indicates that the lung is
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not a major elimination organ, however, pulmonary excretion plays a major role in
pulmonary disposition and the resulting sputum concentrations.
All three models and validated model parameter estimates, satisfied specific aim
#2 as described in Chapter 2.

To better understand the differences between the three drugs in their pulmonary
disposition properties, comparative simulations of cp(t) and cs(t) were performed with a
non-therapeutic INH dose of 500 mg. Deposition data for each drug was set to the
values noted for the devices discussed earlier, and inhalation time was set to zero (i.e.,
instantaneous deposition was assumed). The results of these simulations are shown in
Figure 50.
As can be seen in Figure 50, for BUD after INH, the cs(t) profile shows a rapid
decrease, which reflects rapid (unidirectional) absorption of the deposited dose from
both peripheral and central (unbound) lung compartments into the central body
compartment/plasma. Plasma concentrations initially increase rapidly due to pulmonary
absorption, and, after reaching a maximum concentration, they decline in a first-order
fashion with systemic elimination (k10) as the rate-limiting step.
Concentrations of TOB in the central unbound lung compartment/sputum at first
decrease very rapidly due to a fast kca (faster than BUD or CIP); i.e., rapid uptake into
the central lung sequestration compartment, however, show a second peak. This
second peak is likely due to intrapulmonary recirculation through the peripheral lung
sequestration compartment, which behaves as a reservoir. After initial rapid pulmonary
uptake into this high-capacity compartment, TOB distributes from the central body
compartment/plasma into this peripheral lung sequestration compartment and is slowly
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released into the peripheral unbound lung compartment and subsequently moved into
the central unbound lung compartment/sputum via mucociliary clearance – leading to
the second peak. This is also in agreement with published literature, showing TOB
accumulation in sputum after repeated dosing. Accordingly, the lung compartments
behave as absorption/excretion and sequestration compartments for TOB. Plasma
concentrations of TOB after inhalation peak rapidly due to fast, initial pulmonary
absorption (kca and kcls2). This is followed by a distribution phase which is likely
governed by equilibration with the peripheral sequestration lung compartment, before
reaching its terminal phase, which is governed by equilibration with the central lung
compartment (kcls1).
For CIP, sputum concentrations follow a biphasic decline after inhalation: The
initial decline is due to rapid absorption from the lung compartments into the central
body compartment/plasma (kca and kpa). The slower terminal decline is due to the
subsequent distribution from the central compartment back to the central lung
compartment (kcd) and pulmonary excretion. This further proves that the lung
compartments for CIP behave as absorption/excretion compartments. Plasma
concentrations for CIP achieve their maximum later than TOB and BUD, which is
explained by its slowest pulmonary absorption (kca) among the three drugs. The
terminal phase in the plasma concentration-time profile for CIP declines in parallel with
sputum concentrations and is governed by kcd.
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Figure 50 Simulations for BUD, TOB, and CIP after INH (500 mg, assuming
instantaneous deposition into the lung; deposition for 3 devices, respectively)

6.3.

Comparison of Sensitivity Analysis for Each of the Three Drugs

6.3.1. Plasma Sensitivity Analysis
The results for the plasma and sputum sensitivity analyses are shown in Table
46.

Exposure
metric
Drug
1st
2nd
3rd

Plasma AUC
BUD
V0
k10
Foral

TOB
CLtot
kpls1
kpls2

CIP
CLren
k12
CLnonren

Sputum AUC
TOB
kca
kcm
kpm

CIP
kcm
kca
kpd

Table 50 Top three most influential parameters for each of the exposure metrics
for each of the studied drugs.
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After INH, the plasma AUC for all three drugs was found to be most sensitive to
changes in CLtot. For TOB, this was explicitly seen in the sensitivity analysis, with CLtot
being the most influential parameter. For CIP, CLren and CLnonren, the sum of which is
CLtot, were both among the two three most influential parameters on plasma AUC.
Lastly, for BUD, plasma AUC was most sensitive to V0 and k10, the product of which is
CLtot.
Interestingly, for BUD, plasma AUC was also sensitive to Foral. This is likely due
to the high GI deposition from the Turbuhaler (DtGI = 58%) combined with the low Foral
of 10%. For TOB, plasma AUC was sensitive to the distribution from the central body
compartment to the peripheral lung sequestration compartment (kpls1), and the uptake
from the peripheral lung sequestration compartment into the central body compartment
(kpls2). This is likely due to the high peripheral lung deposition of drug from the nebulizer
combined with a low Fpul of 10%. For both BUD and TOB, given that a large fraction of
their INH dose is deposited in the GI tract and the peripheral lung, a slight increase in
Foral or Fpul, respectively, is expected to lead to a large increase in plasma AUC.
6.3.2. Sputum Sensitivity Analysis
A major underlying assumption of this work was that sputum concentrations
correlate with pulmonary compartments, specifically, concentration in the central
(unbound) lung compartment.
Since the model used for BUD (Model #1) and the final optimized parameter
space were not validated against sputum data (due to absence of published data),
sputum AUC sensitivity was not performed for BUD.
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For TOB and CIP, sputum AUC was consistently sensitive to decreases in kca and
kcm. The sum of these parameters characterizes the rate of loss from the central lung
compartment (equivalent of CLtot from a central compartment). It is that rate of loss from
the central (unbound) lung compartment that is most important for central lung
(unbound) compartment concentrations, i.e., sputum exposure, for both drugs since
their pulmonary absorption is slow and low (see Table 45). kpm and kpd appear also to be
influential parameters with regards to sputum AUC. This is likely due to their influence
on concentrations in the peripheral (unbound) lung compartment which in turn can
(indirectly) influence concentrations in the central (unbound) lung compartment/sputum
as long as some of the inhaled dose is deposited into the peripheral (unbound) lung
compartment.
These findings are in line with the hypothesis stated in Chapter 2, specifically that,
after inhalation, (a) decreasing systemic exposures can be accomplished by increasing
total systemic clearance (CLtot), but are less sensitive to pulmonary absorption, and (b)
increasing pulmonary exposures can be accomplished by slowing down uptake from the
lungs into systemic circulation (kca) and/or slowing down mucociliary clearance from the
lungs into the GI tract (kcm).
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Matlab Script to run MCS for BUD
%Author: Bishoy Erian
%Start date: May 14th, 2015
%Purpose: To plot the 95th & 5th percentile after a Monte Carlo Simulation
%for my inhalation model based on the laplace transformed solution
clear all
close all
clc
clf
close Figure 1
Tstart=tic;
digits(10)
rng('default')
rng(3)
%% User input area
n=20000; %number of simulations to run
Last_time_point=1440; %I typically think this should be in minutes
IFS=0.5; %0.5 means every half a minute; Increment for simulation
%Deposition Parameters
MDem=720; %nmol
CVDem=0; %60;
MFex=0.001175;
CVFex=0;%0.000957;
MFpd=0.098;
CVFpd=0;%0.012;
MFcd=0.117;
CVFcd=0;%0.00495;
%Lung Parameters
Mkpm=0.0078;
CVkpm=0;
Mkcm=0.01563;
CVkcm=0;
Mkpa=0.3333;
CVkpa=0;
Mkca=0.166667;
CVkca=0;
%Oral Absorption Parameters
Mkga=0.0056;
CVkga=0.35;
MForal=0.0995;
171

CVForal=0.3;
%Systemic Disposition Parameters
MV0=58;
CVV0=0.15;
Mk12=0.095;
CVk12=0.2;
Mk21=0.0308;
CVk21=0.2;
Mk10=0.0273;
CVk10=0.15;
%Dosing interval
tau=2000;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%
End User Input
%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Coefficient of Variation to variance conversion
SDem=(CVDem*MDem)^2;
SFex=(CVFex*MFex)^2;
SFpd=(CVFpd*MFpd)^2;
SFcd=(CVFcd*MFcd)^2;
Skpm=(CVkpm*Mkpm)^2;
Skcm=(CVkcm*Mkcm)^2;
Skpa=(CVkpa*Mkpa)^2;
Skca=(CVkca*Mkca)^2;
Skga=(CVkga*Mkga)^2;
SForal=(CVForal*MForal)^2;
SV0=(CVV0*MV0)^2;
Sk12=(CVk12*Mk12)^2;
Sk21=(CVk21*Mk21)^2;
Sk10=(CVk10*Mk10)^2;
%% Parameter distribution creation
%Dose parameters
%Dem1=MDem/5 : MDem/4166.5 : 5*MDem;
Dem1=normrnd(MDem,SDem,[1,n]);
%Fex1=MFex/5 : MFex/4166.5 : 5*MFex;
Fex1=normrnd(MFex,SFex,[1,n]);
%Fpd1=MFpd/5 : MFpd/4166.5 : 5*MFpd;
Fpd1=normrnd(MFpd,SFpd,[1,n]);
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%Fcd1=MFcd/5 : MFcd/4166.5 : 5*MFcd;
Fcd1=normrnd(MFcd,SFcd,[1,n]);

%Lung parameters
%kpm1=Mkpm/5 : Mkpm/4166.5 : 5*Mkpm;
%kpm1=Mkpm/10 : Mkpm/2020.2 : 10*Mkpm;
kpm1=lognrnd(log(Mkpm^2 / sqrt(Skpm+Mkpm^2)),sqrt(log(Skpm/Mkpm^2 + 1)),[1,n]);
%kcm1=Mkcm/5 : Mkcm/4166.5 : 5*Mkcm;
kcm1=lognrnd(log(Mkcm^2 / sqrt(Skcm+Mkcm^2)),sqrt(log(Skcm/Mkcm^2 + 1)),[1,n]);
%kpa1=Mkpa/5 : Mkpa/4166.5 : 5*Mkpa;
kpa1=lognrnd(log(Mkpa^2 / sqrt(Skpa+Mkpa^2)),sqrt(log(Skpa/Mkpa^2 + 1)),[1,n]);
%kca1=Mkca/5 : Mkca/4166.5 : 5*Mkca;
kca1=lognrnd(log(Mkca^2 / sqrt(Skca+Mkca^2)),sqrt(log(Skca/Mkca^2 + 1)),[1,n]);

%Oral Deposition Parameters
%kga1=Mkga/5 : Mkga/4166.5 : 5*Mkga;
kga1=lognrnd(log(Mkga^2 / sqrt(Skga+Mkga^2)),sqrt(log(Skga/Mkga^2 + 1)),[1,n]);
%Foral1=MForal/5 : MForal/4166.5 : 5*MForal;
Foral1=lognrnd(log(MForal^2 / sqrt(SForal+MForal^2)),sqrt(log(SForal/MForal^2 +
1)),[1,n]);

%Systemic Disposition Parameters
%V01=MV0/5 : MV0/4166.5 : 5*MV0;
V01=lognrnd(log(MV0^2 / sqrt(SV0+MV0^2)),sqrt(log(SV0/MV0^2 + 1)),[1,n]);
%k121=Mk12/5 : Mk12/4166.5 : 5*Mk12;
k121=lognrnd(log(Mk12^2 / sqrt(Sk12+Mk12^2)),sqrt(log(Sk12/Mk12^2 + 1)),[1,n]);
%k211=Mk21/5 : Mk21/4166.5 : 5*Mk21;
k211=lognrnd(log(Mk21^2 / sqrt(Sk21+Mk21^2)),sqrt(log(Sk21/Mk21^2 + 1)),[1,n]);
%k101=Mk10/5 : Mk10/4166.5 : 5*Mk10;
k101=lognrnd(log(Mk10^2 / sqrt(Sk10+Mk10^2)),sqrt(log(Sk10/Mk10^2 + 1)),[1,n]);

%
MU = log(M^2 / sqrt(V+M^2))
%
SIGMA = sqrt(log(V/M^2 + 1))
%% Matrix setup/allocation
time=0:IFS:Last_time_point;
t=0;
NoP=(Last_time_point/IFS)+1;%plus one accounts for the
DoseCounter=0;
% the zero time point
AmtPL=ones(NoP,n);
AmtCL=ones(NoP,n);
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AmtGIT=ones(NoP,n);
AmtPC=ones(NoP,n);
AmtCC=ones(NoP,n);
Cp=ones(NoP,n);
ContPL=ones(NoP,n); ContCL=ones(NoP,n); ContGIT=ones(NoP,n);
ContPLCL=ones(NoP,n); ContCLGIT=ones(NoP,n); ContPLCLGIT=ones(NoP,n);
LastCC=ones(NoP,n);
ContPPL=ones(NoP,n); ContPCL=ones(NoP,n); ContPGIT=ones(NoP,n);
ContPPLCL=ones(NoP,n); ContPCLGIT=ones(NoP,n); ContPPLCLGIT=ones(NoP,n);
LastPC=ones(NoP,n);
cmax=ones(1,n); tmax=ones(1,n); Auc=ones(1,n);
thalfbet=ones(1,n);
AAUC=ones(1,n); AUMC=ones(1,n); MRT=ones(1,n);
CCa=ones(1,n);
CCb=ones(1,n);
CCc=ones(1,n);
CCp=ones(1,n);
CCg=ones(1,n);
CC1=ones(1,n);
CC2=ones(1,n);
CC3=ones(1,n);
CC4=ones(1,n);
CC5=ones(1,n);
CC6=ones(1,n);
CC7=ones(1,n);
CC8=ones(1,n);
CC9=ones(1,n);
CC10=ones(1,n); CC11=ones(1,n); CC12=ones(1,n);
CC13=ones(1,n); CC14=ones(1,n); CC15=ones(1,n); CC16=ones(1,n);
CC17=ones(1,n); CC18=ones(1,n); CC19=ones(1,n); CC20=ones(1,n);
CC21=ones(1,n); CC22=ones(1,n);
for j=1:1:n
%Parameter value selection from randomly generated array
Dem=Dem1(1,j);
Fex=Fex1(1,j); Fpd=Fpd1(1,j);
Fcd=Fcd1(1,j);
kpm=kpm1(1,j); kcm=kcm1(1,j);
kpa=kpa1(1,j);
kca=kca1(1,j); kga=kga1(1,j);
Foral=Foral1(1,j);
V0=V01(1,j);
k12=k121(1,j);
k21=k211(1,j);
k10=k101(1,j);
%%Calculation secondary Model Parameters
kp=kpm+kpa;
kc=kcm+kca;
alp_p_bet=k12+k21+k10;
alp_m_bet=k21*k10;
alp=(-alp_p_bet-( (alp_p_bet^2) - ( 4*alp_m_bet) )^0.5)/-2;
bet=(-alp_p_bet+( (alp_p_bet^2) - ( 4*alp_m_bet) )^0.5)/-2;
Fgd=1-Fpd-Fcd-Fex;
PL0=Dem*Fpd;
CL0=Dem*Fcd;
GIT0=Dem*Fgd;
%% Percentage done
if (j*100/n)==0 || (j*100/n)==25 || (j*100/n)==50 || (j*100/n)==75 || (j*100/n)==100
clc
howmuch=num2str(j*100/n);
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disp(strcat('currently',{' '},howmuch, '% done'));
end
for i=1:1:NoP
if(rem(time(1,i),tau)==0);
if (time(1,i)==0);
LastCC(i,j)=0;
LastPC(i,j)=0;
GIT0=Dem*Fgd;
CL0=Dem*Fcd;
PL0=Dem*Fpd;
else
GIT0=(((CL0*kcm*(exp(-kc*(IFS+t))-exp(-kga * (IFS+t)))/(kgakc))+(PL0*kcm*kpm*((exp(-kc*(IFS+t))/((kp-kc)*(kga-kc)))+(exp(-kp*(IFS+t))/((kckp)*(kga-kp)))+(exp(-kga*(IFS+t))/((kc-kga)*(kp-kga)))))+ (GIT0*exp(kga*(IFS+t))))+(Dem*Fgd));
CL0=(((CL0*exp(-kc*(t+IFS)))+(PL0*kpm*(exp(-kc*(t+IFS))-exp(-kp*(t+IFS)))/(kpkc)))+(Dem*Fcd));
PL0=(PL0*exp(-kp*(t+IFS))) +(Dem*Fpd);
LastCC(i,j)=AmtCC(i-1,j);
LastPC(i,j)=AmtPC(i-1,j);
end
t=0;
DoseCounter=DoseCounter+1;
else
LastCC(i,j)=LastCC(i-1,j);
LastPC(i,j)=LastPC(i-1,j);
GIT0=GIT0;
CL0=CL0;
PL0=PL0;
t=t+IFS;
end
AmtPL(i,j)=PL0*exp(-kp*t);
AmtCL(i,j)=CL0*exp(-kc*t)+PL0*kpm*(exp(-kc*t)-exp(-kp*t))/(kp-kc);
GIT1=GIT0*exp(-kga*t);
GIT2=CL0*kcm*(exp(-kc*t)-exp(-kga*t))/(kga-kc);
GIT3=PL0*kpm*kcm*((exp(-kp*t)/((kc-kp)*(kga-kp)))+(exp(-kc*t)/((kp-kc)*(kgakc)))+(exp(-kga*t)/((kp-kga)*(kc-kga))));
AmtGIT(i,j)=GIT1+GIT2+GIT3;
ContPL(i,j)=PL0*kpa*( ((k21-kp)*exp(-kp*t)/((alp-kp)*(bet-kp))) + ((k21-alp)*exp(alp*t)/((kp-alp)*(bet-alp))) + ((k21-bet)*exp(-bet*t)/((kp-bet)*(alp-bet))));
ContCL(i,j)=CL0*kca*( ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc))) + ((k21-alp)*exp(alp*t)/((kc-alp)*(bet-alp))) + ((k21-bet)*exp(-bet*t)/((kc-bet)*(alp-bet))));
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ContGIT(i,j)=GIT0*kga*Foral*( ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga))) +
((k21-alp)*exp(-alp*t)/((kga-alp)*(bet-alp))) + ((k21-bet)*exp(-bet*t)/((kga-bet)*(alpbet))));
ContPLCL(i,j)=PL0*kpm*kca*( ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc)*(kp-kc))) +
((k21-kp)*exp(-kp*t)/((alp-kp)*(bet-kp)*(kc-kp))) + ((k21-alp)*exp(-alp*t)/((kp-alp)*(betalp)*(kc-alp))) + ((k21-bet)*exp(-bet*t)/((kp-bet)*(alp-bet)*(kc-bet))));
ContCLGIT(i,j)=CL0*kcm*kga*Foral*( ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc)*(kgakc))) + ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga))) + ((k21-alp)*exp(alp*t)/((kga-alp)*(bet-alp)*(kc-alp))) + ((k21-bet)*exp(-bet*t)/((kga-bet)*(alp-bet)*(kcbet))));
ContPLCLGIT(i,j)=PL0*kpm*kcm*kga*Foral*( ((k21-kc)*exp(-kc*t)/((alp-kc)*(betkc)*(kga-kc)*(kp-kc))) + ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)*(kp-kga)))
+ ((k21-alp)*exp(-alp*t)/((kga-alp)*(bet-alp)*(kc-alp)*(kp-alp))) + ((k21-bet)*exp(bet*t)/((kga-bet)*(alp-bet)*(kc-bet)*(kp-bet))) + ((k21-kp)*exp(-kp*t)/((kga-kp)*(alpkp)*(kc-kp)*(bet-kp))));
AmtCC(i,j)=ContPL(i,j)+ContCL(i,j)+ContGIT(i,j)+ContPLCL(i,j)+ContCLGIT(i,j)+ContPL
CLGIT(i,j)+LastCC(i,j);
Cp(i,j)=AmtCC(i,j)/V0;
ContPPL(i,j)=PL0*kpa*k12*( (exp(-kp*t)/((alp-kp)*(bet-kp))) + (exp(-alp*t)/((kpalp)*(bet-alp))) + (exp(-bet*t)/((kp-bet)*(alp-bet))));
ContPCL(i,j)=CL0*kca*k12*( (exp(-kc*t)/((alp-kc)*(bet-kc))) + (exp(-alp*t)/((kcalp)*(bet-alp))) + (exp(-bet*t)/((kc-bet)*(alp-bet))));
ContPGIT(i,j)=GIT0*kga*Foral*k12*( (exp(-kga*t)/((alp-kga)*(bet-kga))) + (exp(alp*t)/((kga-alp)*(bet-alp))) + (exp(-bet*t)/((kga-bet)*(alp-bet))));
ContPPLCL(i,j)=PL0*kpm*kca*k12*( (exp(-kc*t)/((alp-kc)*(bet-kc)*(kp-kc))) +
(exp(-kp*t)/((alp-kp)*(bet-kp)*(kc-kp))) + (exp(-alp*t)/((kp-alp)*(bet-alp)*(kc-alp))) +
(exp(-bet*t)/((kp-bet)*(alp-bet)*(kc-bet))));
ContPCLGIT(i,j)=CL0*kcm*kga*Foral*k12*( (exp(-kc*t)/((alp-kc)*(bet-kc)*(kga-kc)))
+ (exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga))) + (exp(-alp*t)/((kga-alp)*(bet-alp)*(kcalp))) + (exp(-bet*t)/((kga-bet)*(alp-bet)*(kc-bet))));
ContPPLCLGIT(i,j)=PL0*kpm*kcm*kga*Foral*k12*( (exp(-kc*t)/((alp-kc)*(betkc)*(kga-kc)*(kp-kc))) + (exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)*(kp-kga))) + (exp(alp*t)/((kga-alp)*(bet-alp)*(kc-alp)*(kp-alp))) + (exp(-bet*t)/((kga-bet)*(alp-bet)*(kcbet)*(kp-bet))) + (exp(-kp*t)/((kga-kp)*(alp-kp)*(kc-kp)*(bet-kp))));
AmtPC(i,j)=ContPPL(i,j)+ContPCL(i,j)+ContPGIT(i,j)+ContPPLCL(i,j)+ContPCLGIT(i,j)+
ContPPLCLGIT(i,j)+LastPC(i,j);

end
%%
CC1(1,j)=PL0*kpa*(((k21-kp)/((alp-kp)*(bet-kp))));
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CC2(1,j)=PL0*kpa*(((k21-alp)/((kp-alp)*(bet-alp))));
CC3(1,j)=PL0*kpa*(((k21-bet)/((kp-bet)*(alp-bet))));
CC4(1,j)= CL0*kca*(((k21-kc)/((alp-kc)*(bet-kc))));
CC5(1,j)=CL0*kca*((k21-alp)/((kc-alp)*(bet-alp)));
CC6(1,j)=CL0*kca*((k21-bet)/((kc-bet)*(alp-bet)));
CC7(1,j)=PL0*kpm*kca*(((k21-kc)/((alp-kc)*(bet-kc)*(kp-kc))));
CC8(1,j)=PL0*kpm*kca*((k21-kp)/((alp-kp)*(bet-kp)*(kc-kp)));
CC9(1,j)=PL0*kpm*kca*((k21-alp)/((kp-alp)*(bet-alp)*(kc-alp)));
CC10(1,j)=PL0*kpm*kca*((k21-bet)/((kp-bet)*(alp-bet)*(kc-bet)));
CC11(1,j)=GIT0*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga)));
CC12(1,j)=GIT0*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp)));
CC13(1,j)=GIT0*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet)));
CC14(1,j)=CL0*kcm*kga*Foral*(((k21-kc)/((alp-kc)*(bet-kc)*(kga-kc))));
CC15(1,j)=CL0*kcm*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga)*(kc-kga)));
CC16(1,j)=CL0*kcm*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp)*(kc-alp)));
CC17(1,j)=CL0*kcm*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet)*(kc-bet)));
CC18(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kc)/((alp-kc)*(bet-kc)*(kga-kc)*(kp-kc)));
CC19(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga)*(kc-kga)*(kpkga)));
CC20(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kp)/((kga-kp)*(alp-kp)*(kc-kp)*(bet-kp)));
CC21(1,j)=PL0*kpm*kcm*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp)*(kc-alp)*(kpalp)));
CC22(1,j)=PL0*kpm*kcm*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet)*(kc-bet)*(kpbet)));

CCa(1,j)=CC2(1,j)+CC5(1,j)+CC9(1,j)+CC12(1,j)+CC16(1,j)+CC21(1,j);
CCb(1,j)=CC3(1,j)+CC6(1,j)+CC10(1,j)+CC13(1,j)+CC17(1,j)+CC22(1,j);
CCc(1,j)=CC4(1,j)+CC7(1,j)+CC14(1,j)+CC18(1,j);
CCp(1,j)=CC1(1,j)+CC8(1,j)+CC20(1,j);
CCg(1,j)=CC11(1,j)+CC15(1,j)+CC19(1,j);
AAUC(1,j)=CCa(1,j)/alp + CCb(1,j)/bet + CCc(1,j)/kc + CCp(1,j)/kp + CCg(1,j)/kga;
Auc(1,j)=AAUC(1,j)/V0;
AUMC(1,j)=CCa(1,j)/(alp^2) + CCb(1,j)/(bet^2) + CCc(1,j)/(kc^2) + CCp(1,j)/(kp^2)
+ CCg(1,j)/(kga^2);
Mrt(1,j)=AUMC(1,j)/AAUC(1,j);
%%
[cmax(1,j),tmaxloc]=max(Cp(:,j));
tmax(1,j)=time(1,tmaxloc);
thalfbet(1,j)=0.693/bet;
end
AUC=cell(5,1);
AUC{1,1}=num2str(mean(Auc),'%.1f');
AUC{2,1}=num2str(std(Auc),'%.1f');
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AUC{3,1}=num2str(std(Auc)/sqrt(n),'%.1f');
AUC{4,1}=num2str(median(Auc),'%.1f');
AUC{5,1}=[num2str(prctile(Auc(1,:),5),'%.1f'),' - ',num2str(prctile(Auc(1,:),95),'%.1f')];
AUC{6,1}=[num2str(min(Auc),'%.1f'),' - ',num2str(min(Auc)+range(Auc),'%.1f')];
Cmax=cell(6,1);
Cmax{1,1}=num2str(mean(cmax),'%.1f');
Cmax{2,1}=num2str(std(cmax),'%.1f');
Cmax{3,1}=num2str(std(cmax)/sqrt(n),'%.1f');
Cmax{4,1}=num2str(median(cmax),'%.1f');
Cmax{5,1}=[num2str(prctile(cmax(1,:),5),'%.1f'),' ',num2str(prctile(cmax(1,:),95),'%.1f')];
Cmax{6,1}=[num2str(min(cmax),'%.1f'),' - ',num2str(min(cmax)+range(cmax),'%.1f')];
Tmax=cell(6,1);
Tmax{1,1}=num2str(mean(tmax),'%.1f');
Tmax{2,1}=num2str(std(tmax),'%.1f');
Tmax{3,1}=num2str(std(tmax)/sqrt(n),'%.1f');
Tmax{4,1}=num2str(median(tmax),'%.1f');
Tmax{5,1}=[num2str(prctile(tmax(1,:),5),'%.1f'),' - ',num2str(prctile(tmax(1,:),95),'%.1f')];
Tmax{6,1}=[num2str(min(tmax),'%.1f'),' - ',num2str(min(tmax)+range(tmax),'%.1f')];
tbethalf=cell(6,1);
tbethalf{1,1}=num2str(mean(thalfbet),'%.1f');
tbethalf{2,1}=num2str(std(thalfbet),'%.1f');
tbethalf{3,1}=num2str(std(thalfbet)/sqrt(n),'%.1f');
tbethalf{4,1}=num2str(median(thalfbet),'%.1f');
tbethalf{5,1}=[num2str(prctile(thalfbet(1,:),05),'%.1f'),' ',num2str(prctile(thalfbet(1,:),95),'%.1f')];
tbethalf{6,1}=[num2str(min(thalfbet),'%.1f'),' ',num2str(min(thalfbet)+range(thalfbet),'%.1f')];
MRT=cell(6,1);
MRT{1,1}=num2str(mean(Mrt),'%.1f');
MRT{2,1}=num2str(std(Mrt),'%.1f');
MRT{3,1}=num2str(std(Mrt)/sqrt(n),'%.1f');
MRT{4,1}=num2str(median(Mrt),'%.1f');
MRT{5,1}=[num2str(prctile(Mrt(1,:),5),'%.1f'),' - ',num2str(prctile(Mrt(1,:),95),'%.1f')];
MRT{6,1}=[num2str(min(Mrt),'%.1f'),' - ',num2str(min(Mrt)+range(Mrt),'%.1f')];
Rowname = {'Mean';'SD';'SEM';'Median';'5 - 95 th Percentile';'Range'};
Table=table(AUC,Cmax,Tmax,tbethalf,MRT,'RowNames',Rowname)
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
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%%%%%%%%%%%
Finding the Median and Percentiles
%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
mCp=zeros(size(Cp,1),1);
sdCp=zeros(size(Cp,1),1);
uci=zeros(size(Cp,1),1);
lci=zeros(size(Cp,1),1);
for i=1:1:NoP
mCp(i,1)=median(Cp(i,:));
sdCp(i,1)=std(Cp(i,:));
uci(i,1)=prctile(Cp(i,:),95);
lci(i,1)=prctile(Cp(i,:),05);
mecp=mean(Cp(i,:));
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%
Graphing
%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
set(0,'DefaultFigureWindowStyle','normal')
figure ('name','Linear','NumberTitle','off')
hold on;
ucig=area(time,uci);
set(ucig,'FaceColor',[0.8 0.8 0.8])
set(ucig,'LineStyle','--')
plot(time,uci,'--r')
lcig=area(time,lci);
set(lcig,'FaceColor',[1 1 1])
set(lcig,'LineStyle','--')
p4=plot(time,lci,'--r');
p5=plot(time,mCp,'k');
TMd90L=[0 15 30 60 120 180 240 360];
CMd90L=[0 2.28 2.59 1.53 1.00 0.68 0.46 0.18];
p6=plot(TMd90L,CMd90L,'+');
TMd45L=[0 15 30 60 120 180 240 360];
CMd45L=[0 2.83 2.44 1.94 1.33 0.73 0.45 0.16];
p7=plot(TMd45L,CMd45L,'o');
TTh60L=[0 15 30 60 120 180 240 360];
CTh60L=[0 3.22 2.99 1.91 1.19 0.84 0.61 0.25];
p8=plot(TTh60L,CTh60L,'*');
TTh30L=[0 15 30 60 120 180 240 360];
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CTh30L=[0 1.30 1.46 1.08 0.44 0.24 0.13 0.05];
p9=plot(TTh30L,CTh30L,'x');
POT201=[0 030 60 90 120 180 240 300 360 480 720 1440];
POC201=[0 0.83 2.32 2.60 2.64 2.47 2.09 1.55 1.1 0.73 0.33 0.04];
%p10=plot(POT201,POC201,'x');
set(gca,'FontSize',14)
xlabel('Time (min)')
ylabel('Plasma Conc (nM)')
legend([p4 p5 p6 p7 p8 p9],{'95% & 5% percentile','Median','Md 90', 'Md 45','Th60',
'Th30'},'location','east')
%legend([p4 p5 p10],{'95% & 5% percentile','Median','Ref #201'},'location','northeast')
title('95 and 5 Percentiles of Plasma Concentration time profile after 20000 MCS ')
axis([0 Last_time_point 0 max(uci)])
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%
Log-Graphing
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
figure ('name','Log-Linear','NumberTitle','off')
hold on;
sucig=area(time,uci);
set(sucig,'FaceColor',[0.8 0.8 0.8])
set(sucig,'LineStyle','--')
plot(time,uci,'--r')
slcig=area(time,lci);
set(slcig,'FaceColor',[1 1 1])
set(slcig,'LineStyle','--')
s4=plot(time,lci,'--r');
s5=plot(time,mCp,'k');
s6=plot(TMd90L,CMd90L,'+');
s7=plot(TMd45L,CMd45L,'o');
s8=plot(TTh60L,CTh60L,'*');
s9=plot(TTh30L,CTh30L,'x');
set(gca,'FontSize',14)
xlabel('Time (min)')
ylabel('Plasma Conc (nM)')
legend([s4 s5 s6 s7 s8 s9],{'95% & 5% percentile','Median','Md 90', 'Md 45','Th60',
'Th30'},'location','northeast')
%legend([s4 s5],{'95% & 5% percentile','Median'},'location','east')
title('95 and 5 Percentiles of Plasma Concentration time profile after 20000 MCS ')
set(gca,'YScale','log')
axis([0 500 0.1 10])
%close Log-Linear
toc(Tstart)
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Scientist Fits of IV TOB
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Figure 1. Simulations results of plasma concentration time profile on a linear-scale for
TOB 101 based on the parameters estimated from various applied weighting factors.
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Figure 2. Simulations results of plasma concentration time profile on a Log-scale for
TOB 101 based on the parameters estimated from various applied weighting factors.
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Figure 3. Simulations results of plasma concentration time profile on a linear-scale for
TOB 102 based on the parameters estimated from various applied weighting factors.

Figure 4. Simulations results of plasma concentration time profile on a Log-scale for
TOB 102 based on the parameters estimated from various applied weighting factors.
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Figure 5. Simulations results of plasma concentration time profile on a linear-scale for
TOB 103A based on the parameters estimated from various applied weighting factors.

Figure 6. Simulations results of plasma concentration time profile on a Log-scale for
TOB 103A based on the parameters estimated from various applied weighting factors.
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Figure 7. Simulations results of plasma concentration time profile on a linear-scale for
TOB 103B based on the parameters estimated from various applied weighting factors.

Figure 8. Simulations results of plasma concentration time profile on a Log-scale for
TOB 103B based on the parameters estimated from various applied weighting factors.
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Weighting Factor
Time
(min)
0
8
12
21
30
35
40
45
60
75
90
105
120
150
180
240
360
480

Conc. In
Plasma
(mg/L)
0
1.69
3.81
6.05
8.19
7.18
6.37
6.07
4.89
4.19
3.68
3.32
2.95
2.58
2.15
1.63
0.83
0.47

Visual inspection
R2
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

None
0
2.5583
3.6864
5.9322
7.8574
7.1681
6.5809
6.0785
4.9513
4.2036
3.6796
3.29
2.9834
2.5128
2.1489
1.5936
0.88439
0.49118
✓
0.99719
4.1802
11.28
0.57
5.02
0.013
0.004
27.02
0.020
0.0065
32.54
104.530
8.1734
7.82

1/y

1/y2

0
2.3939
3.4734
5.6645
7.5825
7.0156
6.5170
6.0772
5.0360
4.2940
3.7469
3.3284
2.9962
2.4923
2.1145
1.5583
0.8645
0.4810
✓
0.99369
3.9724
12.2530
0.7552
6.1634
0.0096
0.0038
39.3457
0.0174
0.0066
38.2758
105.7800
5.2690
4.9811

0
2.1752
3.177
5.2502
7.1071
6.6708
6.2762
5.9186
5.0287
4.3492
3.819
3.3958
3.0503
2.5169
2.1177
1.5432
0.84911
0.4709
✓
0.99057
43644
13.684
0.92067
6.728077
0.006447
0.003371
52.28175
0.015669
0.0054
34.46295
106.82
4.783
4.477626

Table 1. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 101.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)
0
20
30
40
50
60
75
90
120
240
360

Con. In
Plasma
(mg/L)
0
8.00
10.92
9.43
8.69
7.38
6.17
5.60
4.53
2.40
1.26

Visual inspection
R2
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

None

1/y

1/y2

0
7.8898
11.034
9.5378
8.3655
7.4362
6.3706
5.5778
4.4791
2.3487
1.3132
✓
0.99961
5.7219
11.45
0.03

0
0
7.9262
7.9638
11.0620
11.09
9.5225
9.503
8.3371
8.3039
7.4108
7.3811
6.3617
6.3496
5.5874
5.5944
4.5118
4.5422
2.3508
2.3595
1.2849
1.2703
✓
✓
0.99960 0.99965
6.1579
6.9768
11.3130 11.171
0.3176 0.033487

0.27
0.009
0.002
18.74
0.017
0.0046
26.30
95.372
4.3975
4.61

2.8069
0.0100
0.0018
18.0169
0.0193
0.0037
19.0156
96.2260
1.9270
2.0026

0.299767
0.010881
0.001862
17.11148
0.021187
0.003018
14.24506
96.598
0.90778
0.93975

Table 2. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 102.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Con. In
Plasma
(mg/L)

None

1/y

1/y2

0

0

0

0

0

40

15.7

15.6

15.4

14.589

50

11.2

11.5

11.7

11.898

60

9.55

9.35

9.55

9.9445

80

7.78

7.35

7.21

7.4312

90

6.60

6.75

6.54

6.6108

120

5.25

5.43

5.25

5.0427

150

4.16

4.43

4.39

4.128

270

2.09

1.96

2.23

2.2069

480

0.80

0.47

0.68

0.78181

Visual inspection

✓

✓

✓

R2

0.99913

0.99820

0.99799

MSC

5.213

5.1106

5.7534

Vo (Liter)

3.67

5.0473

7.0246

Vo SD

0.73

0.9146

1.0058

19.81

18.12

14.32

0.042
0.010
23.37

0.0270
0.0073
26.98

0.014505
0.004257
29.35

0.024
0.0026
10.81

0.0190
0.0023
12.12

0.014328
0.002035
14.21

87.298
3.6981
4.24

85.9500
3.2398
3.77

88.267
2.2994
2.61

Vo CV
-1

k12 (min )
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

Table 3. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB
103A. Column highlighted in green represented the weighting factor deemed acceptable
for this specific data set.
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Weighting Factor
Time
(min)

Con. In
Plasma
(mg/L)

None

1/y

1/y2

0

0

0

0

0

60

35.23

36.361 36.5410

36.007

70

34.50

32.864 32.8980

32.619

80

29.40

29.757 29.6940

29.599

90

27.06

26.993 26.8710

26.903

105

23.48

23.405 23.2470

23.39

120

20.44

20.386 20.2320

20.419

150

15.75

15.684 15.6020

15.761

180

11.34

12.303 12.3140

12.381

300

6.43

5.6055 5.7722

5.5746

510

1.98

2.2307 2.1958

2.1108

780

0.79

0.86796 0.7288

0.77255

✓

✓

✓

R

0.99893

0.99849

0.99686

MSC

5.1132

6.0122

6.1828

Vo (Liter)

11.27
0.41
3.68

11.0710
0.5230
4.72

11.459
0.71129
6.21

0.003
0.001
37.09

0.0031
0.0009
30.01

0.002489
0.000687
27.62

0.005
0.0047
86.74

0.0071
0.0023
32.38

0.005619
0.001232
21.92

88.812
8.0764
9.09

89.8970
2.2091
2.46

90.337
1.8016
1.99

Visual inspection
2

Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

Table 4. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB
103B. Column highlighted in green represented the weighting factor deemed acceptable
for this specific data set.

MCS Results for IV TOB
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Figure 9. TOB 104 VPC predictions using model 2’s inability to capture pre-dose level
on day 3.

Figure 10. TOB 104 VPC predictions using model 2’s in order to capture pre-dose level,
the remaining data points would not be captured.
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Figure 11. TOB 101 VPC and exposure metric variability comparison. (top left -cp(t)
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP)

Figure 12. TOB 102 VPC and exposure metric variability comparison. (top left -cp(t)
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP)
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Figure 13. TOB 103A VPC and exposure metric variability comparison. (top left -cp(t)
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP)

Figure 14. TOB 103B VPC and exposure metric variability comparison. (top left -cp(t)
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP)
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Table 6. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 102

Table 7. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 103A

Table 8. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 103B

Table 9. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 104
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SD and RD Sensitivity Analysis Plots for IV TOB

Figure 15. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a SD IV
administration of 105 mg

Figure 16. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a SD IV
administration of 105 mg
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Figure 17. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a SD IV
administration of 105 mg

Figure 18. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a SD IV
administration of 105 mg
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Figure 19. Resulting cp(t) and cs(t) from a 25-fold change in kca after a SD IV
administration of 105 mg

Figure 20. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a SD IV
administration of 105 mg
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Figure 21. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a SD IV
administration of 105 mg

Figure 22. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a SD IV
administration of 105 mg
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Figure 23. Resulting cp(t) and cs (t) from a 25-fold change in kcd after a SD IV
administration of 105 mg

Figure 24. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a SD IV
administration of 105 mg
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Figure 25. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a SD IV
administration of 105 mg

Figure 26. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a SD IV
administration of 105 mg
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Figure 27. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a SD IV
administration of 105 mg

Figure 28. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a three-day RD
IV administration of 105 mg
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Figure 29. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a three-day RD IV
administration of 105 mg

Figure 30. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a three-day RD IV
administration of 105 mg
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Figure 31. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a three-day RD IV
administration of 105 mg

Figure 32. Resulting cp(t) and cs(t) from a 25-fold change in kca after a three-day RD IV
administration of 105 mg
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Figure 33. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a three-day RD IV
administration of 105 mg

Figure 34. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a three-day RD IV
administration of 105 mg
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Figure 35. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a three-day RD IV
administration of 105 mg

Figure 36. Resulting cp(t) and cs (t) from a 25-fold change in kcd after a three-day RD IV
administration of 105 mg
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Figure 37. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a three-day RD IV
administration of 105 mg

Figure 38. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a three-day RD IV
administration of 105 mg
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Figure 39. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a three-day RD IV
administration of 105 mg

Figure 40. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a three-day RD IV
administration of 105 mg

VPC Plots for INH TOB
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Figure 41. TOB 302A exposure metric variability comparison. (left -Reported vs
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp,max
WHP)

Figure 42. TOB 302B exposure metric variability comparison. (left -Reported vs
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp,max
WHP)
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Figure 43. TOB 302C exposure metric variability comparison. (left -Reported vs
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp, max
WHP)

Figure 44. TOB 302D exposure metric variability comparison. (left -Reported vs
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp, max
WHP)
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Figure 45. TOB 303A VPC and exposure metric variability comparison. (left -cp(t) VPC
profile, center – Reported vs simulated cp AUC box and whisker plot (WHP), right Reported vs simulated cp, max WHP)

Figure 46. TOB 303B VPC and exposure metric variability comparison. (left -cp(t) VPC
profile, center – Reported vs simulated cp AUC box and whisker plot (WHP), right Reported vs simulated cp, max WHP)
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Figure 47. TOB 307A VPC and exposure metric variability comparison. (Top left -cp(t)
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box
and whisker plot (WHP), bottom left - Reported vs simulated cp, max WHP, bottom center
- Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cp, max
WHP)

Figure 48. TOB 307B VPC and exposure metric variability comparison. (Top left -cp(t)
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box
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and whisker plot (WHP), bottom left - Reported vs simulated cp,max WHP, bottom center
- Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cs,max WHP)

Figure 49. TOB 307C VPC and exposure metric variability comparison. (Top left -cp(t)
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box
and whisker plot (WHP), bottom left - Reported vs simulated cp,max WHP, bottom center Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cs,max WHP)
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Figure 50. TOB 309A VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)

Figure 51. TOB 309b VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)
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Figure 52. TOB 309C VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)

Figure 53. TOB 309D VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)
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Figure 54. TOB 309E VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)

Figure 55. TOB 309F VPC and exposure metric variability comparison. (Top left Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right Reported vs simulated cs,max WHP)
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SD and RD Sensitivity Analysis Plots for INH TOB

Figure 60. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a SD INH
administration of 300 mg

Figure 61. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a SD INH
administration of 300 mg
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Figure 62. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a SD INH
administration of 300 mg

Figure 63. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a SD INH
administration of 300 mg
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Figure 64. Resulting cp(t) and cs(t) from a 25-fold change in kca after a SD INH
administration of 300 mg

Figure 65. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a SD INH
administration of 300 mg
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Figure 66. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a SD INH
administration of 300 mg

Figure 67. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a SD INH
administration of 300 mg
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Figure 68. Resulting cp(t) and cs(t) from a 25-fold change in kcd after a SD INH
administration of 300 mg

Figure 69. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a SD INH
administration of 300 mg
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Figure 70. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a SD INH
administration of 300 mg

Figure 71. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a SD INH
administration of 300 mg
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Figure 72. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a SD INH
administration of 300 mg

Figure 73. Representative predictions of cp(t) and cs(t) profiles for study 307A after
attempts to optimize Fpd using Model 3 and IV optimized systemic and pulmonary
disposition parameters.
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Figure 74. Predictions of both TOB 104 and 307 aftersimulatenous parameter
optimization with both data sets.

Figure 75. Simultaneous predictions of the four cp(t) and cs(t) profiles from TOB 307.
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Table 10. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 302A

Table 11. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 302B

Table 12. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 302C

Table 13. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 302D

Table 14. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 303A
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Table 15. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 303B

Table 16. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 307A

Table 17. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 307B

Table 18. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 307C

Table 19. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 307D
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Table 20. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309A

Table 21. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309B

Table 22. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309C

Table 23. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309D
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Table 24. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309E

Table 25. Reported exposure metric central tendency and dispersion compared to
simulated values for the same metrics for TOB 309F
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Study ID
Group
Device
Dose (mg)
DTL (%)
Estimated DTL (mg)
Inhalation Time (min)
Sputum Tmax (h)
Sputum Cmax (ug/g)
Sputum AUC (ug*h/g)
Sputum t1/2 (h)
Serum Tmax (h)
Serum Cmax (ug/ml)
Serum AUC (ug*h/ml)
Serum t1/2 (h)
Calculated Finh %
Age
BW

307 A
CF
Pari
300
9.1
27
18
0.26
986
1471
1.14
0.38
1.43

30
35.4
11
2.80
0.24
329
361

79

0.98
0.69
2.98

60
35.4
21
5.40
0.38
578
805

70

1.14
0.96
3.94

90
35.4
32
8.00
0.33
958
1275

307D
307C
CF
CF
AeroDose

1.05
1.12
4.96

76

307 B
CF

102

24
57 kg

80
34.3
27
15.00

303B
HV

309A
CF

309C
309B
CF
CF
PulmoSphere
303A
HV
Pari
300
5.3
16
15.00

56
34.3
19
4.20
0.5
515
1195
1.8
1
0.56
2.8
3.5
82
1.75
0.6
4.4
3.7
90

309D
CF
84
56
34.3
34.3
29
19
4.50
2.50
0.5
0.5
1092
574
1340
652
0.8
1.3
1
1
0.7
0.5
3.5
2.5
3.4
3.3
68
73
24/22/22/24/21/20
NA
28
34.3
10
1.70
0.5
258
261
0.9
1
0.33
1.3
2.8
76
2
0.28
2.1
4.2
74
34
NA

309E
CF
112
34.3
38
4.90
0.5
1048
1307
2.2
1
1.02
4.6
3.1
67

309F
CF
Pari
300
10
30
16.00
0.5
737
974
1.7
1
1.04
4.8
3
90

302A
HV
Pari
300
14.8
44
16.00

1
0.6
3.3
5.8
42

302B
HV
eFlow
300
15.1
45
8.50

302C
CF
Pari
300
13.3
40
20.00

1
1
1.2
0.7
5
3.6
2.7
4.6
71
45
33/44/22/21
NA

302D
CF
eFlow
300
8.9
27
8.00

1
0.5
1.9
2.7
40

Table 26. Reported plasma and sputum exposure metrics and relevant study design
components for the analyzed inhalation studies.
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Mass Balance Total Excretion Plots for TOB

Figure 56. Mass balance drug excretion IV administration simulation results based on the
final optimized IV parameter space. Left plot represents cumulative drug eliminated from
the central unbound lung compartment via kcm. Right plot represents cumulative drug
eliminated from the central compartment via CLtot.

Figure 57. Mass balance drug excretion IV administration simulation results based on the
final optimized INH parameter space. Left plot represents cumulative drug eliminated from
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the central unbound lung compartment via kcm. Right plot represents cumulative drug
eliminated from the central compartment via CLtot.

Figure 58. Mass balance drug excretion INH administration simulation results based on
the final optimized IV parameter space. Left plot represents cumulative drug eliminated
from the central unbound lung compartment via kcm. Right plot represents cumulative drug
eliminated from the central compartment via CLtot.

Figure 59. Mass balance drug excretion INH administration simulation results based on
the final optimized IV parameter space. Left plot represents cumulative drug eliminated
from the central unbound lung compartment via kcm. Right plot represents cumulative
drug eliminated from the central compartment via CLtot.
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Various codes utilized for TOB analysis
IndVars: T
DepVars: CP1
Params: D1, Tinf1,V0, k12, k21, Cltot
//
// dose in mg
// conc in mg/L
// time in min
//
// Input
ARATE11=D1/Tinf1
FLAG1=UNIT(T-Tinf1)
ARATE=ARATE11*(1-FLAG1)
//
// PK-Model
AP1'=ARATE+k21*AT1-((Cltot/(V0*1000))+k12)*AP1
AT1'=k12*AP1-k21*AT1
CP1=AP1/V0
//
// Initial Conditions
T=0
AP1=0
AT1=0
***
Code 1. Two compartment open body model describing TOB disposition after IV
infusion administration
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rm(list=ls()); cat("\014");dev.off();set.seed(12301991);Start.time <- proc.time() # start a
timer
BW.me <- 57.4
BW.cv <- 13*100/BW.me
n
<- 300
PerKgDose <- 8 #mg/kg
tinf <- 10
t <- seq(0,3360,10)
Clpop <- 70
Clprop.me <- 1
k12.me <- 0.010
k21.me <- 0.015
V0pop <- 10
V0prop.me <- 1
Clprop.cv <- 20
k12.cv <- 30
k21.cv <- 30
V0prop.cv <- 20
kga.me <- 1
Foral.me <- 0
kga.cv <- 0
Foral.cv <- 0
kpa.me <- 0.006
kca.me <- 0.9
kpm.me <- 0.16
kcm.me <- 0.6
kpd.me <- 0.0008
kcd.me <- 0.001
TLV.me <- 20 #ml
kpls1.me <- 0.0005
kpls2.me <- 0.0001
kcls1.me <- 0.0005
kcls2.me <- 0.0002
kpa.cv <- 30
kca.cv <- 30
kpm.cv <- 20
kcm.cv <- 20
kpd.cv <- 30
kcd.cv <- 30
kpls1.cv <- 30
kpls2.cv <- 30
kcls1.cv <- 30
kcls2.cv <- 30
TLVprop.me <- 1
TLVprop.cv <- 20
kin.me <- 0
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Fex.me <- 0.009
Fpd.me <- 0.21
Fcd.me <- 0.069
Din.me <- 0
kin.cv <- 0
Fex.cv <- 57
Fpd.cv <- 30
Fcd.cv <- 30
Din.cv <- 9
######################################################################
########
##################### Normal Distribution Generator ###########
######################################################################
########
NormGen <- function(simulation.n,samp.m,samp.cv ){
samp.sd <- samp.cv*samp.m/100
out <- rnorm(simulation.n,samp.m,samp.sd)
return(out)
}
LogNormGen <- function(n, Mean, PCV){
CV <- PCV/100
SD <- (CV*Mean)
Variance <- SD^2
mean.in <- log(Mean^2 / sqrt(Variance+Mean^2))
SD.in <- sqrt(log(Variance/Mean^2 + 1))
x=rlnorm(n,mean.in,SD.in)
return(x)
}
######################################################################
########
####################### Generation of numbers
######################################################################
########BW.n <- NormGen(n, BW.me,BW.cv)
Clprop.n <- NormGen(n, Clprop.me,Clprop.cv)
k12.n <- LogNormGen(n, k12.me,k12.cv)
k21.n <- LogNormGen(n, k21.me,k21.cv)
V0prop.n <- NormGen(n, V0prop.me,V0prop.cv)
kga.n <- LogNormGen(n, kga.me,kga.cv)
if (Foral.me==0){Foral.n<-matrix(0,1,n)} else if (Foral.me>0){Foral.n<LogNormGen(n,Foral.me,Foral.cv)}

kpa.n <- LogNormGen(n, kpa.me,kpa.cv)
kca.n <- LogNormGen(n, kca.me,kca.cv)
kpm.n <- LogNormGen(n, kpm.me,kpm.cv)
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kcm.n

<- LogNormGen(n, kcm.me,kcm.cv)

if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n <- NormGen(n, Fex.me,Fex.cv)
Fpd.n <- NormGen(n, Fpd.me,Fpd.cv)
Fcd.n <- NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
########
##############
Set up the ODE Based model function
#######################
######################################################################
########
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,
kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf ){
Dose.Value <- (1-Din)*Dose
Fgd
<- 1-Fex-Fpd-Fcd
ED <- data.frame(var = c("DOSING"), time = c(t[1],tinf,1440,1450,2880,2890), value =
c(Dose.Value/tinf,0), method = c("rep"))
Model.Function <- function(t,IC,Parm) {
with(as.list(IC, Parm), {
dDOSING <- 0
dIn <- -In*kin*(Fex+Fpd+Fcd+Fgd)
dPLU <- In*kin*Fpd + PLS*kpd - PLU*(kpa + kpm)
dCLU <- In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm
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dGI <- In*kin*Fgd + CLU* kcm - GI*kga
dPLS <- PLU*kpa + CC*kpls1 - PLS * (kpd+kpls2)
dCLS <- CLU*kca + CC*kcls1 - CLS * (kcd+kcls2)
dCC <- PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 +
k12 + (Cltot/(V0*1000)))+ DOSING
dPC <- CC* k12 - PC *k21
dEx <- In*kin*Fex
dFe <- GI*kga*(1-Foral)
dEl <- CC*(Cltot/(V0*1000))
return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))
})
}
IC <c(In=0, PLU=0*Fpd, CLU=0*Fcd, PLS=0, CLS=0, GI=0*Fgd, CC=0, PC=0,
Ex=0*Fex, Fe=0, El=0,DOSING=0)
Parm <c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1,
kcls2, kin, Fex, Fpd, Fcd, Fgd)
out <- ode(IC, t,Model.Function,Parm,events = list(data=ED))
return(out)
}
######################################################################
########
#####################
PBPK Model iterations
#####################
######################################################################
########
Dose.n <- BW.n*PerKgDose
Cltot.n <- Clpop*(BW.n/mean(BW.n))^0.75 * Clprop.n
V0.n <- V0pop*(BW.n/mean(BW.n))^1
* V0prop.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
In.Data <- matrix(0,length(t),(n))
PLU.Data <- matrix(0,length(t),(n))
CLU.Data <- matrix(0,length(t),(n))
PLS.Data <- matrix(0,length(t),(n))
CLS.Data <- matrix(0,length(t),(n))
GI.Data <- matrix(0,length(t),(n))
CC.Data <- matrix(0,length(t),(n))
PC.Data <- matrix(0,length(t),(n))
Ex.Data <- matrix(0,length(t),(n))
Fe.Data <- matrix(0,length(t),(n))
El.Data <- matrix(0,length(t),(n))
236

CP.Data <- matrix(0,length(t),(n))
CS.Data <- matrix(0,length(t),(n))
PL.Data <- matrix(0,length(t),(n))
Cmax.n=rep(0,(n))
C30.n=rep(0,(n))
C60.n=matrix(0,1,n)
Smax.n=rep(0,n)
AUC.n=Dose.n*1000/Cltot.n/60
k10.n <- Cltot.n/V0.n/1000
a.p.b.n <- k10.n+k12.n+k21.n
a.t.b.n <- k10.n*k21.n
beta.n <- (a.p.b.n - ( a.p.b.n^2 - 4*a.t.b.n )^0.5 )*0.5
beta.n <- beta.n*60
t0.5.n <- 0.693/beta.n
for (i in 1:n) {
Dose <- Dose.n[i]
Cltot <- Cltot.n[i]
k12 <- k12.n[i]
k21 <- k21.n[i]
V0 <- V0.n[i]
kga <- kga.n[i]
Foral <- Foral.n[i]
kpa <- kpa.n[i]
kca <- kca.n[i]
kpm <- kpm.n[i]
kcm <- kcm.n[i]
kpd <- kpd.n[i]
kcd <- kcd.n[i]
kpls1 <- kpls1.n[i]
kpls2 <- kpls2.n[i]
kcls1 <- kcls1.n[i]
kcls2 <- kcls2.n[i]
CLV <- CLV.n[i]
PLV <- PLV.n[i]
kin <- kin.n[i]
Fex <- Fex.n[i]
Fpd <- Fpd.n[i]
Fcd <- Fcd.n[i]
Din <- Din.n[i]
Current.Iteration.Data <- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd,
kcd, kpls1, kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf)
In.Data[,i] <- Current.Iteration.Data[,2]
PLU.Data[,i] <- Current.Iteration.Data[,3]
CLU.Data[,i] <- Current.Iteration.Data[,4]
PLS.Data[,i] <- Current.Iteration.Data[,5]
CLS.Data[,i] <- Current.Iteration.Data[,6]
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GI.Data[,i] <- Current.Iteration.Data[,7]
CC.Data[,i] <- Current.Iteration.Data[,8]
PC.Data[,i] <- Current.Iteration.Data[,9]
Ex.Data[,i] <- Current.Iteration.Data[,10]
Fe.Data[,i] <- Current.Iteration.Data[,11]
El.Data[,i] <- Current.Iteration.Data[,12]
CP.Data[,i] <- Current.Iteration.Data[,8]/V0
CS.Data[,i] <- Current.Iteration.Data[,4]/CLV
PL.Data[,i] <- Current.Iteration.Data[,3]/PLV
Cmax.n[i]<- max(CP.Data[,i])
C30.n[i] <- CP.Data[292,i]
#C60.n[i]=CP.Data[61,i]
Smax.n [i] <- max(CS.Data[,i])
}
######################################################################
########
################### VPC Plotting Function for TS DATA ###################
######################################################################
########
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){
Size.of.Data<-dim(Data); PlottingData <- matrix(0,Size.of.Data[1],4)
PlottingData[,1] <-Current.Iteration.Data[,1]
for(i in 1:length(t)){
PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <- quantile(Data[i,],0.50)
PlottingData[i,4] <- quantile(Data[i,],0.95) }
Time <- PlottingData[,1]; Bottom <- PlottingData[,2]
Top <- PlottingData[,4]; Middle <- PlottingData[,3]
ColNumbers <- col2rgb(Color); par(TRUE)
mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90)
plot(Time, Bottom, type= "n", col=Color, main=Title,
ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax),
ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color, lwd=2.8)
return()
}
TOB104.Time <- c(0, 30, 60, 240, 360, 480)+2880
TOB104.Conc <- c(0, 29.5, 20.7, 7.8, 4.4, 3.9)
TOB104.Conc.upper <- c(0, 33.3, 23.5, 9.5, 5.6, 4.5)
TOB104.Conc.lower <- c(0, 25.5, 17.9, 5.9, 3.2, 2.8)
TOB104.STime <- c(2880, 3000, 3120,3300)
TOB104.SConc <- c(2.2, 3.1, 3.9, 2.5)
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TOB104.SConc.upper <- c(3.6, 4.3, 5.4, 4.0)
TOB104.SConc.lower <- c(0.9, 1.7, 2.4, 0.9)

#mean(beta.n);max(beta.n);min(beta.n)
#mean(C30.n);max(C30.n);min(C30.n)
#mean(AUC.n);max(AUC.n) ;min(AUC.n)
#mean(Smax.n);max(Smax.n);min(Smax.n);
#dev.off();par(mfrow=c(1,1));hist(TLV.n)
#mean(TLV.n);quantile(TLV.n,0.5);sd(TLV.n);max(TLV.n);min(TLV.n)
End.time <- proc.time();Total.time <- End.time-Start.time;Total.time
AUC.BX<-boxplot(AUC.n,AUC.n, names=c("Rep AUC","Sim AUC")) #, ylim=c(20,100)
AUC.BX$out<-0
AUC.BX$stats[1,1] <- 60
AUC.BX$stats[2,1] <- 82
AUC.BX$stats[3,1] <- 82
AUC.BX$stats[4,1] <- 82
AUC.BX$stats[5,1] <-115
bxp(AUC.BX,ylim=c(40,120))
C30.BX<-boxplot(C30.n,C30.n, names=c("Rep C30","Sim C30"))
C30.BX$out<-0
C30.BX$stats[1,1]
C30.BX$stats[2,1]
C30.BX$stats[3,1]
C30.BX$stats[4,1]
C30.BX$stats[5,1]

<- 23
<- 29.4
<- 29.4
<- 29.4
<- 36

BET.BX<-boxplot(beta.n,beta.n, names=c("Rep Beta","Sim Beta"))
BET.BX$out<-0
BET.BX$stats[1,1]
BET.BX$stats[2,1]
BET.BX$stats[3,1]
BET.BX$stats[4,1]
BET.BX$stats[5,1]

<- 0.22
<- 0.29
<- 0.29
<- 0.29
<- 0.38

dev.off();par(mfrow=c(2,3)); par(TRUE)
VPCP(CP.Data,'green',1,100,2880,3360,'Cp vs t','Plasma Conc (ug/ml)','y')
yLine <- seq(0.001,2000,100); xLine1 <- rep(0,length(yLine))
xLine2 <- rep(1440,length(yLine)); xLine3 <- rep(2880,length(yLine))
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lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
points(TOB104.Time,TOB104.Conc,col='red',pch=20,cex=2.5)
points(TOB104.Time,TOB104.Conc.upper,col='red',cex=2.5,pch='-')
points(TOB104.Time,TOB104.Conc.lower,col='red',cex=2.5,pch='-')
VPCP(CS.Data,'cyan',0.5,10, 2880,3360,'Cs vs t','Sputum Conc (ug/ml)','y')
points(TOB104.STime,TOB104.SConc,col='black',pch=20,cex=2.5)
points(TOB104.STime,TOB104.SConc.upper,col='black',cex=2.5,pch='-')
points(TOB104.STime,TOB104.SConc.lower,col='black',cex=2.5,pch='-')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(PL.Data,'grey',5,90, 2880,3360,'PL Conc vs t','PL Conc (ug/ml)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
bxp(AUC.BX,ylim=c(60,180), main='AUC',ylab='AUC (mg*hr/l)')
bxp(C30.BX,ylim=c(22,50),main='C30',ylab='Plasma Conc at t=2910 min (mg/L)')
bxp(BET.BX,ylim=c(0.1,0.4),main='Beta',ylab='Beta (hr-1)')
######################################################################
########
# #################### Key under the hood plots
######################################################################
########
dev.off();par(mfrow=c(2,3)); par(TRUE)
TL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));return(X)}
LL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));X<-X/100;return(X)}
yLine <- seq(0.0001,10000.0001,100); xLine1 <- rep(0,length(yLine))
xLine2 <- rep(1440,length(yLine)); xLine3 <- rep(2880,length(yLine))
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(PLU.Data,'blue',LL(PLU.Data),TL(PLU.Data), 0,3360,'PLU','PLU (mg)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(CLU.Data,'blue',LL(CLU.Data),TL(CLU.Data), 0,3360,'CLU','CLU (mg)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(PLS.Data,'blue',LL(PLS.Data),TL(PLS.Data), 0,3360,'PLS','PLS (mg)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(CLS.Data,'blue',LL(CLS.Data),TL(CLS.Data), 0,3360,'CLS','CLS (mg)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
VPCP(CC.Data,'blue',LL(CC.Data),TL(CC.Data), 0,3360,'CC','CC (mg)','y')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
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VPCP2 <function(Data1,Data2,Color1,Color2,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){
Size.of.Data<-dim(Data1); PlottingData <- matrix(0,Size.of.Data[1],4)
PlottingData[,1] <-Current.Iteration.Data[,1]
for(i in 1:length(t)){
PlottingData[i,2] <- quantile(Data1[i,],0.05); PlottingData[i,3] <- quantile(Data1[i,],0.50)
PlottingData[i,4] <- quantile(Data1[i,],0.95) }
Time <- PlottingData[,1]; Bottom <- PlottingData[,2]
Top <- PlottingData[,4]; Middle <- PlottingData[,3]
ColNumbers <- col2rgb(Color1); par(TRUE)
mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90)
plot(Time, Bottom, type= "n", col=Color1, main=Title,
ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax),
ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color1, lwd=2.8)
Size.of.Data<-dim(Data2); PlottingData <- matrix(0,Size.of.Data[1],4)
PlottingData[,1] <-Current.Iteration.Data[,1]
for(i in 1:length(t)){
PlottingData[i,2] <- quantile(Data2[i,],0.05); PlottingData[i,3] <- quantile(Data2[i,],0.50)
PlottingData[i,4] <- quantile(Data2[i,],0.95) }
Time<- PlottingData[,1]; Bottom <- PlottingData[,2]
Top <- PlottingData[,4]; Middle <- PlottingData[,3]
ColNumbers <- col2rgb(Color2); par(TRUE)
mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color2, lwd=2.8)
return()
}
VPCP2(CP.Data,CS.Data,'green','cyan',0,50, 2880,3360,'Cp(t) & Cs(t)','Concentrations
(ug/ml)','')
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red')
points(TOB104.Time,TOB104.Conc,col='red',pch=20)
points(TOB104.Time,TOB104.Conc.upper,col='red',cex=2,pch='-')
points(TOB104.Time,TOB104.Conc.lower,col='red',cex=2,pch='-')
points(TOB104.STime,TOB104.SConc,col='black',pch=20)
points(TOB104.STime,TOB104.SConc.upper,col='black',cex=2,pch='-')
points(TOB104.STime,TOB104.SConc.lower,col='black',cex=2,pch='-')
#for(i in 1:length(t)) {print(sum(Current.Iteration.Data[i,seq(2,12)]))}
#Dose.n[n]*3
#Slope <- lm(Current.Iteration.Data[seq(317,337,1),1]~CP.Data[seq(317,337,1),1])
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#-0.693/Slope$coefficients[2]
CPRes1 <- abs(TOB104.Conc[2]-mean(CP.Data[292,]))/TOB104.Conc[2]
CPRes2 <- abs(TOB104.Conc[3]-mean(CS.Data[295,]))/TOB104.Conc[3]
CPRes3 <- abs(TOB104.Conc[4]-mean(CS.Data[313,]))/TOB104.Conc[4]
CPRes4 <- abs(TOB104.Conc[5]-mean(CS.Data[325,]))/TOB104.Conc[5]
CPRes5 <- abs(TOB104.Conc[6]-mean(CS.Data[337,]))/TOB104.Conc[6]
Res1 <- abs(TOB104.SConc[1]-mean(CS.Data[289,]))/TOB104.SConc[1]
Res2 <- abs(TOB104.SConc[2]-mean(CS.Data[310,]))/TOB104.SConc[2]
Res3 <- abs(TOB104.SConc[3]-mean(CS.Data[313,]))/TOB104.SConc[3]
Res4 <- abs(TOB104.SConc[4]-mean(CS.Data[331,]))/TOB104.SConc[4]
(CPRes1+CPRes2+CPRes3+CPRes4+CPRes5)
(Res1+Res2+Res3+Res4)*10

Code 2 Rscript utilized for performing optimization and plotting of MCS
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rm(list=ls()); cat("\014");dev.off();set.seed(12301991);Start.time <- proc.time() # start a
timer
BW.me <- 70
BW.cv <- 0*100/BW.me
n
<- 3
PerKgDose <- 1.5 #mg/kg
tinf <- 10
t <c(0,5,10,15,20,30,45,60,90,120,180,240,300,360,420,480,540,600,660,720,780,840,90
0,960,1020,1080,1140,1200,1260,1320,1380,1440,1450,1500,1560,1620,1680,1740,18
00,1860,1920,1980,2040,2100,2160,2220,2280,2340,2400,2460,2520,2580,2640,2700,
2760,2820,2880,2890,seq(49,72)*60)
Clpop <- 70
Clprop.me <- 1
k12.me <- 0.010
k21.me <- 0.015
V0pop <- 10
V0prop.me <- 1
Clprop.cv <- 0
k12.cv <- 0
k21.cv <- 0
V0prop.cv <- 0
kga.me <- 1
Foral.me <- 0
kga.cv <- 0
Foral.cv <- 0
kpa.me <- 0.006
kca.me <- 0.9
kpm.me <- 0.16
kcm.me <- 0.6
kpd.me <- 0.0008
kcd.me <- 0.001
TLV.me <- 20 #ml
kpls1.me <- 0.0005
kpls2.me <- 0.0001
kcls1.me <- 0.0005
kcls2.me <- 0.0002
kpa.cv <- 0
kca.cv <- 0
kpm.cv <- 0
kcm.cv <- 0
kpd.cv <- 0
kcd.cv <- 0
kpls1.cv <- 0
kpls2.cv <- 0
kcls1.cv <- 0
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kcls2.cv <- 0
TLVprop.me <- 1
TLVprop.cv <- 0
kin.me <- 0
Fex.me <- 0.009
Fpd.me <- 0.21
Fcd.me <- 0.069
Din.me <- 0
kin.cv <- 0
Fex.cv <- 0
Fpd.cv <- 0
Fcd.cv <- 0
Din.cv <- 0
######################################################################
########
##################### Normal Distribution Generator
#####################
######################################################################
########
NormGen <- function(simulation.n,samp.m,samp.cv ){
samp.sd <- samp.cv*samp.m/100
out <- rnorm(simulation.n,samp.m,samp.sd)
return(out)
}
LogNormGen <- function(n, Mean, PCV){
CV <- PCV/100
SD <- (CV*Mean)
Variance <- SD^2
mean.in <- log(Mean^2 / sqrt(Variance+Mean^2))
SD.in <- sqrt(log(Variance/Mean^2 + 1))
x=rlnorm(n,mean.in,SD.in)
return(x)
}
######################################################################
########
####################### Generation of numbers
################################
######################################################################
########
BW.n <- NormGen(n, BW.me,BW.cv)
Clprop.n <- NormGen(n, Clprop.me,Clprop.cv)
Cltot.n <- Clpop*(BW.n/mean(BW.n))^0.75 * Clprop.n
#Cltot.n <- c(Clpop/5,Clpop,5*Clpop)
k12.n

<- LogNormGen(n, k12.me,k12.cv)
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#k12.n

<- c(k12.me/5,k12.me,5*k12.me)

k21.n <- LogNormGen(n, k21.me,k21.cv)
#k21.n <- c(k21.me/5,k21.me,5*k21.me)
V0prop.n <- NormGen(n, V0prop.me,V0prop.cv)
V0.n <- V0pop*(BW.n/mean(BW.n))^1
* V0prop.n
#V0.n <- c(V0pop/5,V0pop,5*V0pop)
kga.n <- LogNormGen(n, kga.me,kga.cv)
if (Foral.me==0){Foral.n<-matrix(0,1,n)} else if (Foral.me>0){Foral.n<LogNormGen(n,Foral.me,Foral.cv)}

kpa.n <- LogNormGen(n, kpa.me,kpa.cv)
#kpa.n <- c(kpa.me/5,kpa.me,5*kpa.me)
kca.n <- LogNormGen(n, kca.me,kca.cv)
#kca.n <- c(kca.me/5,kca.me,5*kca.me)
kpm.n <- LogNormGen(n, kpm.me,kpm.cv)
#kpm.n <- c(kpm.me/5,kpm.me,5*kpm.me)
kcm.n <- LogNormGen(n, kcm.me,kcm.cv)
#kcm.n <- c(kcm.me/5,kcm.me,5*kcm.me)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
kpd.n <- c(kpd.me/5,kpd.me,5*kpd.me)
kpd.n <-c(5*kpd.me,5*kpd.me,5*kpd.me)
kpd.n <-c(kpd.me,kpd.me,kpd.me)
#kpd.n <- c(kpd.me/5,kpd.me/5,kpd.me/5)
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
#kcd.n <- c(kcd.me/5,kcd.me,5*kcd.me)
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
#kpls1.n <- c(kpls1.me/5,kpls1.me,5*kpls1.me)
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
#kpls2.n <- c(kpls2.me/5,kpls2.me,5*kpls2.me)
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
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#kcls1.n

<- c(kcls1.me/5,kcls1.me,5*kcls1.me)

if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
#kcls2.n <- c(kcls2.me/5,kcls2.me,5*kcls2.me)
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n <- NormGen(n, Fex.me,Fex.cv)
Fpd.n <- NormGen(n, Fpd.me,Fpd.cv)
Fcd.n <- NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
########
##############
Set up the ODE Based model function
#######################
######################################################################
########TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2,
kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf ){
Dose.Value <- (1-Din)*Dose
Fgd
<- 1-Fex-Fpd-Fcd
ED <- data.frame(var = c("DOSING"), time = c(t[1],tinf,1440,1450,2880,2890), value =
c(Dose.Value/tinf,0), method = c("rep"))
Model.Function <- function(t,IC,Parm) {
with(as.list(IC, Parm), {
dDOSING <- 0
dIn <- -In*kin*(Fex+Fpd+Fcd+Fgd)
dPLU <- In*kin*Fpd + PLS*kpd - PLU*(kpa + kpm)
dCLU <- In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm
dGI <- In*kin*Fgd + CLU* kcm - GI*kga
dPLS <- PLU*kpa + CC*kpls1 - PLS * (kpd+kpls2)
dCLS <- CLU*kca + CC*kcls1 - CLS * (kcd+kcls2)
dCC <- PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 +
k12 + (Cltot/(V0*1000)))+ DOSING
dPC <- CC* k12 - PC *k21
dEx <- In*kin*Fex
dFe <- GI*kga*(1-Foral)
dEl <- CC*(Cltot/(V0*1000))
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return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))
})
}
IC <c(In=0, PLU=0*Fpd, CLU=0*Fcd, PLS=0, CLS=0, GI=0*Fgd, CC=0, PC=0,
Ex=0*Fex, Fe=0, El=0,DOSING=0)
Parm <c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1,
kcls2, kin, Fex, Fpd, Fcd, Fgd)
out <- ode(IC, t,Model.Function,Parm,events = list(data=ED))
return(out)
}
######################################################################
########
#####################
PBPK Model iterations
#####################
######################################################################
########
Dose.n <- BW.n*PerKgDose
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
In.Data <- matrix(0,length(t),(n))
PLU.Data <- matrix(0,length(t),(n))
CLU.Data <- matrix(0,length(t),(n))
PLS.Data <- matrix(0,length(t),(n))
CLS.Data <- matrix(0,length(t),(n))
GI.Data <- matrix(0,length(t),(n))
CC.Data <- matrix(0,length(t),(n))
PC.Data <- matrix(0,length(t),(n))
Ex.Data <- matrix(0,length(t),(n))
Fe.Data <- matrix(0,length(t),(n))
El.Data <- matrix(0,length(t),(n))
CP.Data <- matrix(0,length(t),(n))
CS.Data <- matrix(0,length(t),(n))
PL.Data <- matrix(0,length(t),(n))
Cmax.n=rep(0,n)
tmax.n=rep(0,n)
Smax.n=rep(0,n)
tsmax.n=rep(0,n)
AUC.n=Dose.n*1000/Cltot.n/60
for (i in 1:n) {
Dose <- Dose.n[i]
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Cltot
k12
k21
V0

<- Cltot.n[i]
<- k12.n[i]
<- k21.n[i]
<- V0.n[i]

kga <- kga.n[i]
Foral <- Foral.n[i]
kpa
kca
kpm
kcm
kpd
kcd
kpls1
kpls2
kcls1
kcls2
CLV
PLV

<- kpa.n[i]
<- kca.n[i]
<- kpm.n[i]
<- kcm.n[i]
<- kpd.n[i]
<- kcd.n[i]
<- kpls1.n[i]
<- kpls2.n[i]
<- kcls1.n[i]
<- kcls2.n[i]
<- CLV.n[i]
<- PLV.n[i]

kin <- kin.n[i]
Fex <- Fex.n[i]
Fpd <- Fpd.n[i]
Fcd <- Fcd.n[i]
Din <- Din.n[i]
Current.Iteration.Data <- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd,
kcd, kpls1, kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf)
In.Data[,i] <- Current.Iteration.Data[,2]
PLU.Data[,i] <- Current.Iteration.Data[,3]
CLU.Data[,i] <- Current.Iteration.Data[,4]
PLS.Data[,i] <- Current.Iteration.Data[,5]
CLS.Data[,i] <- Current.Iteration.Data[,6]
GI.Data[,i] <- Current.Iteration.Data[,7]
CC.Data[,i] <- Current.Iteration.Data[,8]
PC.Data[,i] <- Current.Iteration.Data[,9]
Ex.Data[,i] <- Current.Iteration.Data[,10]
Fe.Data[,i] <- Current.Iteration.Data[,11]
El.Data[,i] <- Current.Iteration.Data[,12]
CP.Data[,i] <- Current.Iteration.Data[,8]/V0
CS.Data[,i] <- Current.Iteration.Data[,4]/CLV
PL.Data[,i] <- Current.Iteration.Data[,3]/PLV
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Cmax.n[i]<- max(CP.Data[57:82,i])
tmax.n[i]<-t[which.max(CP.Data[57:82,i])]
Smax.n[i]<- max(CS.Data[57:82,i])
tsmax.n[i]<-t[which.max(CS.Data[57:82,i])]
}
######################################################################
########
################### VPC Plotting Function for DATA ###################
######################################################################
########
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){
Size.of.Data<-dim(Data); PlottingData <- matrix(0,Size.of.Data[1],4)
PlottingData[,1] <-Current.Iteration.Data[,1]
for(i in 1:length(t)){
PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <- quantile(Data[i,],0.50)
PlottingData[i,4] <- quantile(Data[i,],0.95) }
Time <- PlottingData[,1]; Bottom <- PlottingData[,2]
Top <- PlottingData[,4]; Middle <- PlottingData[,3]
ColNumbers <- col2rgb(Color); par(TRUE)
mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90)
plot(Time, Bottom, type= "n", col=Color, main=Title,
ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax),
ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color, lwd=2.8)
return()
}
TL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));return(X)}
LL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));X<-X/100;return(X)}
plot(t)
dev.off();par(mfrow=c(2,3)); par(TRUE)
dev.off();par(mfrow=c(1,2)); par(TRUE)
VPCP(CP.Data,'green',LL(CP.Data),TL(CP.Data), 0,max(t),'Cp(t)','Plasma Conc
(ug/ml)','y')
VPCP(CS.Data,'blue',LL(CS.Data),TL(CS.Data), 0,max(t),'Cs(t)','Sputum Conc
(ug/ml)','y')
dev.off();par(mfrow=c(2,4)); par(TRUE)
VPCP(PLU.Data,'grey',LL(PLU.Data),TL(PLU.Data), 0,max(t),'PLU(t)','Peripheral Lung
Unbound (ug)','y')
VPCP(CLU.Data,'grey',LL(CLU.Data),TL(CLU.Data), 0,max(t),'CLU(t)','Central Lung
Unbound (ug)','y')
VPCP(PLS.Data,'grey',LL(PLS.Data),TL(PLS.Data), 0,max(t),'PLS(t)','Peripheral Lung
Sequestered (ug)','y')
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VPCP(CLS.Data,'grey',LL(CLS.Data),TL(CLS.Data), 0,max(t),'CLS(t)','Central Lung
Sequestered (ug)','y')
VPCP(CC.Data,'grey',LL(CC.Data),TL(CC.Data), 0,max(t),'CC(t)','Central Cmpt (ug)','y')
VPCP(PC.Data,'grey',LL(PC.Data),TL(PC.Data), 0,max(t),'PC(t)','Peripheral Cmpt
(ug)','y')
VPCP(CP.Data,'green',LL(CP.Data),TL(CP.Data), 0,max(t),'Cp(t)','Plasma Conc
(ug/ml)','y')
VPCP(CS.Data,'blue',LL(CS.Data),TL(CS.Data), 0,max(t),'Cs(t)','Sputum Conc
(ug/ml)','y')
######################################################################
###
######################################################################
###
AUC.Trap.Calc <- function(Time, CP){
n <- length(Time); AUC.Values<-rep(0,n-1)
for (i in 1:(n-1)){
if (i==1){
AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2
}
if (i>1){
AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1] }
}; return(AUC.Values[i])
}
AUCLowerParmValue <-AUC.Trap.Calc(t[57:82], CP.Data[57:82,1])
AUCHigherParmValue <- AUC.Trap.Calc(t[57:82], CP.Data[57:82,3])
AUCS <- c(AUCLowerParmValue,AUCHigherParmValue)
AUCMultiplier=1
if (AUCHigherParmValue<AUCLowerParmValue){AUCMultiplier=-1}
AUCMultiplier*max(AUCS)/min(AUCS)
LCP.Data<-log10(CP.Data)
LowerDataSet<- LCP.Data[70:82,1]
LowerSlope<-lm(LowerDataSet~t[70:82])
thalflower<-log(2)/(LowerSlope$coefficients[2]*-2.303)
HigherDataSet<- LCP.Data[70:82,3]
HighSlope<-lm(HigherDataSet~t[70:82])
thalfhigher<-log(2)/(HighSlope$coefficients[2]*-2.303)
thalf<-c(thalfhigher,thalflower)
thalfmultiplier<-1
if (thalfhigher<thalflower){thalfmultiplier=-1}
thalfmultiplier*max(thalf)/min(thalf)
Cmaxlower <- Cmax.n[1]
Cmaxhigher<- Cmax.n[3]
Cmaxmultiplier<-1
if (Cmaxhigher<Cmaxlower){Cmaxmultiplier=-1}
Cmaxmultiplier*max(Cmax.n)/min(Cmax.n)
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tmaxlower <- tmax.n[1]
tmaxhigher <- tmax.n[3]
tmaxmultiplier<-1
if (tmaxhigher<tmaxlower){tmaxmultiplier=-1}
tmaxmultiplier*max(tmax.n)/min(tmax.n)
##############################################
##############################################
SAUCLowerParmValue <-AUC.Trap.Calc(t[57:82], CS.Data[57:82,1])
SAUCHigherParmValue <- AUC.Trap.Calc(t[57:82], CS.Data[57:82,3])
SAUCS <- c(SAUCLowerParmValue,SAUCHigherParmValue)
SAUCMultiplier=1
if (SAUCHigherParmValue<SAUCLowerParmValue){SAUCMultiplier=-1}
SAUCMultiplier*max(SAUCS)/min(SAUCS)
SLCP.Data<-log10(CS.Data)
SLowerDataSet<- SLCP.Data[70:82,1]
SLowerSlope<-lm(SLowerDataSet~t[70:82])
Sthalflower<-log(2)/(SLowerSlope$coefficients[2]*-2.303)
SHigherDataSet<- SLCP.Data[70:82,3]
SHighSlope<-lm(SHigherDataSet~t[70:82])
Sthalfhigher<-log(2)/(SHighSlope$coefficients[2]*-2.303)
Sthalf<-c(Sthalfhigher,Sthalflower)
Sthalfmultiplier<-1
if (Sthalfhigher<Sthalflower){Sthalfmultiplier=-1}
Sthalfmultiplier*max(Sthalf)/min(Sthalf)
Smaxlower <- Smax.n[1]
Smaxhigher<- Smax.n[3]
Smaxmultiplier<-1
if (Smaxhigher<Smaxlower){Smaxmultiplier=-1}
Smaxmultiplier*max(Smax.n)/min(Smax.n)
tsmaxlower <- tsmax.n[1]
tsmaxhigher <- tsmax.n[3]
tsmaxmultiplier<-1
if (tsmaxhigher<tsmaxlower){tsmaxmultiplier=-1}
tsmaxmultiplier*max(tsmax.n)/min(tsmax.n)
AUCMultiplier*max(AUCS)/min(AUCS)
Cmaxmultiplier*max(Cmax.n)/min(Cmax.n)
tmaxmultiplier*max(tmax.n)/min(tmax.n)
thalfmultiplier*max(thalf)/min(thalf)
SAUCMultiplier*max(SAUCS)/min(SAUCS)
Smaxmultiplier*max(Smax.n)/min(Smax.n)
tsmaxmultiplier*max(tsmax.n)/min(tsmax.n)
Sthalfmultiplier*max(Sthalf)/min(Sthalf)
Code 3. Rscript utilized for performing RD sensitivity analysis simulations.
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Scientist Fits of IV CIP

Figure 1. Simulations results of plasma concentration time profile on a linear-scale for
CIP 101A based on the parameters estimated from various applied weighting factors.

Figure 2. Simulations results of plasma concentration time profile on a linear-scale for
CIP 102A based on the parameters estimated from various applied weighting factors.
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Figure 3. Simulations results of plasma concentration time profile on a linear-scale for
CIP 102B based on the parameters estimated from various applied weighting factors.

Figure 4. Simulations results of plasma concentration time profile on a linear-scale for
CIP 102C based on the parameters estimated from various applied weighting factors.
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Figure 5. Simulations results of plasma concentration time profile on a linear-scale for
CIP 104A based on the parameters estimated from various applied weighting factors.

Figure 6. Simulations results of plasma concentration time profile on a linear-scale for
CIP 105A based on the parameters estimated from various applied weighting factors.
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Figure 7. Simulations results of plasma concentration time profile on a linear-scale for
CIP 105B based on the parameters estimated from various applied weighting factors.

Figure 8. Simulations results of plasma concentration time profile on a linear-scale for
CIP 106A based on the parameters estimated from various applied weighting factors.
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Figure 9. Simulations results of plasma concentration time profile on a linear-scale for
CIP 107A based on the parameters estimated from various applied weighting factors.

Figure 10. Simulations results of plasma concentration time profile on a linear-scale for
CIP 107C based on the parameters estimated from various applied weighting factors.
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Figure 11. Simulations results of plasma concentration time profile on a linear-scale for
CIP 108A based on the parameters estimated from various applied weighting factors.

Figure 12. Simulations results of plasma concentration time profile on a linear-scale for
CIP 108B based on the parameters estimated from various applied weighting factors.
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Weighting Factor
Time
(min)
15
30
45
60
90
120
180
240
360
480
600
720

Conc. In
Plasma
(mg/L)
3.96867
2.26
1.27
0.81
0.70
0.58
0.50
0.46
0.22
0.14
0.07
0.05

Visual inspection
R2
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

None

1/y

1/y2

3.9988
2.1474
1.3208
0.94183
0.66248
0.56391
0.45528
0.3734
0.25153
0.16944
0.11414
0.076889
✓
0.9979
5.01
36.13
1.20
3.32
0.031
0.003
9.66
0.011
0.0020
18.10
607.290
59.1430
9.74

4.05
2.0831
1.2803
0.9375
0.6908
0.5912
0.4623
0.3642
0.2261
0.1404
0.0871
0.0541
✓
0.99425
4.5512
34.6410
2.3016
6.6441
0.0342
0.0046
13.5391
0.0132
0.0017
13.0706
647.2200
27.0520
4.1797

4.165
2.0137
1.2297
0.92404
0.71046
0.61289
0.47336
0.36674
0.22016
0.13217
0.079345
0.047633
✓
0.99119
4.5639
32.357
4.9415
15.27181
0.039563
0.00842
21.28251
0.014786
0.001912
12.9325
654.36
24.085
3.680696

Table 1. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 101A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Conc. In
Plasma
(mg/L)
16.18060056 0.583895914
Time (min)

None

1/y

1/y2

0.57537

1

0.47686

19.78731497

0.34

0.37281

0.3973

0.39018

26.20961971

0.27

0.23823

0.2617

0.28764

35

0.21

45
60
75
90
105
120
135
195
255
375
495
615
735

0.18
0.16
0.14
0.13
0.12
0.11
0.10
0.08
0.07
0.05
0.03
0.02
0.02

0.19273
0.17759
0.16383
0.15177
0.14061
0.13028
0.12071
0.11184
0.082419
0.060737
0.032985
0.017913
0.009728
0.005283
✓
0.99432
3.8829
27.73
4.48
16.16
0.152
0.026
17.10

0.1897
0.1622
0.1474
0.1389
0.1315
0.1247
0.1182
0.1121
0.0905
0.0731
0.0477
0.0311
0.0203
0.0132
✓
0.99171
3.9461
42.2450
6.4174
15.1909
0.0938
0.0171
18.2263

0.21155
0.16996
0.14346
0.13157
0.12395
0.11772
0.11207
0.10677
0.088042
0.072609
0.049385
0.033589
0.022846
0.015539
✓
0.99506
4.9682
63.364
8.8691
13.99706
0.054836
0.01056
19.25742

0.030
0.0031
10.56

0.0230
0.0021
9.2410

0.019937
0.001667
8.36184

Visual inspection
R2
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

1010.100 876.2200 870.8
87.3000 44.7320 18.908
8.64
5.1051 2.171337

Table 2. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Conc. In
Plasma
(mg/L)
16.1806 1.149423

None

1/y

1/y2

1.1068

1

1.0019

19.78731

0.79

0.87296 0.8307

0.85738

26.20962

0.65

0.62226 0.5970

0.66916

35

0.49

45
60
75
90
105
120
135
195
255
375
495
615
735

0.41
0.35
0.31
0.28
0.25
0.23
0.23
0.18
0.15
0.10
0.07
0.05
0.04

Time
(min)

k12 CV

0.4605
0.38342
0.33645
0.3115
0.2919
0.27424
0.25779
0.24236
0.18937
0.14796
0.090324
0.055141
0.033662
0.02055
✓
0.99581
4.1288
49.20
4.26
8.65
0.069
0.010
14.77

0.4496
0.3810
0.3395
0.3170
0.2988
0.2822
0.2667
0.2520
0.2010
0.1603
0.1020
0.0649
0.0413
0.0263
✓
0.99277
4.0679
51.4770
7.1370
13.8644
0.0722
0.0152
20.9979

0.50799
0.40399
0.32609
0.28885
0.26727
0.25193
0.23927
0.22793
0.18895
0.15682
0.10804
0.07443
0.051277
0.035326
✓
0.99726
5.5137
67.739
5.56
8.207975
0.039237
0.005372
13.69014

k21 (min-1)

0.025

0.0262

0.017313

k21 SD

0.0032
12.91

0.0028 0.001182
10.7918 6.826084

Visual inspection
R2
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD

k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

871.860 819.7400
77.3670
8.87

791.26

38.7830 12.449
4.7311 1.573313

Table 3. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102B.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Conc. In
Plasma
(mg/L)
21.84596 1.649272
Time
(min)

None

1/y

1/y2

1.5639

2

1.4246

26.86047

1.20

1.2513 1.2610

1.2371

30.13856

1.04

1.1051 1.1193

1.1354

40

0.86

50
65
80
110
140
200
260
380
500
620
740

0.77
0.64
0.56
0.47
0.42
0.31
0.26
0.17
0.13
0.09
0.06

Visual inspection
2

R
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

0.83456
0.70076
0.60425
0.55167
0.47993
0.42158
0.32592
0.25198
0.15062
0.090037
0.053821
0.032172

0.8452
0.7020
0.5974
0.5441
0.4797
0.4300
0.3470
0.2801
0.1825
0.1189
0.0775
0.0505

0.90491
0.75247
0.61391
0.53425
0.4492
0.39944
0.32752
0.27043
0.18457
0.12597
0.085981
0.058684

✓
0.99678
4.219
70.82
7.42
10.48
0.049
0.010
19.61
0.025
0.0037
14.68

✓
0.99589
4.6395
74.8480
8.7013
11.6253
0.0443
0.0090
20.3875
0.0218
0.0025
11.2977

✓
0.99641
5.52656
98.668
10.239
10.37722
0.024865
0.005299
21.31269
0.016174
0.001853
11.45913

1018.300 917.0600 915.17
76.4390 33.4900 18.024
7.51
3.6519 1.96947

Table 4. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102C.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Conc. In
Plasma
(mg/L)

Time (min)

5.906275599 2.888883679

None

1/y

1/y2

2.876

2.7949

2.3354

1.4375

1.4572

14.04837066

1.29

21.87398853

0.88

0.80108 0.84194

0.9568

34.79201215

0.56

50.11238537

0.42

0.515 0.48128
0.42163 0.36412

0.55153
0.36696

65

0.33

0.37583 0.32508

0.29815

95

0.27

0.30673 0.28327

0.24729

125

0.22

0.25105 0.25035

0.22117

185

0.17

0.1682 0.19584

0.18073

245

0.14

0.1127

0.14792

365

0.10

0.050588 0.093745 0.099092

485

0.06

0.022709 0.057366 0.066383

605

0.04

0.010194 0.035104 0.044471

725

0.03

0.004576 0.021481 0.029792

Visual inspection
2

R
MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

1.3566

✓
0.99781
5.14
25.31
0.73
2.87

0.1532

✓
0.99171
4.2042
27.232
1.6638
6.1097

✓
0.9914
4.3816
35.161
4.2074
11.9661

0.076
0.006
8.51

0.05479 0.04316
0.007027 0.006228
12.8252 14.4291

0.024
0.0038
15.83

0.015382 0.011399
0.00186 0.001092
12.0914 9.58242

900.480
84.7920
9.42

757.91
43.085
5.6847

745.87
22.712
3.045035

Table 5. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 104A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

30

2.48649

2.4865

2

2.4017

60

3.29

3.2821 3.2768

3.2584

75

1.77

1.8169 1.8819

1.9704

90

1.54

120

1.19

1.4319 1.4011
1.1949 1.1094

1.4172
1.0355

180

0.89

0.92797 0.8847

0.81656

240

0.67

0.72302 0.7172

0.67905

300

0.52

0.56334 0.5816

0.56571

360

0.43

0.43892 0.4716

0.47132

480

0.30

0.26645 0.3101

0.32716

600

0.24

0.16175 0.2039

0.2271

720

0.17

0.098196 0.1341

0.15763

✓

✓

✓

R

0.99876

0.99614

0.99373

MSC

5.141

4.4384

4.1086

Vo (Liter)

32.09
3.49
10.87

37.9460 44.505
4.6464
7.3965
12.2448 16.61948

0.064
0.012
18.03

0.0475 0.035459
0.0092 0.007943
19.4007 22.40136

0.018
0.0019
10.58

0.0139 0.011169
0.0017 0.001362
12.0765 12.19357

Visual inspection
2

Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

768.160 735.5200 726.22
28.5890 24.1190 21.659
3.72
3.2792 2.98243

Table 6. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 105A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

30

3.156757

3.035

3

2.9987

60

3.89

4.0115 4.0261

4.0316

75

2.25

2.251 2.3121

2.3896

90

1.84

120

1.47

1.7343 1.7202
1.425 1.3615

1.7354
1.3079

180

1.04

1.121 1.0866

1.0391

240

0.84

0.88758 0.8819

0.85581

300

0.67

0.70277 0.7159

0.70546

360

0.54

0.55644 0.5812

0.58153

480

0.41

0.34884 0.3830

0.39517

600

0.26

0.2187 0.2524

0.26852

720

0.19

0.13711 0.1663

0.18247

Visual inspection

✓

✓

✓

R2

0.99842

0.99738

0.99728

MSC

4.8824

4.8605

4.34

Vo (Liter)

28.07
2.98
10.61

30.9070 34.037
3.1193
4.2862
10.0925 12.59277

0.057
0.010
18.05

0.0474 0.039398
0.0075 0.00674
15.9164 17.1062

0.016
0.0020
12.19

0.0139
0.0014
9.7405

Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

0.012159
0.001072
8.818982

616.120 597.3800 592.58
27.1090 15.9800 12.734
4.40
2.6750 2.148908

Table 7. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 105B.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

120

4.361101381

4.3574

4

4.1982

180

1.94

1.9808

2.0387

2.1136

240

1.43

1.3487

1.3334

1.3602

300

1.14

360

0.91

1.1124
0.97366

1.0713
0.9372

1.0562
0.90659

480

0.72

0.77258

0.7667

0.74016

720

0.50

0.49257

0.5298

0.52757

1440

0.20

0.12781

0.1757

0.19423

✓

✓

✓

R

0.99926

0.99783

0.99709

MSC

5.3819

4.6518

4.841

Vo (Liter)

14.92

19.1260

24.875

Vo SD

3.18

4.2319

6.2531

Vo CV

21.30

22.1264

25.13809

k12 (min-1)

0.010
0.001
9.43

0.0090
0.0011
11.9085

0.007868
0.001104
14.03498

0.003
0.0004
12.20

0.0030
0.0003
10.0579

0.00283
0.000237
8.369258

205.150
12.7100
6.20

210.8500 222.83
13.7570 16.092
6.5245 7.221649

Visual inspection
2

k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

Table 8. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 106A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

15

2.771966

2.6823

3

2.6259

30

3.87

3.8126 3.8409

3.8679

60

4.79

4.9256 4.9776

5.0476

75

2.68

90

2.04

2.651 2.7161
1.8937 1.8857

2.8083
1.9075

120

1.44

1.458 1.3932

1.3392

180

1.06

1.1417 1.1016

1.0482

240

0.87

0.91064 0.9008

0.86772

360

0.57

0.57955 0.6031

0.5965

480

0.38

0.36884 0.4037

0.41008

600

0.29

0.23474 0.2703

0.28191

720

0.19

0.14939 0.1809

0.19381

960

0.10

0.060509 0.0811

0.091596

Visual inspection

✓

R2

0.99895
5.4337
23.53
1.18
5.02

MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

✓

✓

0.99829 0.99774
5.7345
5.9773
24.7160 25.896
1.2223
1.6986
4.9454 6.559314

0.047
0.004
9.56

0.0416
0.0036
8.6971

0.036588
0.003573
9.765224

0.013
0.0126
100.00

0.0109
0.0008
6.8805

0.00967
0.000546
5.645223

554.250 536.4500 532.77
23.8400 11.2850 8.5459
4.30
2.1036 1.604051

Table 9. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 107A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.

268

Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

30

4.45978

4.3914

4

4.2723

60

5.66

5.7165 5.7211

5.696

75

3.02

3.1039 3.1949

3.3223

90

2.55

120

1.88

2.3277 2.3060
1.8846 1.7819

2.3398
1.6934

180

1.38

1.487 1.4285

1.3394

240

1.11

1.1834 1.1713

1.1158

360

0.71

0.74947 0.7880

0.77683

480

0.52

0.47468 0.5301

0.54085

600

0.37

0.30064 0.3566

0.37656

720

0.26

0.19041 0.2399

0.26217

960

0.14

0.076375 0.1086

0.12708

Visual inspection

✓

✓

✓

R2

0.99867

0.99715

0.99615

MSC

5.1818

5.0873

5.2099

Vo (Liter)

19.32
1.72
8.91

21.4630 24.212
0.0039
3.0937
0.0182 12.77755

0.055
0.008
14.89

0.0456 0.036815
0.0065 0.005968
14.2330 16.21051

0.015
0.0016
10.91

0.0123
0.0011
9.0675

Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

0.010531
0.000872
8.281835

447.910 431.6000 431.03
20.2550 11.9210 10.265
4.52
2.7620 2.381505

Table 10. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 107C.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In Plasma
(mg/L)

None

1/y

1/y2

25

4.247037843

4.198

4

3.8746

30

3.19

3.3159

3.3485

3.3304

35.32251

2.77

2.7076

2.7716

2.8728

50

1.96

65

1.62

1.911
1.6076

1.9268
1.5718

2.0529
1.6068

80

1.44

1.4462

1.3931

1.3559

110

1.15

1.2262

1.1848

1.0957

140

1.09

1.0497

1.0313

0.94871

200

0.71

0.77043

0.7862

0.74366

260

0.55

0.56549

0.5996

0.58791

380

0.34

0.30466

0.3488

0.36788

500

0.22

0.16413

0.2029

0.23021

740

0.10

0.047639

0.0687

0.090147

Visual inspection

✓

✓

✓

R2

0.99913
5.5089
35.38
2.98
8.42

0.99779
5.3782
41.1400
4.7043
11.4349

0.99518
5.3129
54.954
7.9321
14.43407

0.052
0.006
11.72

0.0416
0.0071
17.0164

0.024672
0.006129
24.8403

0.029
0.0018
6.13

0.0197
0.0017
8.4818

0.014854
0.001716
11.55446

MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

718.670
27.4360
3.82

695.7700 698.44
19.3410 17.959
2.7798 2.571302

Table 11. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 108A.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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Weighting Factor
Time
(min)

Conc. In
Plasma
(mg/L)

None

1/y

1/y2

10

10.1236947

10.097

10

9.3897

15

5.72

5.8016 5.8773

5.9486

20.32251

3.73

3.6883 3.7624

3.9884

35

1.99

50

1.51

1.8277 1.7871
1.5133 1.4464

1.8435
1.3922

65

1.34

1.3845 1.3271

1.2516

95

1.07

1.1923 1.1651

1.1036

125

0.97

1.029 1.0265

0.98417

185

0.78

0.7664 0.7970

0.78329

245

0.57

0.57083 0.6188

0.62343

365

0.38

0.31667 0.3731

0.39492

485

0.24

0.17567 0.2249

0.25016

725

0.11

0.054063 0.0817

0.10039

Visual inspection

✓

R2

0.99959
6.6979
10.56
0.32
2.98

0.99424 0.99625
5.0964
5.5275
11.7100 13.747
2.2866
1.8439
19.5269 13.41311

0.087
0.003
3.51

0.0868 0.07049
0.0118 0.007542
13.5638 10.69953

0.015
0.0009
6.19

0.0131
0.0010
7.4610

MSC

Vo (Liter)
Vo SD
Vo CV

k12 (min-1)
k12 SD
k12 CV

k21 (min-1)
k21 SD
k21 CV

Cltot (ml*min-1)
Cltot SD
Cltot CV

✓

✓

0.012522
0.000687
5.487622

496.110 463.6500 475.23
21.4480 16.1260
12.28
4.32
3.4781 2.584012

Table 12. Parameter estimates based on simplex fit with either no weighting factor, a
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 108B.
Column highlighted in green represented the weighting factor deemed acceptable for
this specific data set.
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MCS Results for IV CIP

Figure 13 MCS results of CIP 101A

272

Figure 14 MCS results of CIP 102A

273

Figure 15 MCS results of CIP 102B

274

Figure 16 MCS results of CIP 102C

275

Figure 17 MCS results of CIP 104A

276

Figure 18 MCS results of CIP 105A

277

Figure 19 MCS results of CIP 105B

278

Figure 20 MCS results of CIP 106A

279

Figure 21 MCS results of CIP 107A

280

Figure 22 MCS results of CIP 108A

281

Figure 23 MCS results of CIP 108B

282

MCS Results for PO CIP

Figure 24 MCS for PO administration in CIP 102A

283

Figure 25 MCS for PO administration in CIP 102B

284

Figure 26 MCS for PO administration in CIP 102C

285

Figure 27 MCS for PO administration in CIP 102D

286

Figure 28 MCS for PO administration in CIP 104A

287

Figure 29 MCS for PO administration in CIP 105A

288

Figure 30 MCS for PO administration in CIP 105B

289

Figure 31 MCS for PO administration in CIP 106A

290

Figure 32 MCS for PO administration in CIP 108A

291

Figure 33 MCS for PO administration in CIP 108B

292

Figure 34 MCS for PO administration in CIP 204A

293

Figure 35 MCS for PO administration in CIP 204B

294

MCS Results for INH CIP

Figure 36 cp(t) MSC for INH study CIP 301A

295

Figure 37 cs(t) MSC for INH study CIP 302A

296

Figure 38 cp(t) MSC for INH study CIP 302A

297

Figure 39 cs(t) MSC for INH study CIP 302B

298

Figure 40 cp(t) MSC for INH study CIP 302B

299

Figure 41 cp(t) MSC for INH study CIP 303A

300

Figure 42 cp(t) MSC for INH study CIP 303B

301

Figure 43 cp(t) MSC for INH study CIP 304A

302

Figure 44 cp(t) MSC for INH study CIP 304B

303

Figure 45 cp(t) MSC for INH study CIP 304C

304

Sensitivity Analysis Plots for INH CIP

305

306

307

308

309

310

311

312

313

314

315

316

317

Code Utilized for CIP MSC After INH
rm(list=ls()); cat("\014");dev.off();set.seed(123091);Start.time <- proc.time() # start a
timer
BW.me <- 80.2
BW.cv <- 20
n
<- 300
Disease <- 1

# 1= Healthy

2= CF

InhalerDose<-32.5#mg
DtL <- 0.53
DtGI <- 0.43
t<-seq(0,720,5)
Clren.1.me <- 315
#Healthy
Clren.2.me <- 425
#CF
Clnonren.1.me <- 315
#Healthy
Clnonren.2.me <- 225
#CF
k12.1.me <- 0.025
#Healthy
k12.2.me <- 0.050
#CF
k21.1.me <- 0.015
#Healthy
k21.2.me <- 0.020
#CF
V0.1.me <- 75
#Healthy
V0.2.me <- 20
#CF
Clnonren.1.cv <- 20
#Healthy
Clnonren.2.cv <- 20
#CF
Clren.1.cv <- 20
#Healthy
Clren.2.cv <- 20
#CF
k12.1.cv <- 25
#Healthy
k12.2.cv <- 20
#CF
k21.1.cv <- 25
#Healthy
k21.2.cv <- 20
#CF
V0.1.cv <- 20
#Healthy
V0.2.cv <- 20
#CF

Foral.1.me <- 73
Foral.2.me <- 85
kga.1.me <- 0.020
kga.2.me <- 0.011
Foral.1.cv<-35; Foral.2.cv<-30;
kpa.me
kca.me

kga.1.cv<-10; kga.2.cv<-50

<- 0.010
<- 0.020
318

kpm.me <- 0.020
kcm.me <- 0.02
kpd.me <- 0.008
kcd.me <- 0.0002
kpls1.me <- 10000
kpls2.me <- 10000
kcls1.me <- 10000
kcls2.me <- 10000
TLV.me <- 30
kpa.cv<-75;kca.cv<-75;kpm.cv<-75;kcm.cv<-75;kpd.cv<-75;kcd.cv<-75
kpls1.cv<-0;kpls2.cv<-0;kcls1.cv<-0;kcls2.cv<-0
TLVprop.me <- 1
TLVprop.cv <- 0
kin.me <- 0
Fex.me <- 0
Fpd.me <- 0.25
Fcd.me <- 0.75
Din.me <- 0
kin.cv<-0; Fex.cv<-0; Fpd.cv<-0; Fcd.cv<-0; Din.cv<-0
######################################################################
###################
##################### Normal Distribution Generator
#############################
######################################################################
###################
NormGen <- function(simulation.n,samp.m,samp.cv ){
samp.sd <- samp.cv*samp.m/100
out <- rnorm(simulation.n,samp.m,samp.sd)
return(out)}
LogNormGen <- function(n, Mean, PCV){
CV<-PCV/100;SD<-(CV*Mean);Variance<-SD^2;mean.in<log(Mean^2/sqrt(Variance+Mean^2));
SD.in<-sqrt(log(Variance/Mean^2 + 1));x=rlnorm(n,mean.in,SD.in)
return(x)}
AUC.Trap.Calc <- function(Time, CP){
n <- length(Time); AUC.Values<-rep(0,n-1)
for (i in 1:(n-1)){ if (i==1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2}
if (i>1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1]}
} ; return(AUC.Values[i])}
######################################################################
###################
####################### Generation of numbers
##################################
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######################################################################
###################
Cmax.301A.n=rep(0,n);Cmax.302A.n=rep(0,n);Cmax.302B.n=rep(0,n);Cmax.303A.n=re
p(0,n)
Cmax.303B.n=rep(0,n);Cmax.304A.n=rep(0,n);Cmax.304B.n=rep(0,n);Cmax.304C.n=re
p(0,n)
CpAUC.301A.n=rep(0,n);CpAUC.302A.n=rep(0,n);CpAUC.302B.n=rep(0,n);CpAUC.303
A.n=rep(0,n)
CpAUC.303B.n=rep(0,n);CpAUC.304A.n=rep(0,n);CpAUC.304B.n=rep(0,n);CpAUC.304
C.n=rep(0,n)

BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
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if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
##############
Set up the ODE Based model function
#######################
######################################################################
###################
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,
kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf ){
Fgd
<- 1-Fex-Fpd-Fcd
ED <- data.frame(var = c("DOSING"), time = c(0,1), value = c(0,0), method = c("rep"))
Model.Function <- function(t,IC,Parm) {
with(as.list(IC, Parm), {
dDOSING <- 0
dIn <- -In*kin*(Fex+Fpd+Fcd+Fgd);dPLU<-In*kin*Fpd + PLS*kpd - PLU*(kpa +
kpm)
dCLU <-In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm
dGI <-In*kin*Fgd + CLU* kcm - GI*kga;dPLS <-PLU*kpa + CC*kpls1 - PLS *
(kpd+kpls2)
dCLS <-CLU*kca + CC*kcls1 - CLS * (kcd+kcls2);dPC <-CC* k12 - PC *k21
dCC <-PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + k12 +
(Cltot/(V0*1000)))+ DOSING
dEx <-In*kin*Fex;
dFe <- GI*kga*(1-Foral);
dEl <CC*(Cltot/(V0*1000))
return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))
}) }
IC <c(In=0, PLU=LDose*Fpd, CLU=LDose*Fcd, PLS=0, CLS=0, GI=GIDose,
CC=0, PC=0, Ex=0*Fex, Fe=0, El=0,DOSING=0)
Parm <c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1,
kcls2, kin, Fex, Fpd, Fcd, Fgd)
out <- ode(IC, t,Model.Function,Parm)
return(out)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
In.Data <- matrix(0,length(t),(n));PL.Data <- In.Data
PLU.Data <- In.Data;CLU.Data <- In.Data;PLS.Data <- In.Data;CLS.Data <- In.Data
GI.Data <- In.Data;CC.Data <- In.Data;PC.Data <- In.Data;Ex.Data <- In.Data
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Fe.Data <- In.Data;El.Data <- In.Data;CP.Data <- In.Data;CS.Data <- In.Data
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.301A.n[i]<-CP.Data[13,i]*1000
CpAUC.301A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
######################################################################
###################
################### VPC Plotting Function for TS DATA
##############################
######################################################################
###################
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){
Size.of.Data<-dim(Data); PlottingData <- matrix(0,Size.of.Data[1],4)
PlottingData[,1] <-CID[,1]
for(i in 1:length(t)){PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <quantile(Data[i,],0.50)
PlottingData[i,4] <- quantile(Data[i,],0.95) }
Time<-PlottingData[,1];Bottom<-PlottingData[,2];Top <-PlottingData[,4];Middle<PlottingData[,3]
ColNumbers <- col2rgb(Color); par(TRUE)
mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90)
plot(Time, Bottom, type= "n", col=Color, main=Title,ylim=
c(YMin,YMax),log=LogAxis,xlim=c(XMin,XMax),
ylab =Ytitle,xlab ='Time (minutes)',font=2,font.lab =2)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color, lwd=2.8); return()}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip301
A.png")
T301A <- c(15,30,45,60,90,120,150,180,240,360,480,720,960,1440)
C301A <c(0.0498,0.0448,0.0444,0.0430,0.0398,0.0320,0.0294,0.0256,0.0212,0.0172,0.0132,0.0
076,0.0052,0.0030)
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VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 301A Cp(t) -- HV, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T301A,C301A,col='red',pch=20,cex=2.5)

dev.off();set.seed(123091)
BW.me <- 59
Disease <- 2
InhalerDose<-32.5#mg
t<-seq(0,720,5)
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
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kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302A.n[i]<-CP.Data[13,i]*1000
CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
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png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
A.png")
T302A <- c(5,15,30,45,60,90,120,150,180,240,360,480,720,960,1440)
C302A <c(0.008,0.020,0.051,0.060,0.065,0.071,0.065,0.055,0.051,0.043,0.021,0.014,0.006,0.00
4,0.001)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 302A Cp(t) -- CF, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T302A,C302A,col='red',pch=20,cex=2.5)
dev.off()
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
A Sputum.png")
ST302A <- c(0.75,2.00,4.00,8.00,24.00)*60
SC302A <- c(67.58,15.54,1.48,0.39,0.03)
VPCP(CS.Data,'cyan',0.001,100,0,720,'CIP 302A Cs(t) -- CF, Inhaler Dose =
32.5mg','Sputum Conc (mg/l)','y')
points(ST302A,SC302A,col='red',pch=20,cex=2.5)

dev.off();set.seed(123091)
BW.me <- 65
Disease <- 2
InhalerDose<-65#mg
t<-seq(0,720,5)
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######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
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######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302B.n[i]<-CP.Data[10,i]*1000
CpAUC.302B.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
B.png")
T302B <- c(5,15,30,45,60,90,120,150,180,240,360,480,720,960,1440)
C302B <c(0.020,0.050,0.111,0.155,0.137,0.152,0.119,0.104,0.115,0.089,0.053,0.036,0.018,0.01
0,0.004)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 302B Cp(t) -- CF, Inhaler Dose =
65mg','Plasma Conc (mg/l)','y')
points(T302B,C302B,col='red',pch=20,cex=2.5)
dev.off()
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
B Sputum.png")
ST302B <- c(0.75,2.00,4.00,8.00,24.00)*60
SC302B <- c(138.95,208.30,55.88,5.73,0.59)
VPCP(CS.Data,'cyan',0.5,500,0,720,'CIP 302B Cs(t) -- CF, Inhaler Dose =
65mg','Sputum Conc (mg/l)','y')
points(ST302B,SC302B,col='red',pch=20,cex=2.5)
dev.off()
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dev.off();set.seed(123091)
BW.me <- 75
Disease <- 1
InhalerDose<-32.5#mg
t<-seq(0,720,5)
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
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if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302A.n[i]<-CP.Data[13,i]*1000
CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip303
A.png")
T303A <- c(30,60,90,120,150,180,240,360,480,720,1440)
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C303A <- c(0.077,0.095,0.083,0.073,0.065,0.059,0.049,0.034,0.027,0.014,0.004)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 303A Cp(t) -- HV, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T303A,C303A,col='red',pch=20,cex=2.5)

dev.off();set.seed(123091)
BW.me <- 75
Disease <- 1
InhalerDose<-32.5#mg
t<-seq(0,720,5)
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
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if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,0, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
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CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302A.n[i]<-CP.Data[13,i]*1000
CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip303
B.png")
T303B <- c(30,60,90,120,150,180,240,360,480,720,1440)
C303B <- c(0.040,0.032,0.027,0.024,0.022,0.021,0.018,0.013,0.010,0.006,0.001)
VPCP(CP.Data,'green',0.001,0.1,0,720,'CIP 303B Cp(t) -- HV, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T303B,C303B,col='red',pch=20,cex=2.5)

dev.off();set.seed(123091)
BW.me <- 58
Disease <- 2
InhalerDose<-32.5#mg
t<-seq(0,720,5)
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######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
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######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302A.n[i]<-CP.Data[13,i]*1000
CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
A.png")
T304A <- c(5,15,60,90,120,150,180,240,360,480,720,960,1440)
C304A <c(0.017,0.024,0.085,0.072,0.062,0.060,0.046,0.036,0.021,0.013,0.006,0.003,0.002)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304A Cp(t) -- CF, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T304A,C304A,col='red',pch=20,cex=2.5)
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dev.off();set.seed(123091)
BW.me <- 60
Disease <- 2
InhalerDose<-65#mg
t<-seq(0,720,5)
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
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if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302B.n[i]<-CP.Data[10,i]*1000
CpAUC.302B.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
B.png")
T304B <- c(5,15,45,60,90,120,150,180,240,360,480,720,960,1440)
C304B <c(0.055,0.115,0.249,0.259,0.249,0.190,0.190,0.151,0.107,0.070,0.044,0.022,0.011,0.00
7)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304B Cp(t) -- Inhaler CF, Dose =
65mg','Plasma Conc (mg/l)','y')
points(T304B,C304B,col='red',pch=20,cex=2.5)
dev.off()
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dev.off();set.seed(123091)
BW.me <- 64
Disease <- 2
InhalerDose<-32.5#mg
t<-seq(0,720,5)
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
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if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV
Cmax.302A.n[i]<-CP.Data[13,i]*1000
CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000
}
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
C.png")
T304C <- c(5,15,45,60,90,120,180,240,360,480,720)
C304C <- c(0.029,0.032,0.107,0.124,0.120,0.115,0.099,0.070,0.042,0.028,0.012)
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304C Cp(t) -- CF, Inhaler Dose =
32.5mg','Plasma Conc (mg/l)','y')
points(T304C,C304C,col='red',pch=20,cex=2.5)
dev.off()
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mean(CpAUC.301A.n)
mean(CpAUC.302A.n)
mean(CpAUC.302B.n)

sd(CpAUC.301A.n)
sd(CpAUC.302A.n)
sd(CpAUC.302B.n)

mean(Cmax.301A.n)
mean(Cmax.302A.n)
mean(Cmax.302B.n)
sd(Cmax.301A.n)
sd(Cmax.302A.n)
sd(Cmax.302B.n)

(mean(CpAUC.301A.n)-482)*100/482
(mean(CpAUC.302A.n)-520)*100/520
(mean(CpAUC.302B.n)-1237)*100/1237

(mean(Cmax.301A.n)-79)*100/79
(mean(Cmax.302A.n)-128)*100/128
(mean(Cmax.302B.n)-289)*100/289

(((mean(CpAUC.301A.n)-482)*100/482)+
((mean(CpAUC.302A.n)-520)*100/520)+
((mean(CpAUC.302B.n)-1237)*100/1237))/4
sd(c(((mean(CpAUC.301A.n)-482)*100/482),
((mean(CpAUC.302A.n)-520)*100/406),
((mean(CpAUC.302B.n)-1237)*100/1237)))

(((mean(Cmax.301A.n)-79)*100/79)+
((mean(Cmax.302A.n)-128)*100/128)+
((mean(Cmax.302B.n)-289)*100/289))/4
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sd(c(((mean(Cmax.301A.n)-79)*100/79),
((mean(Cmax.302A.n)-127)*100/127),
((mean(Cmax.302B.n)-289)*100/289)))
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Code Utilized for Sensitivity Analysis After INH
rm(list=ls()); cat("\014");dev.off();set.seed(123091)
BW.me <- 70
BW.cv <- 0
n
<- 3
Disease <- 1

# 1= Healthy

2= CF

InhalerDose<-32.5#mg
DtL <- 0.53
DtGI <- 0.43
t<-seq(0,720,5)
Clren.1.me <- 315
#Healthy
Clren.2.me <- 425
#CF
Clnonren.1.me <- 315
#Healthy
Clnonren.2.me <- 225
#CF
k12.1.me <- 0.025
#Healthy
k12.2.me <- 0.050
#CF
k21.1.me <- 0.015
#Healthy
k21.2.me <- 0.020
#CF
V0.1.me <- 75
#Healthy
V0.2.me <- 20
#CF
Clnonren.1.cv <- 0
#Healthy
Clnonren.2.cv <- 0
#CF
Clren.1.cv <- 0
#Healthy
Clren.2.cv <- 0
#CF
k12.1.cv <- 0
#Healthy
k12.2.cv <- 0
#CF
k21.1.cv <- 0
#Healthy
k21.2.cv <- 0
#CF
V0.1.cv <- 0
#Healthy
V0.2.cv <- 0
#CF

Foral.1.me <- 73
Foral.2.me <- 85
kga.1.me <- 0.020
kga.2.me <- 0.011
Foral.1.cv<-0; Foral.2.cv<-0;

kga.1.cv<-0; kga.2.cv<-0

kpa.me <- 0.010
kca.me <- 0.020
kpm.me <- 0.020
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kcm.me <- 0.02
kpd.me <- 0.008
kcd.me <- 0.0002
kpls1.me <- 10000
kpls2.me <- 10000
kcls1.me <- 10000
kcls2.me <- 10000
TLV.me <- 30
kpa.cv<-0;kca.cv<-0;kpm.cv<-0;kcm.cv<-0;kpd.cv<-0;kcd.cv<-0
kpls1.cv<-0;kpls2.cv<-0;kcls1.cv<-0;kcls2.cv<-0
TLVprop.me <- 1
TLVprop.cv <- 0
kin.me <- 0
Fex.me <- 0
Fpd.me <- 0.25
Fcd.me <- 0.75
Din.me <- 0
kin.cv<-0; Fex.cv<-0; Fpd.cv<-0; Fcd.cv<-0; Din.cv<-0
######################################################################
###################
##################### Normal Distribution Generator
#############################
######################################################################
###################
NormGen <- function(simulation.n,samp.m,samp.cv ){
samp.sd <- samp.cv*samp.m/100; out <- rnorm(simulation.n,samp.m,samp.sd);
return(out)}
LogNormGen <- function(n, Mean, PCV){
CV<-PCV/100;SD<-(CV*Mean);Variance<-SD^2;mean.in<log(Mean^2/sqrt(Variance+Mean^2));
SD.in<-sqrt(log(Variance/Mean^2 + 1));x=rlnorm(n,mean.in,SD.in); return(x)}
AUC.Trap.Calc <- function(Time, CP){
n <- length(Time); AUC.Values<-rep(0,n-1)
for (i in 1:(n-1)){ if (i==1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2}
if (i>1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1]}
} ; return(AUC.Values[i])}
######################################################################
###################
####################### Generation of numbers
##################################
######################################################################
###################
BW.n <- NormGen(n, BW.me,BW.cv)
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if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if
(Disease==2)
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)}
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2)
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)}
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2)
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)}
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2)
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)}
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2)
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)}
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2)
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)}
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2)
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100}
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv)
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv)
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n,
kpd.me,kpd.cv)}
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n,
kcd.me,kcd.cv)}
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n,
kpls1.me,kpls1.cv)}
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n,
kpls2.me,kpls2.cv)}
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n,
kcls1.me,kcls1.cv)}
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n,
kcls2.me,kcls2.cv)}
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv)
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)}
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<NormGen(n, Fcd.me,Fcd.cv)
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n,
Din.me,Din.cv)}
Clren.n <- c(Clren.1.me/5,Clren.1.me,5*Clren.1.me)
#Clnonren.n <- c(Clnonren.1.me/5,Clnonren.1.me,5*Clnonren.1.me)
#k12.n <- c(k12.1.me/5,k12.1.me,5*k12.1.me)
#k21.n <- c(k21.1.me/5,k21.1.me,5*k21.1.me)
#V0.n <- c(V0.1.me/5,V0.1.me,5*V0.1.me)
#kga.n <- c(kga.1.me/5,kga.1.me,5*kga.1.me)
#Foral.n <- c(Foral.1.me/5,Foral.1.me,5*Foral.1.me)
#kpa.n <- c(kpa.me/10,kpa.me,10*kpa.me)
#kca.n <- c(kca.me/10,kca.me,10*kca.me)
#kpm.n <- c(kpm.me/10,kpm.me,10*kpm.me)
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#kcm.n <- c(kpm.me/10,kpm.me,10*kpm.me)
#kpd.n <- c(kpd.me/10,kpd.me,10*kpd.me)
#kcd.n <- c(kcd.me/10,kcd.me,10*kcd.me)

#Clren.n <- c(Clren.2.me/5,Clren.2.me,5*Clren.2.me)
#Clnonren.n <- c(Clnonren.2.me/5,Clnonren.2.me,5*Clnonren.2.me)
#k12.n <- c(k12.2.me/5,k12.2.me,5*k12.2.me)
#k21.n <- c(k21.2.me/5,k21.2.me,5*k21.2.me)
#V0.n <- c(V0.2.me/5,V0.2.me,5*V0.2.me)
#kga.n <- c(kga.2.me/5,kga.2.me,5*kga.2.me)
#Foral.n <- c(Foral.2.me/5,Foral.2.me,5*Foral.2.me)
#kpa.n <- c(kpa.me/10,kpa.me,10*kpa.me)
#kca.n <- c(kca.me/10,kca.me,10*kca.me)
#kpm.n <- c(kpm.me/10,kpm.me,10*kpm.me)
#kcm.n <- c(kpm.me/10,kpm.me,10*kpm.me)
#kpd.n <- c(kpd.me/10,kpd.me,10*kpd.me)
#kcd.n <- c(kcd.me/10,kcd.me,10*kcd.me)
######################################################################
###################
##############
Set up the ODE Based model function
#######################
######################################################################
###################
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,
kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf ){
Fgd
<- 1-Fex-Fpd-Fcd;ED <- data.frame(var = c("DOSING"), time = c(0,1), value
= c(0,0), method = c("rep"))
Model.Function <- function(t,IC,Parm) {
with(as.list(IC, Parm), {
dDOSING <- 0
dIn <- -In*kin*(Fex+Fpd+Fcd+Fgd);dPLU<-In*kin*Fpd + PLS*kpd - PLU*(kpa +
kpm)
dCLU <-In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm
dGI <-In*kin*Fgd + CLU* kcm - GI*kga;dPLS <-PLU*kpa + CC*kpls1 - PLS *
(kpd+kpls2)
dCLS <-CLU*kca + CC*kcls1 - CLS * (kcd+kcls2);dPC <-CC* k12 - PC *k21
dCC <-PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + k12 +
(Cltot/(V0*1000)))+ DOSING
dEx <-In*kin*Fex;
dFe <- GI*kga*(1-Foral);
dEl <CC*(Cltot/(V0*1000))
return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))
}) }
IC <c(In=0, PLU=LDose*Fpd, CLU=LDose*Fcd, PLS=0, CLS=0, GI=GIDose,
CC=0, PC=0, Ex=0*Fex, Fe=0, El=0,DOSING=0)
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Parm <c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1,
kcls2, kin, Fex, Fpd, Fcd, Fgd)
out <- ode(IC, t,Model.Function,Parm)
return(out)}
######################################################################
###################
#####################
PBPK Model iterations
################################
######################################################################
###################
Cltot.n<-Clren.n+Clnonren.n
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n
CLV.n <- TLV.n*0.8/1000
PLV.n <- TLV.n*0.2/1000
In.Data <- matrix(0,length(t),(n));PL.Data<-In.Data;Cmax.n=rep(0,n);Smax.n<-Cmax.n
PLU.Data <- In.Data;CLU.Data <- In.Data;PLS.Data <- In.Data;CLS.Data <- In.Data
GI.Data <- In.Data;CC.Data <- In.Data;PC.Data <- In.Data;Ex.Data <- In.Data
Fe.Data <- In.Data;El.Data <- In.Data;CP.Data <- In.Data;CS.Data <- In.Data
for (i in 1:n) {
Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i]
Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i]
kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<kcls2.n[i];CLV<-CLV.n[i]
PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i]
LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI
CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1,
kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf)
In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5]
CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9]
Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<CID[,8]/V0
CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV;Cmax.n[i]<max(CP.Data[,i]);Smax.n[i]<- max(CS.Data[,i])}
######################################################################
###################
################### VPC Plotting Function for TS DATA
##############################
######################################################################
###################
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){
Size.of.Data<-dim(Data); PlottingData<-matrix(0,Size.of.Data[1],4);PlottingData[,1] <CID[,1]
for(i in 1:length(t)){
PlottingData[i,2] <-min(Data[i,]);PlottingData[i,3] <- mean(Data[i,]);PlottingData[i,4] <max(Data[i,])}
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Time<-PlottingData[,1];Bottom<-PlottingData[,2];Top<-PlottingData[,4];Middle<PlottingData[,3]
ColNumbers<-col2rgb(Color);par(TRUE);mycol4<rgb(ColNumbers[1],ColNumbers[2],ColNumbers[3],max=255,alpha=90)
plot(Time,Bottom,type="n",col=Color,main=Title,ylim=c(YMin,YMax),log=LogAxis,xlim=c
(XMin,XMax),
ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2)
polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA)
lines(Time, Middle, type= "l", col=Color, lwd=2.8); return()}
png(width=12,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/ HV
Clrenal.png");par(mfrow=c(1,2))
VPCP(CP.Data,'green',0.001,10,0,720,'','Plasma Conc (mg/l)','y')
VPCP(CS.Data,'cyan',0.1,1000,0,720,'','Sputum Conc (mg/l)','y')
mtext("Sensitivity of cp(t) (left plot) and cs(t) (right plot) to Clrenal after INH Dosing in
HV", cex=1.2,side = 3,line =-2,outer=T,font=2);dev.off()
AUCLowerParmValue<-AUC.Trap.Calc(t,CP.Data[,1]);AUCHigherParmValue<AUC.Trap.Calc(t,CP.Data[,3])
AUCS <- c(AUCLowerParmValue,AUCHigherParmValue);AUCMultiplier=1
if (AUCHigherParmValue<AUCLowerParmValue){AUCMultiplier=-1}
Cmaxlower <- Cmax.n[1];Cmaxhigher<- Cmax.n[3];Cmaxmultiplier<-1
if (Cmaxhigher<Cmaxlower){Cmaxmultiplier=-1}
SAUCLowerParmValue<-AUC.Trap.Calc(t,CS.Data[,1]);SAUCHigherParmValue<AUC.Trap.Calc(t,CS.Data[,3])
SAUCS <- c(SAUCLowerParmValue,SAUCHigherParmValue);SAUCMultiplier=1
if (SAUCHigherParmValue<SAUCLowerParmValue){SAUCMultiplier=-1}
Smaxlower <- Smax.n[1];Smaxhigher<- Smax.n[3];Smaxmultiplier<-1
if (Smaxhigher<Smaxlower){Smaxmultiplier=-1}
Clrenal.1.AUC<-AUCMultiplier*max(AUCS)/min(AUCS)
Clrenal.1.cmax<- Cmaxmultiplier*max(Cmax.n)/min(Cmax.n)
Clrenal.1.SAUC<-SAUCMultiplier*max(SAUCS)/min(SAUCS)
Clrenal.1.smax <- Smaxmultiplier*max(Smax.n)/min(Smax.n)
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